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Abstract 
 
Approximately 30 – 40% of severely injured civilian and military casualties 
develop acute coagulopathy before arrival into hospital, with significant clinical 
implications such as increased mortality. The aetiology of trauma coagulopathy 
is multifactorial and thought to include consumption of clotting factors, acidosis 
and haemodilution. More recently attention has focussed on the role of tissue 
hypoperfusion and shock in the development of acute trauma coagulopathy. 
Coagulopathy is currently managed by the early use of blood products with or 
without adjuncts such as antifibrinolytics, and procoagulant agents. This can be 
guided by repeated assessment of clotting status to monitor the effects of 
therapy e.g. using TEG® or ROTEM®. Work presented in this thesis 
demonstrates the value of using interim values of coagulation, to accelerate the 
assessment of coagulation. ROTEM® A10 predicted coagulopathy with a 
sensitivity/specificity of 1.0/0.7, nineteen minutes earlier than running the test to 
completion. 
 
 
In a randomised controlled trial in terminally anaesthetised pigs the implications 
of clinical treatment of coagulopathy were assessed. The implications of 
administering early oxygen or rFVIIa on coagulation were compared in a model 
of complex battlefield trauma. The administration of intravenous rFVIIa 
conferred a “boost” in clotting, however it was followed by an exaggerated 
deterioration in coagulation. By contrast coagulation was better maintained in 
the group treated with oxygen. A second, or delayed dose of rFVIIa was 
simulated in an in vitro study where blood from these groups was spiked with 
rFVIIa. In the animals treated with intravenous rFVIIa, the effect of the second 
dose was attenuated, while a comparable dose had a greater effect in the 
oxygen group. 
 
 
  ii 
These findings have implications for austere, resource constrained military 
settings since a boost in clotting might reduce immediate blood loss. However, 
this needs to be balanced against the loss of responsiveness over time. Limiting 
shock with oxygen may have a greater long term potential should evacuation be 
delayed. 
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Chapter 1. Background 
1.1 The nature of civilian and military trauma  
Trauma remains the leading cause of death in young adults in the western 
world (Narayan et al., 2008; Sauaia et al., 1995), however the term trauma is a 
used to cover a wide variety of injury mechanisms, injuries sustained, and 
degree of physiological insult. It is therefore important to clarify the predominant 
type of trauma when comparing published evidence. The traditional UK civilian 
trauma patient is young, male and suffers blunt trauma, mostly from motor 
vehicle collision (Spinella et al., 2008; Brohi et al., 2003; London Trauma Office, 
2012). When penetrating injuries are present, they are generally simple stab 
wounds or low velocity gunshots. Civilian trauma in the US has a more evenly 
distributed ratio of penetrating to blunt injury (Wade et al., 2010; Demetriades et 
al., 2005; Truitt et al., 2011; Kauvar and Wade, 2005) but remains 
predominantly young male with blunt trauma from motor vehicle collisions 
(Hauser et al., 2010; World Health Organization. Injuries Department, 2002). 
 
Military trauma, in contrast, is characterised by blast and penetrating trauma 
(McMullin et al., 2008; Truitt et al., 2011). The penetrating trauma tends to be 
secondary to munitions and are therefore complex injuries due to ballistic 
threats such as fragments from explosive devices or high velocity bullets 
(Klemcke et al., 2005; Truitt et al., 2011; Jeroukhimov et al., 2002). Military 
wounds also tend to have a higher level of soft tissue disruption due to the 
cavitating effects of high velocity projectiles. This makes the wounds more 
complex with a greater degree of tissue damage than low velocity penetrating 
trauma seen in civilian practice (Sapsford et al., 2007; Hankin and Jeffery, 
2010). Military trauma also differs form civilian trauma in that haemorrhage is 
the leading cause of death in the battlefield (Sapsford et al., 2007; Champion et 
al., 2003).  
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For many years trauma care has been based on the belief that death after 
trauma follows a trimodal response (Baker et al., 1980) with immediate death at 
the point of injury, early death within 1 hour and late death after 1 week. 
Recently this view has been challenged (Meislin et al., 1997; Demetriades et al., 
2005)  and the late death due to sepsis and multiorgan failure is no longer seen 
as a third peak. In hospital deaths are more evenly distributed after 1 hour. This 
is attributed to better trauma care systems. Despite the reduction in late deaths, 
the leading cause of death in civilian trauma remains head injury (Sauaia et al., 
1995; Pfeifer et al., 2009; Kauvar and Wade, 2005), followed closely by 
haemorrhage which is the most common form of potentially preventable death 
after trauma. 
 
Recent conflicts have not been conventional, and injury patterns have changed 
due to an increasing use of improvised explosive devices (IED) (Kamphuisen et 
al., 2002; Truitt et al., 2011). This has lead to an increase in the number of blast 
casualties seen (Smith, 2011; Ritenour et al., 2010) in hospital, many with 
associated blast lung damage. As a response to the change in weapons used 
against coalition troops, there have been improvements in personal protective 
equipment, and changes in medical practice. This has returned the focus on the 
prehospital treatment of catastrophic haemorrhage with direct pressure over 
bleeding points, and the application of tourniquets with the rapid evacuation of 
the casualty to a surgical facility (Hodgetts et al., 2006). There is improved 
medical training for all combat troops and rapid access to combat medical 
technicians1 (CMT’s) and prehospital care doctors. This allows for potential 
prehospital therapies to be administered, such as the use of prehospital 
recombinant factor VIIa (rFVIIa), or oxygen delivered at the point of wounding. 
There are logistical and safety constraints with some therapies, such as oxygen, 
which may explode if hit by bullets or shrapnel, therefore their use must be fully 
evaluated prior to incorporation into protocols, especially in light of new, 
potentially safer technologies for O2 delivery 
 
These improvements in medical care have resulted in the early survival of 
casualties that would previously have died on the battlefield. This cohort of 
severely injured, hypovolaemic, blast injured patients with catastrophic 
                                            
1 Combat medical technicians are military paramedics 
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extremity injury (Truitt et al., 2011) now enter the medical chain generating new 
demands on resuscitation strategies. Old resuscitation protocols focused on 
geographically distinct echelons of care with sequential resuscitation, followed 
by surgery and finally critical care. Once a casualty arrived in critical care, up to 
18% were found to be cold acidotic and coagulopathic (Gonzalez et al., 2007). 
This set of symptoms, the lethal triad, or bloody vicious cycle (Kashuk et al., 
1982), was associated with increased mortality.  
1.2 Coagulopathy after trauma 
Historically, trauma patients who died in hospital were coagulopathic when they 
died (Sauaia et al., 1995) and recent changes in resuscitation protocols have 
focused on arresting this process. Civilian data suggests that approximately 30 
– 40% of patients who arrive at hospital after trauma, have an acute 
coagulopathy on admission (Brohi et al., 2003; Maegele et al., 2007; MacLeod 
et al., 2003). The proportion of military patients from recent conflicts, who have 
coagulopathy on admission remains unclear, however several papers have 
suggested rates around 40 - 50% (Niles et al., 2008; Plotkin et al., 2008; Doran 
et al., 2010).  
 
Originally coagulopathy after trauma was thought to be due to consumption and 
dilution of clotting factors. However recent work has suggested the presence of 
a primary coagulopathy not associated with hypothermia, dilution and 
consumption at the time of admission to hospital. This coagulopathy, termed 
acute trauma coagulopathy (ATC) is associated with a significant increase in 
mortality, injury severity and the presence of shock (Brohi et al., 2003; MacLeod 
et al., 2003; Maegele et al., 2007).  
 
Treatment options that may target ATC hold a great deal of interest for the 
military since any potential modulation of this process by simple, therapies 
without the logistical burden of providing fresh and frozen blood products, may 
have a profound impact on future conflicts. In order to effectively investigate 
treatment options, there needs to be a full understanding of the processes 
involved in normal clotting and where potential deficits might be occurring.  It is 
generally accepted that ATC exists, but the theories behind its pathophysiology 
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remain divided although microcirculatory shock and subsequent prolonged 
endothelial activation seems to be an underlying theme (Curry et al., 2012). 
 
Assessment of clotting in blast injured casualties needs to be fully elucidated 
since there are limitations with the current standard tests of prothrombin time 
(PT) and activated partial thromboplastin time (aPTT) (Doran et al., 2010). 
Interest in viscoelastic methodology in elective surgery has translated to 
renewed interest in the trauma setting (NHS Quality Improvement Scotland, 
2008). Viscoelastic methods can potentially diagnose coagulopathy in a more 
rapid and relevant way than standard tests. One particular device, ROTEM®, 
has proved to be of use in a deployed military environment, however its 
usefulness in determining the coagulation profile in blast injured casualties is 
yet to be fully determined (Doran et al., 2010).  
1.3 The purpose of this research 
The work in this the thesis forms part of a larger ongoing programme of work 
aimed at improving combat casualty care. The purpose of this research is to 
assess the impact of prehospital treatment of casualties with recombinant factor 
VIIa (rFVIIa) or oxygen as a treatment for blast lung, on their admission 
coagulation status.  
 
In Chapters 2-4 I will explore and explain the pathophysiology and assessment 
of coagulation and coagulopathy after trauma, Chapter 5 explains the physics of 
blast and the effects blast injury has on the body and on coagulation. Chapter 6 
deals with the physiological responses to trauma and Chapter 7 the rationale for 
the use of rFVIIa to treat blast lung and coagulopathy. Chapters 8 to11 provide 
the details and the results of the experimental work, firstly a clinical assessment 
of ROTEM® in the diagnosis of acute trauma coagulopathy in Afghanistan and 
secondly a series of experiments conducted on an animal model of a survivable 
battlefield injury. In Chapter 12, I will discuss the findings of the experimental 
work and explore a surprising finding in the assessment of coagulation after 
administration of rFVIIa. Finally I will discuss the findings of a study designed to 
assess the optimum time for administration of rFVIIa and the effects of a second 
dose of rFVIIa after a blast injury and traumatic haemorrhage. 
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Chapter 2. Normal Coagulation 
2.1 Overview of haemostasis 
Haemostasis is a physiological process that is initiated when tissue damage 
occurs. Primary haemostasis occurs in seconds, when sympathetic nerve 
activity and neurohormonal signalling causes vasoconstriction and a platelet 
plug forms at the site of injury. Exposed tissue factor (TF) from the 
subendothelial tissues, activates secondary haemostasis when coagulation 
enzymes produce thrombin and fibrin. Platelets activated by collagen and 
thrombin, catalyse further thrombin production at the site of injury and activate 
inflammatory mediators to promote wound repair (Figure 2-1) 
 
It is important that once the biological process has started, it remains local to 
the site of injury and does not propagate downstream. Regulation of 
haemostasis occurs by multiple processes including endothelial suppression of 
platelet activation, anticoagulant pathways, specific protease inhibitors and 
fibrinolytic pathways. This process is called localisation and prevents the 
formation of intravascular thrombus (Gomez et al., 2011). Many of the 
localisation pathways are also linked to fibrinolysis, the final process in normal 
haemostasis, and cause the breakdown of the fibrin clot. Haemostasis is 
therefore a balance between anticoagulation, coagulation, and fibrinolysis.  
 
The ultimate goal of coagulation after stopping bleeding, is to allow wound 
healing and tissue repair (Gomez et al., 2011; Smith, 2009)  and therefore 
coagulation is intimately linked to inflammation and tissue repair mechanisms. 
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2.1 Vasoconstriction 
After vessel damage, circular smooth muscle in the vessel wall contracts 
(spasm) in an attempt to pinch off the vessel and reduce blood loss. Vascular 
spasm reduces the blood flow to the injured area, reducing downstream flow 
and increasing the chance of a stable clot forming (Hoffbrand et al., 2006). 
2.2 Platelets 
Platelets are understood to have a key role in allowing coagulation to occur 
(Gomez et al., 2011). The platelets first role in coagulation is to form a platelet 
plug at the site of injury. Once a platelet interacts with the subendothelial matrix 
after vessel injury, a series of events occur with the platelet adhering to the 
damaged area (adhesion), release of intracellular enzymes from organelles with 
expression of procoagulant glycoproteins (activation) and recruitment of other 
platelets to the damaged area (aggregation) ((Smith, 2009; Levrat et al., 2008; 
Hoffman and Monroe, 2001; Sawamura et al., 2009; Schöchl et al., 2009; 
2010).  
 
Figure 2-1. Mechanisms involved in haemostasis (From Essential Haematology 6th Edn. © 
2011 Blackwell Publishing) 
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Platelets now provide an activated, procoagulant membrane on which clotting 
factors can assemble allowing efficient thrombin production and ultimately an 
insoluble fibrin mesh at the site of injury. 
 
2.2.1 Platelet physiology 
 
Figure 2-2. Platelet ultrastructure (From Essential Haematology 6th Edn. © 2011 Blackwell 
Publishing) 
 
Platelets are extremely small, discoid cells.  Their ultra structure is represented 
in Figure 2-2 The plasma membrane invaginates into the cell producing canaliculi 
that give rise to a large surface area to absorb coagulation proteins. The platelet 
surface is packed with functional glycoprotein (GP) receptors, to facilitate 
platelet activation and interactions with the subendothelial matrix, other blood 
cells and other platelets (Hoffbrand et al., 2006). 
 
The platelet also contains several granules that upon activation can fuse with 
the platelet membrane and thereby release their contents into the surrounding 
media (Harrison, 2005). The granules are categorized into larger α-granules, 
the smaller dense granules and lysosomes. (King and Reed, 2002).  
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2.2.2 Platelet adhesion 
Following vessel wall injury, platelets adhere to collagen in the subendothelial 
matrix by synergistic reactions between several receptors on the platelet 
surface (Figure 2-3)(Furie and Furie, 2008). Local flow conditions can affect 
platelet function. In low flow areas platelets will tend to marginate increasing the 
chance of interacting with the damaged endothelium. Margination is therefore 
increased after vascular spasm. In high flow vessels (such as arterioles) platelet 
adhesion is augmented by the interaction of von Willebrand Factor (vWF) with 
platelet glycoproteins.(Hoffbrand et al., 2006) 
 
 
Figure 2-3. Schematic representation of the platelet and its functional receptors. (From 
www.platelets.se) 
2.2.3 Platelet activation 
Once a platelet adheres to the subendothelial matrix it becomes activated (Furie 
and Furie, 2008).  Platelets become more spherical than discoid and extrude 
pseudophobia, enhancing vessel wall and inter platelet interactions. Changes in 
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the cytoskeleton cause the classic “fried egg” appearance of a long, flat platelet 
with central granules and organelles.  
 
 In order for platelet recruitment to continue, the activated state of adhered and 
aggregated platelets must be transferred to newly arriving platelets. This occurs 
either due to potent autocrine and paracrine signalling after the release of 
intracellular granules (degranulation), or directly from thrombin produced via the 
clotting pathways. 
2.2.4 Platelet aggregation 
Once a primary layer of platelets has covered the exposed subendothelial 
matrix, adhesion continues, but in the form of aggregation, when two platelets 
bind to the same fibrinogen molecule. (Figure 2-3).  
2.3 Coagulation 
2.3.1 The Clotting cascade 
Traditionally clotting was described as a cascade system where activation of 
one particular clotting factor (serine proteases) led to the activation of another 
factor and so on. The process was split into two. The intrinsic system, also 
known as contact activation, has all the proteins required to form clot in the 
blood. The extrinsic system, in contrast, required the presence of extrinsic 
tissue factor found in the subendothelial matrix. Finally both the intrinsic and 
extrinsic pathways came together to form the final “common” pathway, 
ultimately resulting in the conversion of soluble fibrinogen to insoluble fibrin  
Figure 2-4). 
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 Figure 2-4. The "clotting cascade" (From (Smith, 2009)) 
 
This view is now challenged since the cascade system did not explain why 
deficiency of a certain factors e.g. FXII, may have no effect on clotting, where 
as deficiency of other factors, e.g. FVIII (haemophilia A) had a profound effect 
on clotting. Hoffman and Monroe (2001) have subsequently proposed a “cell 
based theory” of clotting where the role of platelets, in particular, are central to 
the assembly and function of clotting factors  
2.3.2 The role of Thrombin 
At the centre of the whole process is thrombin and all aspects of haemostasis 
feed into the regulation and control of thrombin (Figure 2-5). Thrombin is a 
procoagulant protein and is produced early on in the clotting process to activate 
platelets, and later on, in a “thrombin burst”, to cause fibrinogen conversion to 
insoluble fibrin. Thrombin can also be an anticoagulant protein as it promotes 
protein C pathways via thrombomodulin (see section 2.6.3). Thrombin also 
affects clot structure by stabilising clot by the formation of factor XIIIa from FXIII 
and preventing fibrinolysis by the action of thrombin activated fibrinolysis 
inhibitor (TAFI) (See section 2.4.4). Thrombin is crucial in the inflammatory 
response as it activates white cells and the endothelium. 
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Figure 2-5. The central role of thrombin in coagulation 
2.4 Cell based theory of clotting 
A more modern theory of coagulation is the cell-based theory, which 
incorporates the role of cells (platelets) and membrane surfaces in conjunction 
with the interaction with clotting factors. Platelets are integral to this process as 
they provide the framework on which all coagulation occurs. The process itself 
occurs in three distinct phases, initiation, amplification and propagation. 
2.4.1 Initiation 
It seems that the sole initiator of coagulation is extracellular TF wrapped around 
the blood vessels, which binds to circulating FVIIa. Factor VII is the only factor 
that normally exists in its active form in circulating blood (about 1%). Once 
tissue damage occurs, this FVIIa binds to the exposed TF producing a TF-VIIa 
complex, which in turn activates further FVII to FVIIa in an autoactivation 
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process (Figure 2-6). With the interaction of other clotting factors, small 
amounts of thrombin, FIXa and FXa are produced.  FIXa and FXa are required 
later on in clot propagation unless inactivated by TFPI or anti thrombin (AT) 
(see section 2.6.2). The thrombin produced in clot initiation is available to 
directly activate local platelets  
 
 
Figure 2-6. Clot initiation (Adapted from (Smith, 2009)) 
2.4.2 Amplification 
The small amount of thrombin generated during initiation diffuses away from the 
TF bearing cell causing platelet activation. Platelet degranulation occurs with 
expression of Factor V on the outer surface (Figure 2-7). Thrombin also allows 
vWF to be realised from FVIII augmenting platelet adhesion. 
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Figure 2-7. Clot amplification (Adapted from (Smith, 2009) 
2.4.3 Propagation 
Once platelets are adhered to the site of injury and are activated, they provide a 
procoagulant membrane on which to assemble the clotting factors to efficiently 
produce a thrombin burst and ultimately convert fibrinogen to insoluble fibrin. 
This is called propagation (Figure 2-8).  
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Figure 2-8. Clot propagation (Adapted from (Smith, 2009) 
2.4.4 Post clot formation 
Thrombin’s additional functions after the initial fibrin polymerisation include 
activation of FXIII to FXIIIa and the activation of thrombin activatable fibrinolysis 
inhibitor (TAFI).  
 
FXIIIa has important roles in cross-linking fibrin strands improving strength and 
elasticity of the clot and rendering it more resistant to fibrinolysis. This stability is 
mediated via the thrombomodulin (TM) bound TAFI. (Cesarman-Maus and 
Hajjar, 2005). It binds to the same binding sites on fibrin as plasminogen and 
tissue plasminogen activator (tPA) thereby attenuating their effects. 
2.5 The Vascular Endothelium 
The resting endothelium provides a physical barrier between blood, 
extravascular collagen and tissue factor (Figure 2-9) and has an intimate 
relationship with flowing blood and blood cells. It plays a crucial role in 
haemostasis, by preventing thrombosis and in linking coagulation to 
inflammation (Levi et al., 2002).  
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The endothelium is lined by a glycocalyx of membrane bound macromolecules 
comprised of sulphated proteoglycans (see section 2.6.2), glycoproteins and 
plasma proteins. The constituents of the glycocalyx influences anticoagulation, 
fibrinolysis and inflammatory processes whilst the physical presence of these 
molecules in the microvascular lumen impacts blood flow, transmission of shear 
forces and oxygen diffusion (Pries et al., 2000). 
 
The intact endothelium maintains blood in a fluid state by a complex set of 
interactions. Arguably the most important mechanism is the physical barrier 
between blood, extravascular collagen and tissue factor (Figure 2-9). Since 
tissue factor is the sole initiator of coagulation, physical separation provides 
much of the anticoagulant effect. 
2.6 Natural anticoagulation Pathways 
2.6.1 Tissue factor pathway inhibitor 
Endothelium derived tissue factor pathway inhibitor (TFPI), found mainly in 
capillaries, bound to the glycocalyx, (Lupu et al., 1995), and reduces the 
procoagulant effects of the TF-VIIa complex by inhibiting FXa.  It inhibits the TF-
VIIa complex in a FXA dose dependent manor. Its role is to inactivate FXa that 
might flow downstream of the injury, thus localising coagulation to the site of 
injury.  
 
Blood levels of TFPI are known to increase after injection of heparin or low 
molecular weight heparin (Abildgaard, 1993), although this effect is transient 
and TFPI is sequestered from the blood as the level of heparin decreases (Lupu 
et al., 1995).  
2.6.2 Antithrombin and heparin sulphated proteoglycans 
Antithrombin (also known as antithrombin III) is a potent inhibitor of clotting 
factors, particularly FXa, thrombin and to a lesser extent FIXa (Zhang et al., 
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2005). Unusually it requires activation by heparin or heparan sulfates (Levi and 
Van Der Poll, 2010) to inhibit its target protein at physiologically significant 
rates.  
 
Heparan sulfates (HS) are polysaccharides attached to a protein core 
(proteoglycans) the most common being the syndecans and the glypicans 
(Bernfield et al., 1999).Syndecan 1 is present on epithelial cells (Tumova et al., 
2000) and is therefore the most important proteoglycan involved in coagulation.  
 
Heparin is present on mast cells and is commonly isolated to be used as an 
anticoagulant whilst HS is found on cell surfaces (Sasisekharan and 
Venkataraman, 2000). Both will bind to AT causing a conformational change 
and increasing AT’s activity up to 1000 fold (Levi and Van Der Poll, 2010).  
Heparan sulfates therefore function as an activator of AT attached to the vessel 
wall.  
2.6.3 The Protein C pathway 
The protein C pathway responds to the presence of thrombin (Esmon, 2003). 
As the thrombin concentration rises, much of it is bound to thrombomodulin 
expressed on the endothelial surface. The thrombin-thrombomodulin complex 
(T-TM) activates protein C (aPC), a process that is enhanced 20 fold if PC is 
bound to the endothelial protein C receptor (EPCR). Thrombin associated in the 
T-TM complex is more readily inactivated by AT than free thrombin.  
 
aPC, in conjunction with protein S inactivates factors Va and VIIIa, causing 
anticoagulation, and inhibits plasminogen activator inhibitor-1 (PAI-1) allowing 
increased fibrinolysis. TM concentration is 100 fold higher in capillaries than in 
large vessels, thereby extracting any circulating thrombin. The T-TM complex is 
also a potent activator of thrombin activatable fibrinolysis inhibitor (TAFI) (see 
section 2.4.4) 
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Figure 2-9. The role of the vascular endothelium (From Essential Haematology  6th Edn. © 2011 
Blackwell Publishing) 
2.7 Fibrinolysis 
Fibrinolysis occurs to ensure blood fluidity and is tightly controlled by specific 
activators and inhibitors in conjunction with endothelial receptors (Figure 2-10). 
Activation of coagulation leads to generation of thrombin and ultimately to fibrin 
deposition. Plasmin is the main fibrinolytic protease, derived from plasminogen, 
responsible for cleaving fibrin. 
 
Plasminogen derived from the liver is cleaved to plasmin under the control of 
tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). 
tPA is the dominant stimulant and is synthesised from endothelial cells under 
the influence of many stimuli including thrombin. Its half-life is extremely short 
and on its own is a poor activator of plasminogen, however its action is 
increased in the presence of fibrin and strongly localises the plasmin production 
to the site of the clot. Plasmin binds to terminal lysine residues on fibrin and 
cleaves off soluble degradation products, and degrades the clot.  
 
Plasmin activity can also be reduced by the presence of thrombin activatable 
fibrinolysis inhibitor (TAFI) which binds to partially degraded fibrin reducing the 
efficacy of plasmin and stabilises the fibrin clot (Cesarman-Maus and Hajjar, 
2005). 
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2.7.1 Inhibitors of fibrinolysis 
Plasmin is inhibited by serpins such as α2-plasmin inhibitor, where as 
plasminogen is inhibited by the plasminogen activator inhibitors 1 and 2 (PAI-1 
and PAI-2). PAI-1 is the most significant of the inhibitors inhibiting both tPA and 
uPA. The release of PAI-1 is stimulated by various inflammatory and 
coagulation mediators including thrombin(Cesarman-Maus and Hajjar, 2005). 
 
Figure 2-10. Fibrinolytic pathway (Modified from Essential Haematology  6th Edn. © 2011 
Blackwell Publishing) 
2.8 Summary 
Coagulation is a complex interaction between coagulation, anticoagulation and 
fibrinolytic pathways. It is intimately linked with inflammation and its ultimate 
goal is cessation of bleeding followed by wound repair. 
 
After tissue damage, vasospasm limits blood flow, allowing the interaction of 
FVIIa and platelets with subendothelial tissue factor and collagen. The ensuing 
coagulation cascade coupled with activation and aggregation of platelets leads 
to an insoluble fibrin and platelet clot. Coagulation is localised to the site of 
injury due to the natural anticoagulant effects of the vascular endothelium and 
specific factor inhibitors. Finally, fibrinolysis removes any unwanted clot. 
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Abnormalities in the coagulation system are called coagulopathies and can be 
congenital, acquired and iatrogenic. The next chapter will discuss the aetiology 
of coagulopathies, concentrating on coagulopathy after trauma.  
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Chapter 3. Coagulopathy after Trauma 
3.1 Overview of coagulopathy 
The term coagulopathy is generally used to describe a deficiency in the clotting 
system. Technically coagulopathy occurs after a disease state and can cause a 
decrease in clotting (hypocoagulopathy), or an increase in clotting, 
(hypercoagulopathy). 
 
Coagulopathies can be inherited or acquired. Acquired coagulopathies can be 
further divided into iatrogenic, such as warfarin therapy, or pathological, such as 
disseminated intravascular coagulopathy. Inherited coagulopathies may 
complicate acquired coagulopathies, however they are not the focus of this 
discussion. This thesis shall focus on trauma induced coagulopathies and their 
potential aetiologies. The generally accepted term of “coagulopathy” will be 
used to describe a deficiency in clotting ability, and “hypercoagulopathy” to 
describe an increase in clotting ability. 
 
Trauma induced coagulopathies are driven by consumption of clotting factors, 
hypothermia and acidosis impairing enzymatic and platelet function, dilution of 
available clotting factors after resuscitation, and hormonal and cytokine 
changes. Recently a previously unrecognised phenomenon of acute trauma 
coagulopathy has been described.   
 
Interpretation of the published literature is complicated by the lack of consensus 
of definitions and terminology of coagulopathy, however these aspects shall all 
be dealt with in the following chapter. 
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3.2 Trauma induced Coagulopathy (TIC) 
3.2.1 Historical Perspective 
Coagulation abnormalities after trauma are not new. In 1985 Hewson et al. 
(Hewson et al., 1985) described coagulopathy in massively transfused patients 
after dilution with crystalloid. Associations between shock and clotting 
abnormalities were noticed during the Vietnam war demonstrating an early 
hypercoagulopathy and a later coagulopathy (Simmons et al., 1969). Risberg et 
al. (Risberg et al., 1986) demonstrated that clotting systems were activated after 
trauma and this was related to a fall in the systolic blood pressure (Bp) below 
110 mmHg. 
 
Until a decade ago resuscitation followed Advanced Trauma Life Support 
(ATLS) principles focussing on the restoration of circulating volume with 
crystalloid solutions (American College of Surgeons Committee on Trauma, 
1993). Anaemia was treated with packed red blood cells (PRBC) whilst fresh 
frozen plasma (FFP) and other component therapy was only started after a 
significant number of PRBC’s had been transfused (Curry et al., 2012). This 
resulted in dilution of available clotting factors leading to a dilutional 
coagulopathy. Coupled with this, large amounts of clot formed as the body tried 
to stem bleeding by activating coagulation, leading to a consumptive 
coagulopathy, and if the bleeding could not be stopped a loss of a clinically 
significant amount of clotting factors occured. The casualty also became cold 
due to environmental factors and infusion of cold fluids, and remained acidotic 
due to inadequate resuscitation, both of which can worsen (or cause) 
coagulopathy.  
 
This combination of events (hypothermia, acidosis and consumptive/dilutional 
coagulopathy) is commonly termed the lethal triad or bloody vicious cycle 
(where each component can augment the others) (Curry et al., 2012; Midwinter 
and Woolley, 2011; Kashuk et al., 1982) and was originally described after 
haemorrhage from major abdominal vascular trauma.  
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3.2.2 Hypothermia 
Hypothermia impairs the body’s ability to clot, as the temperature falls so 
protease activity decreases (Reed et al., 1990). Factor VII activity decreases 
linearly with temperature, only retaining 80% of its activity at 33˚C (Meng et al., 
2003).  However these effects are minor compared to the effect of hypothermia 
on platelets. Platelet aggregation and adhesion were decreased by 30 – 40% at 
33˚C compared to 37˚C (Wolberg et al., 2004) although in this study the amount 
of thrombin generated was the same at both temperatures. 
 A core temperature of 34˚C is a critical point at which a significant alteration in 
platelet physiology occurs in trauma patients and at which enzyme activity 
decreases (Watts et al., 1998). In this study the patients had 
Thromboelastography (TEG®), PT, aPTT and platelet count performed, and 
patients were stratified according to admission temperatures. The PT and aPTT 
showed no difference between the temperature groups, however TEG® showed 
differences in maximum amplitude (MA) only once the temperature dropped to 
less than 34 degrees. MA is a measure of clot strength, the stronger the clot, 
the greater the MA, and is determined by the amount of functional fibrinogen 
and platelets. The change in MA was attributed to platelet function. 
 
Hypothermia is directly correlated to injury severity and is an independent risk 
factor for mortality, reaching 100% when core temperature is less than 32˚C in 
patients undergoing surgery (Jurkovich et al., 1987). Hypothermia leads to α-
adrenergic stimulation, which in turn leads to, vasoconstriction, exacerbating 
any organ hypoperfusion, which may be already present secondary to 
hypotension from the injury. This hypoperfusion leads to worsening acidosis.  
3.2.3 Acidosis 
Acidosis significantly affects haemostasis. At a pH less than 7.4 a normal 
platelet will change internal structure and lose the ability to change shape 
(Djaldetti et al., 1979). At a pH of 7.0 platelets show reduced signs of activation 
and microparticle formation, compared with a pH of 7.4 (Etulain et al., 2012). 
Coagulation factors are each affected differently by acidosis, and calcium 
binding site affinity is decreased. At pH 7.1, thrombin produced in clot 
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propagation is decreased by 50%, fibrinogen by 35% and platelet count by 50% 
(Martini and Holcomb, 2007).  
3.2.4 Haemodilution 
Haemodilution can play a part in (Gando et al., 2002)the development of 
coagulopathy. Initially there is a shift of extracellular fluid to the intravascular 
space which will dilute clotting factors (Carey, 1973). Resuscitation with 
crystalloid has been shown to further dilute factors, and the use of colloids that 
expand plasma volume to a greater extent can dilute even further, as well as 
directly inhibiting coagulation pathways and inducing a profibrinolytic state 
(Bolliger et al., 2010). Resuscitation with component therapy equivalent to 
whole blood still has a dilution effect since component therapy equivalent to 
whole blood contains a haematocrit of 29%, Plts 88 x109/l and 65% coagulation 
activity (D'Angelo and Dutton, 2010). This dilution, however is less than that 
produced by the transfusion of red cells with crystalloid alone. 
3.2.5 Consumption 
Once the coagulation cascade has started there is inevitable consumption of 
the basic building blocks of a clot, i.e. factors, fibrinogen and platelets. Dunbar 
and Chandler (Dunbar and Chandler, 2009) demonstrated non wound related 
thrombin production within an hour of trauma due to the systemically activated 
coagulation system.  This could potentially lead to widespread coagulation 
activation, which would in turn lead to widespread activation of fibrinolytic 
pathways and disseminated intravascular coagulation (DIC).  
 
Gando et al (Gando et al., 2011) believe that DIC occurs in response to the 
massive thrombin surge caused by high amounts of free TF found in blood 
immediately after trauma.  This inevitably leads to widespread coagulation 
activation and consumption of clotting factors.  
 
The early clinical picture of ATC does look similar to DIC with low platelet 
counts, low fibrinogen levels, raised PT and high fibrin degradation products 
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(FDP’s). However there is no disseminated coagulation in ATC, only 
coagulation at the site of injury (Curry et al., 2012). And therefore Gando’s 
opinion of DIC as a cause of coagulopathy after trauma is in contrast to the 
opinions of others (Lin et al., 2011; Hess et al., 2008) who argue that DIC is not 
a feature of early coagulopathy after trauma.  
 
Several studies report low levels of clotting factors on admission after traumatic 
injury, however this is discussed in more detail in section 3.4 
3.2.6 Hormone and cytokine changes 
Following tissue damage there is release of hormones and cytokines. There are 
two temporal phases; immediate release of catecholamines and vasopressin 
and later effects of endothelial cell activation.  
 
Vasopressin stimulates the release of vWF, production of tPA from the 
endothelium and increased expression of P selectin (Kenet et al., 1999; Hunt 
and Jurd, 1998). 
 
Release of inflammatory cytokines such as TNF and IL-1 as well as thrombin, 
cause endothelial cell activation resulting in a change of the endothelial cell 
phenotype from antithrombotic to pro thrombotic. There is down regulation of 
fibrinolysis by the increase in PAI-1 levels and reduction in the activation of 
antithrombin (Hunt and Jurd, 1998; Johansson et al., 2011b). 
3.2.7 On-going bleeding 
Anaemia has a profound effect on haemostasis. Normal clotting requires 
platelets to adhere to the endothelial wall. This is augmented by margination of 
the platelets and increases platelet endothelial interaction. A low haematocrit 
will reduce this effect (Valeri et al., 2007). 
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3.3 Acute Trauma Coagulopathy 
Recent research has shown that a trauma patient who is coagulopathic on 
admission to hospital is more likely to require massive blood transfusion, 
develop multi-organ failure and has up to a fourfold chance of dying (Brohi et 
al., 2003; Maegele et al., 2007; MacLeod et al., 2003). In 2003, Brohi et al. 
studied 1088 of 1867 trauma patients admitted to the Royal London Hospital 
between 1993 and 1998 (Brohi et al., 2003). This was a typical UK civilian major 
trauma population with 75% blunt trauma and a median injury severity score 
(ISS) of 20. These authors found that 24.4% of patients had a coagulopathy on 
admission although this figure rose to 33.1% in those patients who had an 
ISS>15 (major trauma). Coagulopathy was defined as a prothrombin time (PT) 
or activated partial thromboplastin time (aPTT) of 1.5 times normal. Median 
prehospital times were 73 minutes and median prehospital fluid administration 
was 800mls. Patients with a coagulopathy had a median volume of 700ml prior 
to admission and those without coagulopathy a median value of 1000ml. The 
presence of coagulopathy was not found to be related to fluid administration in 
this study.  
 
As ISS increased, so did the proportion of coagulopathic patients. Age and 
mechanism of injury had no effect on presence of coagulopathy. The overall 
mortality rate was 19.5%. However, mortality was associated with the presence 
of coagulopathy (mortality in coagulopathic patients 46% versus 10.9% non-
coagulopathic patients) but statistically independent of ISS. 
 
This important study suggested that there is an acute coagulopathy early in 
trauma that is unrelated to dilution, but is related to ISS and confers an 
increased mortality independent of ISS. These findings were confirmed by 
studies from the USA (MacLeod et al., 2003) and Germany (Maegele et al., 
2007). 
 
Macleod and colleagues reviewed prospectively collected data from 20,103 
trauma patients admitted to the University of Miami/Jackson Memorial hospital, 
Florida between 1995 and 2000, of whom 7638 had complete data sets for final 
analysis. The population was similar to that of the Royal London study 
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(predominantly male, blunt trauma and 66min (non coagulopathic group) and 74 
min (coagulopathic group) prehospital times), although the median ISS and 
mortality rate were lower with median ISS of 9 and overall mortality of 8.9%. 
Coagulopathy was defined as those with an abnormal PT or abnormal aPTT. 
Patients with a normal PT had a mortality of 6.3%, and those with an abnormal 
PT 19.3%. This study showed that 28% of trauma patients are coagulopathic on 
admission to hospital and they have an increased risk of early death.  
 
Maegele retrospectively examined 17200 trauma cases from the German 
trauma registry (Maegele et al., 2007) of which 8724 entries had complete data 
on coagulopathy. The population was very similar to the London and US 
populations, although 96% had blunt trauma. He found that 34.2% of patients 
were coagulopathic. The definition of coagulopathy differed from the previous 
studies, however, and was defined as a PT<70% and/or a platelet count <100 
x109/l. Using this definition, coagulopathy also increased with ISS and mortality 
was increased in the coagulopathic group. It was shown that the coagulopathic 
patient group had a statistically significant increase in multiple organ failure 
(MOF), ventilator dependant days and ICU length of stay and hospital length of 
stay. The prehospital fluid administration volume findings were different to those 
of the two previous studies. The coagulopathic group received a mean of 2198 
millilitres, and the non-coagulopathic group 1372 millilitres. Also as the volume 
of prehospital fluid increased, so did the numbers with coagulopathy, although 
10% of coagulopathic patients received less than 500 millilitres. The 
conclusions from this study were much the same as Brohi’s and MacLeod’s, 
namely that coagulopathy on admission increased mortality independent of ISS 
and as ISS increased so did the presence of coagulopathy and mortality. 
However, unlike Brohi’s findings, the amount of prehospital fluid administration 
had an effect on presence of coagulopathy.  This is a reflection of the 
prehospital trauma systems where large amounts of crystalloid are often given 
in Germany, whereas at the Royal London Hospital due to short prehospital 
times, very little fluid was given. Brohi was therefore unable to comment on the 
role of crystalloid administration in the development of admission coagulopathy.  
 
Despite the three studies having differing definitions of coagulopathy, they all 
find that approximately a third of major trauma patients arriving at Emergency 
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Departments are coagulopathic and that the presence of coagulopathy is 
associated with increased mortality. As yet there is disagreement on the correct 
terminology for this condition, however the increasingly accepted term is “Acute 
Trauma Coagulopathy” (Midwinter and Woolley, 2011; Gruen et al., 2012) and 
represents another subset of TIC. 
3.3.1 Military rates of ATC 
The proportion of military patients who have ATC remains unclear, although 
several papers have suggested rates around 40 - 50% (Niles et al., 2008; 
Plotkin et al., 2008; Doran et al., 2010). Since the presence of ATC on 
admission carries a significant increase in mortality (Brohi et al., 2003; MacLeod 
et al., 2003; Maegele et al., 2007), treatment options that may modulate this 
process hold a great deal of interest for the military. 
3.4 Mechanisms of ATC 
The pathophysiology of ATC is incompletely understood but appears to be an 
excessive stimulation of the normal processes of coagulation and fibrinolysis 
(Sapsford et al., 2007; Curry et al., 2012). Tissue damage leads to exposure of 
collagen and TF. Collagen leads directly to platelet activation, and TF stimulates 
clotting by interactions with FVIIa. Large amounts of thrombin are generated, 
dependent on the amount of TF exposed (Dunbar and Chandler, 2009). This 
leads to a consumption coagulopathy. Supporting this is observational data 
suggesting that those with ATC have high thrombin generating capacity 
(Sapsford et al., 2007; Dunbar and Chandler, 2009; Chandler, 2010; Woolley et 
al., 2013) and low clotting factors with reduced protein C levels, platelet counts, 
fibrinogen and antithrombin (Kamphuisen et al., 2002; Brohi et al., 2007b; 
Floccard et al., 2012; Jansen et al., 2011; Shaz et al., 2011; Woolley et al., 
2013).The lowest factor consistently appears to be FV with levels at 41-46% of 
normal values (Jansen et al., 2011; Yuan et al., 2007; Bickell et al., 1994; 
Woolley et al., 2013).  
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Thrombin generation not only leads to fibrin deposition, but also activates the 
endothelium, as well as platelets and white cells and causes the release of tPA. 
tPA release is compounded in the presence of hypoperfusion as is commonly 
seen after trauma (Liener et al., 2001; Brohi et al., 2008; Hayakawa et al., 
2011). 
3.4.1 Hypoperfusion 
The proposed underlying driving mechanism for early ATC is tissue 
hypoperfusion leading to inadequate oxygen supply to the microcirculation 
(microcirculatory shock) (Johansson et al., 2011a; Gruen et al., 2012; Brohi et 
al., 2003). In normal coagulation, thrombin formation leads to fibrinogen 
conversion to insoluble fibrin. Fibrin will in turn be broken down to its 
degradation products by the action of plasmin. Normal localisation pathways 
include removal of thrombin by thrombomodulin to produce a thrombin-
thrombomodulin complex (T-TM), thus stopping the activity of thrombin on 
fibrinogen. The T-TM complex activates protein C which directly inhibits factors 
Va and VIIIa on the platelet leading to less thrombin production. T-TM will also 
increase the effect of plasmin by removing inhibition of tissue plasminogen 
activator (tPA) on plasminogen (see Figure 3-1). The overall effect is to produce 
anticoagulation and increased fibrinolysis. It is postulated that ATC is a 
coagulopathy due to pathologically exaggerated activation of protein C as a 
consequence of tissue hypoperfusion, rather than simply a factor consumption 
effect (Brohi et al., 2008). 
 
To investigate this, a blinded study (Brohi et al., 2008) of 208 major trauma 
patients arriving at a single level 1 trauma centre was conducted. The patients 
had a mean ISS of 17 and a median time from injury to blood sampling of 32 
minutes. There was no vasopressor or colloid use and mean crystalloid 
administration was 150 millilitres. Platelet counts were normal in all patients. 
Hypoperfusion was judged to be present if there was a base deficit (BD) of 6 or 
greater, and coagulopathy to be present if aPTT or PT were 1.5 times normal. 
As injury severity increased, so did the amount of thrombin generation, but the 
amount was unchanged as hypoperfusion increased. Coagulopathy only 
occurred if there was a BD>6. It was found that a BD>6 was associated with a 
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rise in thrombomodulin levels and a fall in protein C (PC) levels. Activated 
protein C levels (aPC) could not be measured and the assumption was that a 
drop in PC levels was due to a rise in conversion of PC to aPC. Thus the 
hypothesis is that a greater base deficit reflects the tissue hypoperfusion 
leading to a rise in TM-T complexes, conversion of PC to aPC and therefore 
anticoagulation via inhibition of factors V and VIII. The fall in PC levels were 
also associated with fall in plasminogen activator inhibitor one (PAI-1). PAI-1 
inhibits tissue plasminogen activator (tPA), so as PAI-1 levels fall, tPA activity 
increases and hyperfibrinolysis occurs.  
 
Figure 3-1 Protein C pathway causing anticoagulation (inhibition of FV and VIII, and fibrinolysis 
(removal of PAI-1 inhibition of tPA on plasminogen) (reproduced from (Brohi et al., 2007a)) 
 
Supporting this theory is the fact that FV levels are consistently low in those 
with ATC representing inactivation by the aPC pathway (van 't Veer and Mann, 
1997; Cella et al., 1996; Jansen et al., 2011; Yuan et al., 2007; Haywood-
Watson et al., 2011; Woolley et al., 2013). Patient studies (Johansson et al., 
2008; Brohi et al., 2003; Frith et al., 2010; Davenport et al., 2011; Jansen et al., 
2011; Niles et al., 2008), as well as animal studies (Faller, 1999; Doran, 2012), 
have demonstrated that as shock worsened, as measured by worsening BD, so 
the proportion of coagulopathy increased coupled with a fall in clotting factors. It 
appears that injury severity and hypoperfusion in combination increase the 
amount of ATC. 
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3.4.2 Endothelial Cell Activation 
Superimposed on these immediate changes are the results of endothelial cell 
activation (ECA) as described in section 3.2.6. Thrombin and various cytokines 
cause ECA, an effect that is potentiated by hypoxia and hypoperfusion. Hypoxia 
causes a fall in cAMP levels with alterations in intracellular signalling. This leads 
to increases in adhesion molecules with neutrophil recruitment and adherence, 
exocytosis of Weibel-Palade bodies and reduction in nitric oxide. This results in 
a proinflammatory, vasoconstricted state (Michiels et al., 2000).  This effect is 
worsened if the hypoxia and hypoperfusion are allowed to continue with 
inadequate or in appropriate resuscitation. As the endothelial cell changes from 
antithrombotic to prothrombotic, there is a switch from a net production of tPA, 
to a net production of PAI-1. This process is effected by Egr-1, a transcription 
factor present in activated endothelial cells after hypoxia (Ten and Pinsky, 
2002). PAI-1 supresses fibrinolysis and, combined with suppression of 
thrombomodulin, causes a prothrombotic state. The timing of this switch is 
unclear, it may occur much sooner than previously thought, i.e. in a matter of 
hours rather than days. It may help to explain the hypercoagulability of patients 
after trauma as the initial effects of fibrinolytic activation, responding to TXA, are 
replaced with fibrinolytic shutdown (Curry et al., 2012). 
3.4.3 Inflammation, Tissue, endothelial cell and glycocalyx degradation 
Traumatic injury is a strong inducer of inflammation and the systemic 
inflammatory response syndrome (SIRS) is common after significant traumatic 
injury. SIRS causes endothelial and complement activation (Ganter and Hofer, 
2008a; Gando et al., 2002; Lenz et al., 2007). The immune response senses 
danger through pattern-recognition receptors (PRRs) such as the toll like 
receptors (TLRs) on immune cells and the endothelium. Recognition of 
pathogen associated molecular patterns (PAMPs), derived from 
microorganisms, and damage associated molecular patterns (DAMPs) or 
alarmins, produced from stressed or damaged cells by TLRs causes 
upregulation of inflammation. DAMPs are produced in response to trauma, 
haemorrhagic shock and ischaemia/ reperfusion (Gando et al., 2011). Both 
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DAMPs and PAMPs have the ability to elicit the inflammatory response, which 
in turn stimulates coagulation pathways (Levi and Van Der Poll, 2010).  
 
TNFα and IL1b, released as part of the inflammatory response, induces TF 
expression on microparticles endothelial cells and monocytes (Levi et al., 2002). 
Pro inflammatory cytokines IL-6, IL-1, IL-12 and TNF all cause an increase in 
TF expression, increasing thrombin production. Tissue factor in turn can affect 
the levels of IL-6 and IL-8 whilst thrombin generation will induce monocyte 
production of TNF-α, IL-1 and IL-6.  
 
High-mobility group box-1 (HMGB1) is a newly recognised "danger signal", that 
is released after ischaemia reperfusion injuries, by necrotic cells and by 
activated immune cells. HMGB1 signals via the receptor for advanced glycation 
end-product (RAGE) and members of the toll-like receptor (TLR) family (Volz et 
al., 2010).  
 
Recent studies at the Defence Science and Technology Laboratory (DSTL) in a 
porcine blast/haemorrhage model have demonstrated an increase in HMGB1 
expression in animals that were hypotensively resuscitated. It has been 
suggested that HMGB1 and RAGE may initiate and sustain the inflammatory 
response (Kirkman et al., 2011). Follow up work also in a pig blast and 
haemorrhage model investigated the effect of resuscitation strategies on the 
development of ATC and systemic inflammation (Doran, 2012). They found that 
animals resuscitated with targeted fluid resuscitation, after 60 mins, to 
normotension rather than hypotension, had longer survival, lower prothrombin 
times, less severe base deficit and lower peak levels of IL-6. The suggestion is 
that reversal of tissue hypoxia and hypoperfusion modulates the inflammatory 
response after blast and haemorrhage. 
 
Johansson et al looked at the glycocalyx and inflammatory response to trauma 
in a number of recent studies (Johansson et al., 2011a; 2013; 2012) and linked 
tissue damage with high catecholamine levels, increased inflammation and 
increased coagulopathy.  
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The first study (Johansson et al., 2011a) looked at glycocalyx degradation 
(syndecan-1), inflammatory markers (IL-6, IL10), DAMPS (HMGB1, histone 
complexed DNA fragments), natural anticoagulation (TM, PC, TFPI, AT), 
fibrinolysis (D-Dimer, tPA and PAI-1) and catecholamine levels in 75 patients in 
three ISS bins (<16, 16-27 and >27) admitted to a level 1 trauma centre. He 
related these finding to syndecan-1 levels as a marker of glycocalyx 
degradation and divided the groups into those with high syndecan-1 levels (≥ 
median) or low syndecan-1 levels (< median). He found that those with high 
syndecan-1 levels also had higher catecholamines, inflammatory markers, 
DAMPS, TM, fibrinolysis and a higher mortality (42% vs 14%). 
 
In the second study (Johansson et al., 2012), recruited 80 patients admitted to a 
level 1 trauma centre as part of the Activation of Coagulation and Inflammation 
after Trauma 3 (ACIT3) trial between March and November 2010. He looked at 
link between soluble CD40L (a platelet derived mediator that links inflammation, 
haemostasis and vascular dysfunction) and similar markers to the first study 
(endothelial damage, adrenal stimulation, coagulation, inflammation and 
mortality).  He found that when stratified for sCD40L (high sCD40L > median, 
low sCD40L ≤ median), there is an increase in ISS, tissue and endothelial 
damage, adrenal stimulation, coagulopathy (reduced thrombin generation, 
prolonged aPTT), hyperfibrinolysis and inflammation. 
 
The third study (Johansson et al., 2013) looked at the association of tissue 
damage (increased histone complexed DNA fragments (hcDNA)) to trauma 
induced coagulopathy, inflammation and endothelial damage. This was 
performed in 80 patients recruited to the ACIT3 trial between March and 
November 2010.  Patients were stratified to those with high and low hcDNA 
levels. The results are similar to previous studies in that high hcDNA relates to 
increased endothelial damage, increased inflammation, coagulopathy and 
increased glycocalyx degradation. Unlike the previous studies, however, there 
was an association between high hcDNA and increased TFPI levels. There was 
also increased platelet activation with an associated reduction in thrombin 
generation with a prolonged aPTT. 
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Whilst these three studies broadly say the same things, increased trauma leads 
to increased tissue damage, increased sympatho-adrenal stimulation, 
inflammation, coagulopathy, natural anticoagulation and glycocalyx disruption, 
the third study leads Johansson to speculate that nucleic acids can be potent 
activators of the contact pathway of coagulation and platelets and affect natural 
anticoagulant pathways. 
3.4.4 Fibrinolysis 
Fibrinolysis has a key role in ATC, although opinion remains divided to the 
pathophysiology behind it. Some clinicians agree with Brohi et al and think that 
fibrinolysis is driven by an exaggerated aPC pathway mediated by increased 
TM release from the hypoxic vascular endothelium (Brohi et al., 2008).Others, 
including Gando, believe that the increase in fibrinolysis is due to DIC. Gando 
divides fibrinolysis into primary and secondary. Primary fibrinolysis occurs via 
the aPC pathway without activation of coagulation. Secondary fibrinolysis is the 
normal response to clot formation and is activated by the presence of thrombin. 
In DIC the associated increase in fibrinolysis is, in fact, secondary fibrinolysis 
rather than primary fibrinolysis and so Gando believes that the fibrinolysis seen 
in ATC is a normal physiological response (Gando et al., 2011). 
 
Regardless of the cause of fibrinolysis, it is well accepted that the presence of 
fibrinolysis correlates with transfusion requirement and mortality (Kashuk et al., 
2010; Levrat et al., 2008; Sawamura et al., 2009; Schöchl et al., 2009; 2010).  
 
A large multinational randomised controlled trial with over 20,000 patients 
therefore investigated the use of tranexamic acid (a treatment for 
hyperfibrinolysis) in trauma (CRASH-2 trial). It demonstrated a 9% reduction in 
mortality in bleeding trauma patients (CRASH-2 trial collaborators et al., 2010). 
A retrospective study of the use of tranexamic acid in UK Military data also 
supported this finding (Morrison et al., 2012). However, the effect appears to be 
greatest when given in the first 3 hours after trauma. After 3 hours there is little 
benefit and possible harm (CRASH-2 collaborators et al., 2011). 
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After a period of prolonged endothelial activation, the activated endothelium 
produces increased amounts of PAI-1, inhibiting tPA action on plasminogen and 
decreasing fibrinolysis. This is a postulated mechanism for hypercoagulopathy 
post trauma (Selby et al., 2009; Curry et al., 2012). It is possible that this 
”switch” occurs early in trauma; hence TXA administration after 3 hours might 
be harmful. 
3.4.5 Implications for treatment of ATC 
The important implication from the Brohi study (Brohi et al., 2008) is that if ATC 
exists as a result of activation of the thrombomodulin-protein C pathway 
secondary to tissue hypoperfusion, then there is no failure of thrombin 
generation. Treatment of ATC would require reversing tissue hypoperfusion 
rather than simply treatment with blood component therapy. If Gando’s DIC 
hypothesis is true, (Gando et al., 2011) then early reversal of shock is the key to 
minimising primary fibrinolysis, minimising the ischaemia reperfusion injury. 
Treatment of the DIC is by replacing the factors lost during the consumptive 
phase and supporting the coagulation system as it rebalances anticoagulation, 
coagulation and fibrinolysis. Importantly both theories presume normal thrombin 
generation, the coagulopathy is an imbalance in haemostasis rather than a 
reduced factor activity and failure to produce clot. 
 
The different mechanisms causing TIC have different implications for potential 
management strategies at different time points during the resuscitation of the 
trauma patient. Initially it may be that ATC is related to hypoperfusion not 
abnormal clotting pathways or deficiencies in normal coagulation. Later on the 
process may be driven by consumption or dilution. This may mean that the 
treatment goals are different depending on the underlying mechanism involved 
at that particular time point (Midwinter and Woolley, 2011). Initial resuscitation 
may need to emphasise tissue oxygenation. It has been shown that early 
supplementary oxygen after blast injury and haemorrhage improved survival 
when a hypotensive resuscitation strategy was employed in an animal model 
(Granville-Chapman et al., 2010). Component therapy in the presence of tissue 
hypoxia might potentially worsen hyperfibrinolysis by increasing the available 
thrombin to conjugate with thrombomodulin, driving aPC production (Midwinter 
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and Woolley, 2011). Therefore initial hypotensive resuscitation, if it leads to 
significant critical tissue hypoperfusion and hypoxia, could exacerbate ATC. 
 
Once a major trauma casualty arrives in hospital, the requirement for 
hypotensive resuscitation may no longer be pertinent if systems allow access to 
the rapid control of major surgical haemorrhage, as the concern over disruption 
of native clot will no longer pertain (Spahn et al., 2013). Fluid and targeted 
therapy should be used in order to reverse tissue hypoxia and restore 
haemostasis. This is not always a trivial objective and requires the ability to 
closely monitor the patient’s tissue oxygenation and coagulation status and 
changes that occur in these parameters as resuscitation, including surgical 
manoeuvres, proceed. This requires clinically informed, real-time patient 
monitoring and evaluation in order to manage the transition through the 
resuscitation process including surgical haemorrhage control (Gruen et al., 
2012). 
3.5 Definitions of coagulopathy 
Definitions of coagulopathy have been well established in the literature, and 
include Abnormal PT/ aPTT, PT >18 seconds, aPTT>60 seconds (Hewitt and 
Machin, 1990; Lundberg, 1994),  PT ratios> 1.5 times normal (Hoyt et al., 
2008), low platelet count and abnormal INR’s (Sauaia et al., 1995). There is no 
consensus for what criteria should be used in the diagnosis of ATC. Different 
peer reviewed papers use different definitions. In the pivotal papers describing 
the presence of ATC, Brohi et al used a definition of PT or aPTT of 1.5 times 
normal (Brohi et al., 2003). MacLeod’s follow up paper from the US used an 
abnormal PT or aPTT as their definition of coagulopathy (MacLeod et al., 2003), 
whilst Maegele used a PT<70% normal and a platelet count <100 x109/l 
(Maegele et al., 2007). 
 
Not only do definitions differ, but also the clinical significance of abnormal 
values. An abnormal number does not necessarily mean a clinical problem.  A 
patient arriving at hospital who was previously well and suffered trauma who 
has an INR of 1.5 is deemed to be coagulopathic and at increased risk of dying. 
A patient who is on therapeutic warfarin therapy with an INR of 1.5 is deemed 
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not coagulopathic enough. Definitions of coagulopathy do not take into account 
the clinical scenario. 
 
Recently some groups have challenged these definitions of coagulopathy and 
have tried to relate the abnormal number with a clinical significance (Frith et al., 
2010; Davenport et al., 2011). A retrospective multicentre cohort study looked at 
patients from five trauma registries in London, Germany, Amsterdam, Oslo and 
San Francisco. Since each centre had different assay methods and reagents for 
PT, the PT ratio (PTr) was used.  If standard definitions of coagulopathy had 
been used, a PTr of 1.5, then overall 19% of patients were coagulopathic, 
whereas 36% had a PTr of grater than 1.2. A significant increase in mortality 
and transfusion requirement was seen at a PTr of 1.2 and the authors suggest a 
PTr of 1.2 to be diagnostic of ATC (Frith et al., 2010). 
3.5.1 Definitions of Coagulopathy with Viscoelastic methods 
Accepting that the practical use of PT, aPTT in trauma for clinical decision 
making is limited (section 4.2.4) some effort has been focussed on using 
ROTEM®/ TEG® to determine the presence of coagulopathy, and to see if its 
rapid assessment can aid decision making (Johansson et al., 2009; Doran et 
al., 2010). Since the use of ROTEM®/TEG® in trauma is relatively recent, there 
are no formally accepted definitions of coagulopathy using ROTEM®/TEG® 
parameters (Curry et al., 2012). This makes the incorporation of 
ROTEM®/TEG® into standard protocols that can be used by the non-expert 
clinician difficult. 
 
Davenport et al (Davenport et al., 2011) performed a prospective observational 
study on 300 patients arriving at the Royal London Hospital between Jan 2007 
and Jun 2009. Main laboratory and point of care (POC) PT as well as ROTEM® 
parameters were collected. They adopted the definition of Frith et al (Frith et al., 
2010) that a PTr of >1.2 was diagnostic of ATC.  
 
POC PT did not correlate well with lab PT in those cases of ATC and had a 
29% false negative rate. ROTEM® amplitude at 5 mins (CA5) of <35mm were 
more likely to receive red cell and plasma transfusions and had a 77% detection 
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rate of ATC with a 13% false positive rate. Compared to PT, ROTEM® was 
better at determining those likely to receive massive transfusion (71% vs 43%). 
However the positive predictive values for PT and ROTEM were low. The 
authors concluded that there was a ROTEM® trace characteristic of the 
presence of ATC. 
3.5.2 Military experience of ROTEM® 
UK DMS deployed ROTEM® to Bastion for the first time in Jan 2009 and 
demonstrated that the machine was robust enough withstand field conditions, 
and detected more abnormalities than standard laboratory testing (Doran et al., 
2010). As yet there is no published data on any definition of coagulopathy in 
military trauma as determined by ROTEM®. 
 
Thus definitions of coagulopathy remain variable with little clinical application in 
acute haemorrhage. Point of care tests may be able to provide more useful 
results in the context of acute trauma coagulopathy Their role, however, is likely 
to be limited to evaluating changes, trends and responses to interventions until 
exact definitions of ATC can be determined. It is unlikely that any test will 
replace the clinical assessment of the patient and the clinical scenario at the 
time of testing. 
3.6 Summary 
Coagulopathy after trauma is complex, and remains poorly understood. There is 
little doubt that up to a third of civilian trauma patients arrive in hospital 
coagulopathic, and their outcomes are worse than those who arrive without 
coagulopathy. The rates of coagulopathy are likely to be worse in the military 
environment. The pathophysiology remains uncertain. Fibrinolysis is a key 
component, however differences in opinion exist as to the role that 
consumption, DIC and natural anticoagulation have in the development of acute 
trauma coagulopathy. It is increasingly accepted that the likely driver of the 
pathophysiological process is microcirculatory shock due to inadequate tissue 
oxygen delivery, which in turn leads to activation of the vascular endothelium, 
although its role is yet to be determined fully. 
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Individualising the treatment of coagulopathy has important implications in 
resuscitation, appropriate blood use and patient safety. This is even more 
important in a resource limited military environment. Before we target therapy, 
we must be able to detect the presence of coagulopathy in clinically relevant 
time lines. The following chapter will discuss the methods of assessing 
coagulation in research and clinical settings. 
  39 
Chapter 4.  Assessment of Clotting 
Coagulation is a highly complex interaction of enzymes, factors, cells and 
proteins. Like all biological systems, it is possible to measure all, or most, of 
these individual factors in isolation. However in a clinical setting, especially in 
an on-going haemorrhage situation, specific factor assays are not appropriate 
and global tests of coagulation are required.  
4.1 The ideal test 
The ideal test would provide an in vivo assessment of which component of the 
clotting process is at fault, i.e. clot initiation, platelet function, factor function or 
fibrinolysis. It should be reproducible by non-technical persons, rapidly available 
and be sensitive and specific. Recommended screening tests in trauma (Doran 
et al., 2010; Rossaint et al., 2010; SGOPL 0809, 2009) include the INR, aPTT, 
fibrinogen and platelets. European guidelines also suggest the use of 
thromboelastometry to characterise coagulopathy and to guide haemostatic 
therapy (Spahn et al., 2013).  
 
No one test, including the recommended tests, fulfils all the required criteria for 
the ideal test, although in combination a representative clinical picture can be 
built up. 
4.2 Routine laboratory testing. 
4.2.1 Activated Partial Thromboplastin Time and Prothrombin time. 
Commonly the activated partial thromboplastin time (aPTT) and prothrombin 
time (PT) are performed together. Both tests were originally designed to aid the 
diagnosis of inherited bleeding disorders, such as haemophilia, however its use 
has migrated to that of routine screening. Whilst it is generally accepted that the 
traditional clotting cascade of the intrinsic and extrinsic pathway is no longer 
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represents the situation in vivo, it is still useful in describing how PT and aPTT 
detect coagulopathy.  
4.2.2 aPTT 
The aPTT test activates the intrinsic pathway by using contact activators such 
as kaolin, silica or ellagic acid. These activators bind directly to FXII resulting in 
surface activation to FXIIa and on-going clot formation. The aPTT test utilises 
platelet poor plasma, at 37 degrees with the addition of calcium. The aPTT 
represents the time taken for clot to start to form, i.e. initiation, and provides no 
measurement of clot strength or clot stability. It detects deficiencies in the 
intrinsic pathway, FVIII, FIX, FXI, FXII, and the final common pathway, FII, FV, 
and FX.  Mild deficiencies, up to 40% of factors, will still produce a normal aPTT 
4.2.3 PT 
The PT test activates clotting via the extrinsic pathway using tissue factor 
(normally thromboplastin from brain tissue). This binds to factor VII forming a 
TF-VIIa complex that activates the final common pathway. Like the aPTT test it 
also uses platelet poor plasma at 37 degrees with the addition of calcium. The 
PT, like the aPTT, represents the time taken for clot to start to form, i.e. 
initiation, and similarly provides no measurement of clot strength or clot stability. 
The test detects deficiencies in the extrinsic pathway, FVII, and the final 
common pathway, FII, FV, and FX. Mild deficiencies, up to 40% of factors, will 
still produce a normal PT 
 
In 1977 the Word Health Organisation released a standardised preparation of 
thromboplastin allowing the PT to be expressed as an International normalised 
ratio (INR). The INR is the standard test used to measure warfarin therapy. 
4.2.4 Limitations of PT and aPTT 
It is increasingly accepted that PT and aPTT are not useful in screening for, or 
detecting clinically significant abnormalities during acute haemorrhage 
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(Davenport et al., 2011; Johansson et al., 2009). This is for two main reasons, 
firstly processing up to 45 minutes (Doran et al., 2010), making the result is 
historic by the time it is available (Brohi, 2009; Segal et al., 2005; Curry et al., 
2012; Toulon et al., 2009) and secondly PT and aPTT do not measure the 
whole clotting process or the elements that are responsible in TIC mechanisms 
(Rossaint et al., 2010; Brohi, 2009; SGOPL 0809, 2009). Plasma does not 
contain phospholipid membrane (platelets or microparticles) and the tests do 
not assess the thrombin potential of the sample. 
 
There are rapid, point of care PT measuring devices. Davenport et al (Solomon 
et al., 2011; Davenport et al., 2011) compared one such machine, 
coagulocheck®, to laboratory PT tests in a series of trauma patients attending 
the Royal London Hospital. He found a good correlation between 
coagulocheck® and the laboratory for normal samples, however the accuracy of 
POC testing falls off as the PT prolongs and the haematocrit falls and would be 
of limited use in the trauma setting. 
 
The PT is run in platelet poor plasma, and thus not physiological, and only gives 
information of the time taken for clot initiation and does not represent clot 
strength, clot dynamics (the speed and efficiency at which the clot is 
developing), clot stability or fibrinolysis. The tests are also designed to detect a 
fall in coagulation factors to <30 – 40%. In a trauma situation, where trends are 
important, a clinician needs to know there is a developing problem before levels 
of clotting factors have fallen to as low as 40% of normal. In this context PT and 
aPTT are not sensitive enough to give reliable clinical information during acute 
haemorrhage. 
 
Abnormalities in PT and aPTT are still recognised as one definition of 
coagulopathy and there is reluctance to fully embrace other coagulation 
monitors, such as ROTEM® and TEG®, until formal definitions can be 
produced (De Caterina et al., 1994; Brohi, 2009; Curry et al., 2012). In spite of 
their clinical limitations, PT and aPTT are still routinely performed in many 
institution’s trauma blood panels, especially since as a retrospective tool they 
are still the only formal definitions of coagulopathy that can be used to compare 
populations. 
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4.2.5 Platelet count 
Platelets are integral to coagulation and for a clot to form a minimum number of 
functioning platelets is required. New European and Defence Medical Services 
(DMS) guidelines state that in a bleeding patient platelet numbers should be 
kept greater than 100x109/l (Spahn et al., 2013; Joint Service Publication 999, 
2012). However, the platelet count does not take into account platelet function. 
Since the DMS started using ROTEM® in Afghanistan there has been some 
speculative evidence that platelet function may be particularly affected after 
blast trauma. Recent reports (Doran et al., 2010; Davenport et al., 2011; Jansen 
et al., 2013) have highlighted abnormalities in platelet activity after trauma in 
spite of adequate platelet numbers, although the exact mechanism is yet to be 
determined.  
 
ROTEM® will give an indication of platelet activity and recent interest in the use 
of multiplate as a measure of platelet aggregation may add an extra dimension 
to the understanding of platelet activity after trauma (Ganter and Hofer, 2008b; 
Foex, 1999; Solomon et al., 2011; Hett et al., 1995). We are becoming 
increasingly aware of the highly influential role platelets and microparticles have 
in clotting, inflammation and wound healing. Platelet function, rather than 
absolute number, is key for these processes to occur. 
4.3 Whole blood assessment of clotting 
Since the cellular components of blood are required for coagulation, it is 
reasonable to have coagulation tests that assess all the components of blood, 
namely the clotting factors, and the cells.  
4.3.1 The Bleeding Time 
Historically clotting has been assessed by the bleeding time (Foex, 1999; 
Hewson et al., 1985; De Caterina et al., 1994). The bleeding time is an 
assessment of platelet function. It involves a standard incision to the upper arm 
below a blood pressure cuff inflated to 40mmHg. Filter paper is used to blot the 
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edges of the wound every 30s until bleeding stops. Normal values are 2 to 9 
minutes. This is an in vivo test of the whole process of clot formation, and is no 
longer routinely practised due to difficulties in standardisation and inter-user 
variability.  
4.3.2 Activated coagulation time (ACT) 
The ACT is measured by adding fresh whole blood to a test tube containing 
negatively charged surfaces (celite, kaolin or glass). The test tube is placed into 
a warmed rotating device. A small magnet is displaced, once enough clot has 
formed, which activates a proximity switch. Clinically the test is used to assess 
adequacy of heparin effect, but results may be prolonged due to hypothermia, 
platelet dysfunction, “intrinsic” factor deficiencies or hypofibrinogenaemia. 
 
Both the bleeding time and the ACT may well give a global picture of clotting 
function, however any abnormality does not provide information of the specifics 
of what is wrong. In addition, the bleeding time is impractical during an acute 
haemorrhage situation.  
4.3.3 Viscoelastic methods 
The viscoelastic method of detecting clot formation is a technique invented in 
1948 with the thromboelastography machine, the TEG®. This measures the 
viscosity of whole blood from clot initiation through to clot lysis. A refinement of 
this method, rotational thromboelastometry (ROTEM®) is a recent, more 
modern and robust equivalent. Due to legal issues ROTEM® and TEG® have 
different terminologies for the same parameters, these are outlined in Table 4-2. 
The British Military have adopted ROTEM® as its viscoelastic method of choice 
since it is more robust in an austere environment due to the measurement pin 
mounted on sapphire ball bearings rather than a freely suspended wire (see 
section 4.4 and 4.5) 
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4.4 ROTEM® 
The ROTEM® works by measuring the change in torque of a rotating pin as clot 
forms. A pin mounted on sapphire ball bearings, is inserted into a cuvette of 
340µl of blood and the appropriate initiators are added following the on screen 
instructions on the machine. The blood is maintained at 37°C and the test 
initiated (TEM, 2010). The pin rotates back and forth and as clot begins to form 
between the walls of the cuvette and the pin, pin movement is inhibited. Using 
optical sensors, the degree of pin movement inhibition is graphically displayed 
and various parameters are calculated.  
4.4.1 ROTEM® parameters: 
A classical ROTEM® trace (TEMogram) is depicted in Figure 4-1. It is divided in 
to certain routinely measured parameters 
 
Figure 4-1. Illustration of a TEMogram showing routinely measured parameters. (Figure taken 
from TEM® training material.) 
 
Clotting Time (CT):  
This is the time taken, in seconds, from the start of activation to the initial clot 
formation once the amplitude reaches 2mm on the trace. This relates to clot 
initiation and initial thrombin production. Any prolongation of CT is due to factor 
deficiency (including severe hypofibrinogenaemia) or the presence of 
anticoagulants. 
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Clot Formation Time (CFT):  
This is the time taken, in seconds, from CT until amplitude of 20mm is reached. 
This represents a measure of the rate of clot formation, or clot dynamics, and is 
dependant on fibrinogen, platelet and factor interactions. 
 
α angle: This is the angle from the centre line and a tangent to the curve at the 
2mm point. This is another representation of clot dynamics 
 
Maximum Clot Firmness (MCF):  
This is a measurement of the maximum amplitude, and therefore maximum 
strength of the clot. It is determined by the amount of functioning platelets and 
fibrinogen available for clot formation. Any loss in MCF indicates a deficiency in 
functional fibrinogen or platelets. Deficiencies in platelets will either be a 
quantitative or qualitative deficiency. The MCF may well take many minutes to 
be available. The amplitude at various time points after CT (AX where X = time) 
are routinely reported. The firmness at A5 (5 mins) and A10 (10 mins) have 
been reported to be useful in trauma (Davenport et al., 2011). 
 
Maximum Lysis (ML):  
Any reduction in clot firmness after MCF is due to loss in clot integrity. The ML 
is the maximum lysis at the end of the test. If the test is run for 60 mins, then 
any ML>15% represents hyperfibrinolysis, although this is an arbitrary value 
(Curry et al., 2012).Since test may be run for variable length of times, it is more 
usual to use the lysis index. LY30 represents lysis index at 30 mins and is the 
percentage of clot remaining compared to MCF. An LI30 <94% or an LI60<85% 
indicates hyperfibrinolysis. 
4.4.2 ROTEM® tests 
 If blood was simply added to the cup and allowed to clot, it would take many 
hours to produce a result (NATEM). This may well be very sensitive to subtle 
changes in coagulation, but of limited use clinically. In order to speed up the 
process, and to allow specific components of the clotting process to be 
examined, a number of initiators and inhibitors are added to the blood sample. 
These are summarised in  
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Table 4-1. Comparison of assessment tests of ROTEM® and TEG®, the activating/inhibiting 
additive and the information being assessed.  
 
ROTEM® 
Information 
Provided 
TEG® 
Test Activator/ Inhibitor   Test Activator/ Inhibitor 
EXTEM 
Recombinant Tissue 
Thromboplastin 
(Tissue Factor) 
Assesses factors 
VII, X, V, II, I, 
platelets and 
fibrinolysis 
  
  
Assesses all 
factors, platelets 
and fibrinolysis 
Rapid TEG TF- Kaolin 
INTEM Ellagic acid 
Assesses factors 
XII, XI, IX, VIII, X, 
V, II, I, platelets 
and fibrinolysis 
Sensitive to 
heparin 
Kaolin 
Kaolin (hydrate 
aluminium silicate) 
FIBTEM 
Activated as 
EXTEM. Platelet 
function inhibited by 
Cytochalasin D 
Assesses 
fibrinogen levels 
and fibrin 
polymerisation 
Functional 
Fibrinogen 
TEG 
TF + abciximab 
(ReoPro®) 
APTEM 
Activated as 
EXTEM. Aprotinin 
inhibits fibrinolytic 
processes 
Confirms presence 
of fibrinolysis 
  
HEPTEM 
Ellagic Acid and 
Heparinase 
Determines if 
prolonged clot 
initiation is due to 
heparin or not. 
Heparinase Kaolin + Heparinase 
NATEM Calcium only added 
Allows very 
sensitive 
assessment of 
coagulation 
activation or 
inhibition – mainly 
for in-vitro 
experimentation 
  
  47 
The standard test is the EXTEM, where tissue factor is added to initiate the clot 
via the extrinsic pathway, the intrinsic equivalent is the INTEM where a contact 
activator is used (Figure 4-2).  
 
Figure 4-2. Normal EXTEM and INTEM traces 
The EXTEM analysis can be used in conjunction with the FIBTEM. The FIBTEM 
has TF activation in the same way as EXTEM, however with the addition of a 
platelet inhibitor. Since clot strength (MCF) is determined by functioning 
platelets and fibrinogen, comparison of EXTEM MCF (PLT and fibrinogen) and 
FIBTEM MCF (fibrinogen) can give an estimate of the relative contributions to 
the clot strength of platelets and fibrinogen. 
 
Figure 4-3. Normal EXTEM and FIBTEM traces 
 
In Figure 4-3 the EXTEM MCF is 57mm and in normal limits. The FIBTEM MCF 
is 10mm and in normal limits. It has been suggested that as an approximate 
guide the platelet contribution of the clot is EXTEM MCF – FIBTEM MCF = 
40mm in this case. This view is unsubstantiated, but as a clinical guide is a 
useful concept. 
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The APTEM uses EXTEM activation with the addition of aprotonin. Since 
aprotonin reverses hyperfibrinolysis, any differences between APTEM and 
EXTEM are due to hyperfibrinolysis and should be treated if not already done 
so  
In Figure 4-4.the EXTEM trace has formed a clot with an MCF of 48mm, 
however after about 20 minutes the clot begins to lose strength and by 30 
minutes has an LY30 of 0%. Comparison with the APTEM, which shows a 
return to normal with no loss of clot strength, confirms that the loss in clot 
strength is due to hyperfibrinolysis. 
  
In Figure 4-5 the CT in INTEM is very prolonged. Since this effect is reversed in 
the HEPTEM, the abnormality is solely due to heparin effect. 
 
In 2009 The DMS underwent an evaluation of ROTEM® in Afghanistan and 
concluded that ROTEM® was a useful tool (Doran et al., 2010). Since the 
machine itself has 4 channels, and since INTEM was found to be abnormal only 
Figure 4-4. EXTEM trace shows loss of clot strength, which is returned in APTEM confirming 
hyperfibrinolysis 
Figure 4-5. INTEM trace shows a long CT, which is reversed in HEPTEM confirming heparin 
effect 
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when EXTEM was abnormal, it was decided that the routine screening test 
would be EXTEM and FIBTEM. This allowed the second pair of channels to be 
made available either for a second patient, or a second sample on the same 
patient. 
4.5 TEG® 
The TEG® works by measuring the change in tensile strength of the clot as it 
forms, in a similar way as ROTEM®. The major difference in TEG® is that the 
cup rotates round a freely suspended torsion wire, rather than the reverse in 
ROTEM®. This makes the TEG® susceptible to knocks and movements, which 
tends to cause the test to fail, and as such TEG® is not suitable for use in an 
austere military environment. As clot forms between the cuvette and the wire, 
the change in torsion reflects the clot strength.  
 
TEG® analysis is performed in a standard way. 360µL of whole blood is added 
to TEG® cuvette with the appropriate initiator. The cuvette is then raised in its 
carrier and the test initiated (Haemoscope, 2007). A classical TEG® trace is 
depicted in 
Figure 4-6 
 
 
Figure 4-6. Illustration of a routine TEG® trace with routinely measured parameters 
r time R-time 
k time K-time 
α Alpha angle 
MA Maximum amplitude 
A60 Amplitude 60 min 
after R-time 
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4.5.1 TEG® parameters 
Terminology is different, although the measured parameters are the same (see 
Table 4-2). Clot initiation is measured as the r-time, clot strength as maximum 
amplitude (MA) with amplitudes at timed intervals, commonly CA30 and CA60. 
The dynamic portion of clot formation is measured by the K-Time and the alpha 
angle. The clot should remain at, or nearly at full strength for longer than the 
standard 60 minutes of the test, however any significant loss in strength 
(reduction in MA) is due to excess clot breakdown, hyperfibrinolysis. 
Comparison with ROTEM parameters is made in Table 4-1. 
 
Table 4-2. Comparison of ROTEM® and TEG® terminology 
TEG ROTEM Description of parameter Parameter interpretation 
R 
Reaction 
time (sacs) 
CT 
Clotting Time 
(secs) 
Time from start of sample run 
to appearance of first 
detectable clot (amplitude of 
2mm) 
Initiation phase 
Lag-phase of thrombin 
generation (dependent on 
activity of coagulation 
factors) 
K 
(secs) 
CFT 
Clot 
Formation 
Rate (secs) 
Time from R or CT until level 
of clot firmness reaches 
20mm 
Amplification phase 
Initial clot strengthening by 
formation of fibrin fibres 
α-angle 
(degrees) 
α-angle 
(degrees) 
Kinetics of clot development - 
angle between centre line 
and tangent to the curve 
through the 2mm amplitude 
point 
Thrombin burst 
Maximum velocity of clot 
formation (dependent on 
platelet function and fibrin 
polymerisation) 
Ax 
Clot 
Amplitude 
(mm) 
Ax 
Clot 
Amplitude    
(mm) 
Mechanical clot quality at 
fixed time point e.g. 10 
minutes (CA10) 
Propagation phase 
Clot strength at fixed time 
point determined by 
platelets, fibrinogen and 
Factor XIII 
MA 
Maximum 
Amplitude 
(mm) 
MCF 
Maximum 
Clot 
Firmness 
(mm) 
Mechanical clot quality 
Maximal clot strength – 
determined by platelets, 
fibrinogen and Factor XIII 
CLx 
(%) 
LYx 
(%) 
Ratio of the amplitude to 
MA/MCF at a given time point 
after R/CT 
Clot termination 
Percentage clot lysis at 
fixed time e.g. 30 minutes 
(CL30, LY30) 
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4.5.2 TEG® tests 
A number of initiators and inhibitors are added to the sample. And are 
summarised in Table 4-1 
 
The standard TEG® uses kaolin as an initiator and effectively gives an 
equivalent to INTEM. Rapid TEG uses tissue factor as an initiator and it is 
possible to use these tests in conjunction with heparinase containing cuvettes, 
to measure heparin effect. Functional Fibrinogen is measured by the addition of 
ReoPro®  (abciximab) to the sample. This is a platelet inhibitor equivalent to 
FIBTEM. In essence the TEG® results can be interpreted in exactly the same 
way as the ROTEM®. 
4.6 Alternative initiators for ROTEM® and TEG®. 
For research purposes it is possible to use alternative initiators that can 
potentially provide a more sensitive assessment of clotting in either TEG® or 
ROTEM®. A commercially available recombinant tissue factor preparation 
(Innovin®) is used to determine INR and is highly sensitive to deficiencies in 
factor II, VII, IX and X. It is possible to use dilute Innovin® as a more sensitive 
initiator and can be compare to standard TEG® or ROTEM®, especially in 
detecting the effects of rFVIIa (see section 4.7) (Ganter et al., 2008a; Sørensen 
et al., 2003).  
 
4.7 Monitoring of rFVIIa activity 
There is no well accepted monitor of rFVIIa therapy (Lin et al., 2011; Pusateri 
and Park, 2005). PT and aPTT do not always fully reflect clinical effectiveness. 
Dutton et al (Kenet et al., 1999; Dutton et al., 2004) noted that 78/78 patients 
had improved PT after administration of rFVIIa, but not all of them had a clinical 
improvement in bleeding.  
 
Recently there has been renewed interest in using dilute TF (Innovin) test on 
ROTEM® or TEG® to monitor rFVIIa therapy. The rationale for the use of dilute 
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Innovin as a reagent for TEG® analysis comes from the presumption that the 
increased sensitivity is likely to detect subtle, but important changes not seen in 
the standard TEG®, ROTEM® or PT. 
 
PT and ROTEM® are designed so that the amount of tissue factor used 
overwhelmingly activates all the clotting factors present in the sample.  In vivo 
however visible fibrin clot develops after only 3-5% of total thrombin is 
produced, the remaining 95% of thrombin production occurring after clot 
formation has started (Dutton et al., 2004; Young et al., 2013; O'Neill et al., 
2002; Martinowitz et al., 2001).  
 
Sørensen and colleagues tested whole blood and platelet rich plasma with 
different concentrations of tissue factor on ROTEM®. The authors found that as 
the concentration of TF decreased, so clotting time and clot dynamics 
increased, whereas clot strength remained unaffected (Boffard et al., 2005; 
Sørensen et al., 2010). 
 
In another study Sørensen and colleagues looked at ROTEM® activation using 
different dilutions of TF (diluted from 1:17 to 1:34 000) (Narayan et al., 2008; 
Sørensen et al., 2003). He compared haemophiliacs, who clinically had slow, 
depressed clotting, with normal volunteers. Both groups of patients had identical 
results when high concentrations of TF were used. However lower 
concentrations of TF revealed  
differences between the groups that were commensurate with the clinical 
effects of haemophilia. He found the best dilution to be 1:17 000 providing  
enough initiation to activate the test in a useful time, but sensitive enough to  
detect differences between groups. This is taken as evidence that the dilute 
innovin test is more sensitive to subtle, clinically important changes, compared 
to conventional tests, and is ideal for situations where speed of reporting is not 
essential. 
 
Ganter et al (Ganter et al., 2008b) recommend that to detect the effects of 
rFVIIa, only dilute amounts of TF should be used for best sensitivity since high 
amounts of TF may directly activate coagulation and bypassing the 
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requirements for FVIIa. The authors recommended a dilution of 1:1000 to 
effectively monitor rFVIIa therapy. 
 
4.8 Sonoclot 
Sonoclot is very similar to TEG® and ROTEM®, however it uses a vertically 
vibrating probe to detect changes in viscosity, rather than rotation. Is produces 
a characteristic signature, and determines the time taken for initial fibrin 
formation, rather than the fibrin/platelet bond which is measured in TEG®/ 
ROTEM®. Clot initiation is therefore a reflection of fibrin formation, rather than 
the fibrin/platelet bond. The latter being detected in TEG®/ ROTEM® and more 
comparable to clot strength. There has been speculation as to the 
reproducibility of Sonoclot, and its results appear to be influenced by age/ sex 
and platelet count (Risberg et al., 1986; Ganter and Hofer, 2008a; Hett et al., 
1995). 
4.9 Individual Factor assays 
Individual factor assays are functional measurements of the individual clotting 
factors. To perform a factor assay, sample plasma is diluted with a reference 
plasma deficient in a single factor but with normal amounts of all other clotting 
factors. Mixing the sample plasma with this factor deficient reference plasma 
will correct all factor deficiencies in the patient’s plasma except for the factor 
being tested. The mixed plasma is then serially diluted and tested using a 
prothrombin time. The degree of correction in the clotting time is proportional to 
the amount of factor present in the patient’s plasma. 
4.10 Summary 
There are many ways to detect abnormalities in the coagulation system.  
Clotting is a delicate balance between procoagulant, anticoagulant and 
fibrinolytic pathways, and is intimately related to vascular endothelial function. 
Therefore, any test that is ex vivo and does not look at the whole process of 
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coagulation is limited. In acute haemorrhage situations, results need to be 
available in a very short time frame so that they are useful clinically. 
 
Currently viscoelastic methods, TEG® and ROTEM®, are the closest to the 
ideal test, however both have their limitations. In a military clinical setting 
ROTEM® has proved to be the more useful of these machines principally due to 
the robustness of the measurement module. 
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Chapter 5. Blast 
Blast as a mechanism of military trauma has increased during the current 
conflicts in Iraq and Afghanistan. Recent estimates suggest that up two thirds of 
casualties have exposure to blast (Hodgetts et al., 2007).  Blast is also an 
increasing problem in civilian trauma with recent bombings in London, Madrid 
and the United States of America. 
 
An understanding of the physics and haemostatic changes after blast are 
essential if treatments aimed at modulating them are to be investigated. 
5.1 Classification of blast injuries 
Blast injuries are usually divided into four and occasionally five main categories 
(Kirkman et al., 2011; Champion et al., 2009) primary, secondary, tertiary, 
quaternary and quinary 
5.1.1 Primary Blast injury 
Primary blast injury occurs from the effect of the shock wave depositing energy, 
mainly at gas liquid interfaces. This particularly affects the alveoli (leading to 
blast lung), the bowel and the inner ear. Often the injury leads to no external 
signs. The incidence and extent of injury depends on the duration of exposure 
and the level of the peak over pressure. 
5.1.2 Secondary blast injury 
Secondary blast injury occurs from fragmentation of the device. Tissue 
destruction and loss occur due to the penetrating nature of fragments from the 
device and other particles, such as stones, surrounding the device. 
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5.1.3 Tertiary blast Injury 
Tertiary Injuries are as a result of the blast wind. This causes a sudden and 
dramatic movement of air causing the body to be thrown against objects 
resulting in blunt injury. 
5.1.4 Quaternary and quinary injury 
Quaternary effects are those of burns or crush resulting from the explosion. 
Quinary injuries are as a result of the environmental exposure, such as 
radiation, that may occur following the explosion. 
5.2 Physics of Blast Injury 
An explosion is a chemical reaction liberating vast amounts of energy in the 
form of heat, kinetic energy and shock waves. Detonation causes an 
exponential increase in heat within the explosive increasing the pressure. It 
rapidly releases energy in the form of heat, gaseous products and a blast wave. 
5.2.1 Blast Wave 
The blast wave consists of the shock wave and the dynamic overpressure (or 
blast wind). The shock wave is the front edge and consists of a rim of 
compressed air surrounding an expanding ball of explosive materiel. Within a 
few metres of the explosion, the dynamic overpressure slows down, separating 
from the shock wave, which continues to travel faster than the speed of sound 
(Figure 5-1). 
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Figure 5-1.Shock wave depicted from the main weapon of a warship. The shock wave can be seen with 
the blast wind and finally the flame from the explosion. 
 
If the pressure of the shock wave is measured, there is an almost instantaneous 
rise in pressure, reaching a peak (overpressure), a drop to subatmospheric 
pressure followed by a return to atmospheric pressure. This is known as the 
Friedlander wave Figure 5-2. This wave becomes more complex once inside an 
enclosed space, such as a building, due to the reflective nature of the walls. 
5.2.2 Interaction with the body 
The interaction of the shock wave with the human body is complex and not 
attenuated by the presence of clothing and body armour. At air/liquid interfaces 
the shock wave will cause differential movement of tissues leading to shear 
stresses and tearing of delicate structures. 
 
The primary blast wave will commonly affect the ear, rupturing the tympanic 
membrane, the lungs with the development of blast lung, and the abdominal 
viscera, most often the colon. There is a well documented physiological 
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Figure 5-2. Schematic representation of a shock of pressure magnitude vs time showing the Friedlander 
Waveform pressure changes in a undisturbed, free field environment. 
 
response to blast that shows a biphasic response. There is an immediate 
tachycardia, followed by bradycardia and hypotension (Ohnishi et al., 2001; 
Irwin et al., 1997) which is presumed to be a vagal response (Sawdon et al., 
2002). The bradycardia typically returns to normal after about 15 minutes, 
although the hypotension may persist. These cardiovascular events are coupled 
with immediate and delayed respiratory effects. 
 
The immediate respiratory response is apnoea lasting from a few seconds to 
about a minute, followed by rapid, shallow breathing (Guy et al., 1998). The 
shock wave causes immediate lung injury with rupture of alveolar capillaries 
leading to intrapulmonary haemorrhage and oedema (Damon et al., 1971). This 
will lead to V/Q mismatch and hypoxaemia. This is similar to pulmonary 
contusion from blunt chest trauma (Gorbunov et al., 1997; Brown et al., 1993). 
The presence of blood and haemoglobin in the alveoli leads to free radical 
production and the inflammatory response. There is leucocyte accumulation 
(within 3 hours) followed by epithelial cell damage at 12- 24 hours. Leading to a 
picture similar to the adult respiratory distress syndrome (ARDS) (Gorbunov et 
al., 1997) 
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5.2.3 Blast and Haemorrhage 
Animal studies have demonstrated that blast coupled with haemorrhage (as 
seen in military casualties) causes a profound, and prolonged hypotension 
(Sawdon et al., 2002) that coupled with hypoxaemia will result in poor tissue 
oxygen delivery (Garner et al., 2010). 
 
Rats were exposed to blast or sham blast and underwent a controlled 40% 
blood volume haemorrhage. There was initial tachycardia followed by 
bradycardia in the sham blast group However the blast group did not exhibit the 
initial tachycardia and were immediately bradycardic with no compensatory 
maintenance of blood pressure. A likely explanation was that the response to 
blast augmented the depressor response to severe blood loss mediated by the 
vagal reflexes (Sawdon et al., 2002).  
5.2.4 Blast and Haemostasis 
Early after blast there appears to be a hypercoagulable state (Granville-
Chapman et al., 2010). The cause of this is unknown, but it is postulated that it 
is due to blast related tissue damage. There is no published evidence on the 
relationship between blast injury and tissue factor levels. Since blast causes 
endothelial disruption in the colon and lung, it is likely that there is increased 
amount of exposure of blood to tissue factor, thereby causing significant 
activation of coagulation pathways. Coupled with poor tissue oxygen delivery 
experienced after blast and haemorrhage, military casualties are at high risk for 
developing ATC. 
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5.3 Summary 
In summary, blast interacts with the body either as a pressure wave disrupting 
air/ fluid interfaces, or causes trauma via the effects of the body being thrown 
against objects, or objects being thrown against the body. The effects of blast 
on the cardiovascular and coagulation systems are well understood and 
complicate the normal response to trauma. This is discussed in more detail in 
chapter 6. 
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Chapter 6. Cardiovascular response to simple haemorrhage 
6.1 Biphasic response to haemorrhage 
The loss of blood volume from the circulation leads to a development of 
hypovolaemia and shock. Shock is defined as the body’s inability to adequately 
perfuse the tissues and meet the oxygen demand. 
 
During the extensive blood donor programme of the second world war, it had 
been noted that a small percentage of blood donors lost consciousness related 
to the amount of blood donated (Barcroft and Edholm, 1945). Barcroft et al in 
1944 investigated the physiological response to this simple haemorrhage by 
venesecting volunteers and noting heart rate, blood pressure, cardiac output, 
right atrial pressure and forearm blood flow. 
 
Barcroft demonstrated a biphasic response after haemorrhage Figure 6-1. Initially 
there was development of a tachycardia with a compensatory rise in systemic 
vascular resistance maintaining blood pressure despite a fall in cardiac output. 
Once 20 – 30 % of blood volume was lost, there was a bradycardia coupled 
with a loss in systemic vascular resistance and a loss in blood pressure, this 
coincided with a profound increase in forearm blood flow.  This loss of blood 
pressure was called the decompensation phase. 
 
The biphasic response is mediated by two reflexes. 
6.1.1 The arterial baroreceptor reflex. 
A small haemorrhage results in unloading of arterial baroreceptors in the aortic 
arch and carotid sinuses. This causes a reflex reduction in cardiac vagal activity 
and an increase in sympathetic activity of the heart. At the same time there is 
an increase in sympathetic vasomotor tone causing an increase in systemic 
vascular resistance. This change in vascular resistance is not uniform 
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throughout the body and appears to follow a hierarchy. This will maintain 
cardiac output to tissues critically dependant on cardiac output (Barcroft and 
Edholm, 1945; Foex, 1999). 
 
Figure 6-1 Graph showing the biphasic response to haemorrhage with the initial increase in HR, 
SVR, and maintenance of SBP but drop in CO. Followed by the depressor phase. Adopted from 
Barcroft et al., 1944 
6.1.2 Depressor reflex 
Once blood loss exceeds a critical volume (around 20% of circulating volume) 
the “depressor reflex” seems to override the baroreceptor reflex (Foex, 1999). 
An increase in vagal tone leads to bradycardia, increased diastolic time, with an 
increase in cardiac filling and coronary blood flow (Little et al., 1989).  There is a 
concurrent inhibition of sympathetic vasomotor tone leading to vasodilatation. 
 
Barcroft found this depressor phase to be reversible by reinfusion of donated 
blood. However a third, pre terminal, phase has since been described when 
over 40% blood volume has been lost, consisting of increased sympathetic 
drive with tachycardia and hypotension. 
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Other reflexes also occur during haemorrhagic shock. Stagnant blood flow, 
hypoxia and acidosis stimulate arterial chemoreceptors leading to rapid, deep 
breathing with increased vasoconstriction potentiating the baroreceptor reflex 
(Acker and O'Regan, 1981). 
6.2 Cardiovascular response to tissue injury and haemorrhage 
Haemorrhage associated with trauma is complicated by soft tissue injury, 
nociception and pain. Isolated tissue injury causes a pressor response with 
increased blood pressure, tachycardia and increased systemic vascular 
resistance (Redfern et al., 1984).  It was noted that when a minor haemorrhage 
is coupled with tissue injury, mortality is increased (Overman and Wang, 1947). 
It is postulated that the sympathetic “fight or flight “ response to pain, overrides 
the depressor reflex to simple haemorrhage. This occurs at the expense of 
perfusing the vital organs. 
6.3 The inflammatory response to injury 
The inflammatory response to injury is caused by tissue hypoperfusion leading 
to ischaemia and a subsequent reperfusion injury during resuscitation. This 
effect is mediated by two components, the humoral and the cellular response. 
6.3.1 Humoral response to injury 
In response to injury both up and down regulation of many mediators occurs, 
including cytokines, complement, free radicles and nitric oxide. A loss in the 
balance between pro and anti inflammatory cytokines leads to the systemic 
inflammatory response syndrome. Activation of complement will cause 
chemotaxis of leucocytes, degranulation of phagocytic cells and an increase in 
vascular permeability. These levels are related to the severity of injury and 
related to mortality (Tsukamoto et al., 2010).  
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6.3.2 Cellular response to trauma 
Neutrophils, leucocytes, monocytes and macrophages all become activated 
after trauma (Pillay et al., 2007). Upregulation of adhesion molecules causes 
increased permeability and dysfunction of endothelial cells. Activated 
polymorphonuclear neutrophils further release proinflammatory cytokines 
potentiating the humoral response (Tsukamoto et al., 2010). 
6.3.3 Ischaemia/reperfusion 
Ischaemia sees a switch from aerobic to anaerobic respiration in the cells, 
which results in increased permeability of cell membranes and cell swelling. If 
reperfusion occurs, oxygen is reintroduced into the cells creating superoxides 
and hydroxyl free radicles. This can in turn lead to cellular necrosis and 
apoptosis (Nathan and Singer, 2000). Cellular swelling in the endothelium 
results in narrowing of capillary lumens, further reducing blood flow, and loss of 
intercellular adhesion leading to “leaky” capillaries.  This results in loss of 
plasma and proteins, compounding the hypovolaemia and worsening tissue 
oxygenation (Tsukamoto et al., 2010). 
6.4 Summary 
In summary, the normal response to simple haemorrhage is the maintenance of 
arterial blood pressure via increased systemic vascular resistance and 
tachycardia. As haemorrhage continues this is followed by a second phase of 
bradycardia and hypotension, in an effort to preserve blood flow to the vital 
organs. This second phase may be cardio-protective. If haemorrhage is 
complicated by trauma, the second phase is overridden by nociceptive 
responses, which in turn leads to increased mortality.  
 
The inflammatory response to trauma is characterised by an increase in pro-
inflammatory processes, which is augmented by an ischaemia reperfusion type 
injury once resuscitation has started. 
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Chapter 7. Recombinant factor VIIa 
7.1 Mechanisms of action of rFVIIa 
Factor VIIa is one of the coagulation factors produced in the liver. It is crucial in 
the activation of coagulation once it comes into contact with tissue factor (TF). 
Factor VII is the only factor present in its active form in the normal circulation 
and the active form represents approximately 1% of the total factor VII. Once it 
binds to TF it promotes clot initiation at the site of injury.  
 
Recombinant factor VIIa (rFVIIa) was manufactured in the 1980’s by Novo 
Nordisk (Maaloev, Denmark) for the treatment of haemophilia patients with 
inhibitors of FVIII and FIX. These factors are important in the production of 
thrombin once coagulation has been activated by the exposure of TF to FVIIa. 
Haemophilia patients either lack FVIII (haemophilia A) or FIX (haemophilia B) 
and as such are at risk of life threatening haemorrhage from relatively minor 
injuries, and are a significant surgical risk. Some Haemophiliacs develop 
antibodies to FVIII and FIX and so it is not possible to simply treat them with 
specific factor concentrates.  
 
Administration of rFVIIa will increase the concentration of FVIIa approximately 
100 fold (Hauser et al., 2010; Pusateri and Park, 2005), promoting thrombin 
generation at the site of injury. There appears to be two mechanisms by which 
rFVIIa exerts its effect. The first is TF-independent and the second TF-
dependent (Meng et al., 2003; Pusateri and Park, 2005; Hoffman, 2003; 
Hedner, 2006). 
 
The TF dependent mechanism occurs in a physiologically normal way, rFVIIa 
binds to TF at the site of injury causing clot initiation. Under the TF independent 
mechanism, rFVIIa weakly binds to the activated platelet activating FX to FXa. 
Although the efficiency of this reaction is low, the concentrations of rFVIIa offset 
this, and FXa production thus becomes independent of the presence of TF 
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(Pusateri and Park, 2005; Hoffman, 2003). Both mechanisms cause an increase 
in the production of FXa and FVa on the surface of activated platelets, thereby 
converting prothrombin to thrombin. After administration of rFVIIa, the rate of 
thrombin production is greater resulting in thinner, more tightly packed fibrin 
strands that are more resistant to fibrinolysis (Dutton et al., 2004; He et al., 
2003). 
7.2 Clinical use of rFVIIa 
rFVIIa license for use is restricted to: congenital haemophilia with inhibitors, 
acquired haemophilia, Glanzmann’s thrombasthenia and congenital FVII 
deficiency. However in one recent study of 12,644 hospitalisations where rFVIIa 
was used, 97% were for reasons outside these licensed (off label) indications 
(Martinowitz et al., 2005; Logan et al., 2011). rFVIIa has therefore been used in 
a wide range of clinical conditions in an attempt to control bleeding including 
cardiac and thoracic surgery, post partum haemorrhage and spontaneous 
intracerebral bleeding. 
 
Lin et all (2011) performed a meta analysis looking at 26 trials where there had 
been off label use of rFVIIa. There were 14 off label prophylactic trials and 12 
off label treatment trials. There was no significant effect on mortality in either 
group, and a non significant increase in thromboembolic events (Petersen et al., 
1999; Lin et al., 2011). Studies had varied dosing regimes (5µg/kg – 360 µg/kg 
prophylactic group, and 5µg/kg to 1120 µg/Kg therapeutic group). None of the 
groups included military trauma, and none of them looked at the effect of rFVIIa 
on blast lung. Four of the studies however (Pusateri and Park, 2005; Rizoli et 
al., 2006; Boffard et al., 2005) do demonstrate a reduction in ARDS in rFVIIa 
treated groups, especially after blunt trauma. 
 
The conclusion from this meta analysis was: 
“Clinically significant benefits of recombinant factor VIIa as a general 
haemostatic agent in patients without haemophilia remain unproven. Given its 
potential risks, such use cannot be recommended, and in most cases, it should 
be restricted to clinical trials (Pusateri and Park, 2005; Lin et al., 2011). 
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7.2.1 rFVIIa in trauma 
The use of rFVIIa in trauma was first documented in 1999 in a case report of an 
Israeli solider with uncontrolled haemorrhage from a gunshot wound to the 
inferior vena cava (Dutton et al., 2004; Kenet et al., 1999). Since then its (off 
label) use in trauma has become widespread and there have been a some 
other reports favouring its use in trauma (Young et al., 2013; Dutton et al., 2004; 
O'Neill et al., 2002; Martinowitz et al., 2001). It would appear to offer a potential 
increase in clotting ability at the site of injury. 
 
Subsequently Boffard et al (2005) studied patients with penetrating and blunt 
trauma with administration of rFVIIa or placebo at 1 and 3 hours after 
transfusion of 8 units of blood (Sørensen et al., 2010; Boffard et al., 2005). 
There was a significant reduction in blood transfused in the rFVIIa group for 
blunt trauma, and a non-significant trend in penetrating trauma. There was no 
difference in hospital length of stay, ICU days, ventilated days or mortality and 
no difference in the rate of thromboembolic events. 
 
The use of rFVIIa has also been looked at in traumatic intracerebral 
haemorrhage. Extradural and subdural haemorrhage were excluded due to the 
surgical treatment required. Patients either received placebo or increasing 
doses of rFVIIa (40µg/kg to 200 µg/kg). There was no difference in survival, but 
there was a trend towards reduction in expansion of haematoma, and a trend 
towards thromboembolic events (Sørensen et al., 2003; Narayan et al., 2008). 
 
In military trauma the only evidence available comes from retrospective 
analyses (Ganter et al., 2008b; Spinella et al., 2008). Spinella et al looked at 
those patients in a combat support hospital who had received massive 
transfusion (>10 units of blood in 24 hours). The rFVIIa group had a lower 
mortality at 24 hours and 30 days with no increase in thromboembolic events. 
(Wade et al., 2010) looked at patients between 2003 and 2009 who had 
received a transfusion and had rFVIIa. There was no difference in survival or 
adverse events. 
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7.2.2 CONTROL trial 
Following these inconclusive trials, a large multicentre trial (CONTROL) was 
conducted to look at the role of rFVIIa in traumatic haemorrhage (Pusateri and 
Park, 2005; Hauser et al., 2010). The aims were to collect 1502 patients with 
blunt or penetrating trauma with continued bleeding after 4 units of red cell 
transfusion. Patients received either rFVIIa (200µg/Kg followed by 100µg/Kg at 
1 hour and 3 hours) or placebo. The study was powered for a mortality of 27.5% 
in the placebo group. The study was terminated early after interim analysis due 
to a lower than expected mortality of 10.8% and thus the study was 
underpowered. In the patients that were recruited, there was no difference in 
mortality and no statistically different number of thromboembolic events. 
7.3 rFVIIa and physiological abnormalities 
Acidosis affects enzymatic activity and platelet function (see section 3.2.3), but 
it also affects the activity of rFVIIa. A pH of 7.0 will reduce rFVIIa TF 
independent activity by 90% and TF dependent activity by 60% (Pusateri and 
Park, 2005; Meng et al., 2003; Hoffman, 2003; Hedner, 2006). However the 
large pharmacological dose of rFVIIa (a 100 fold increase) may still have 
enough activity to exert a significant effect (Hoffman, 2003; Pusateri and Park, 
2005). Dutton et al. (Dutton et al., 2004) and Martinowitz et al. (Martinowitz et 
al., 2005) have both suggested that a pH of 7.2 decreases rFVIIa effect. 
However in Dutton’s study there was an improvement of PT in both responders 
and non-responders (78/78 patients) in spite of the non-responding group 
having a pH of 7.02 compared to the responding group having a pH of 7.29. 
However 6 of the non-responders had a pH of greater than 7.1 and 5 
responders had a pH< 7.1. Martinowitz showed a decline in efficacy below 7.2, 
which only reached significance at a pH of 7.0. In summary the effect of pH on 
the action of pharmacological doses of rFVIIa remains unclear but the drug is 
likely to have a reduced efficacy below pH 7.0 and possibly even below a pH of 
7.2.  
 
Temperature also affects rFVIIa activity. TF-dependent activity drops by 20% at 
33 °C, although interestingly the TF-independent pathway increases as 
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temperature drops. Previous work by Petersen et al. (Petersen et al., 1999) 
suggest that FVIIa is only stable in conjunction with its cofactor (TF) and 
therefore increasing temperature in the absence of TF decreases its stability. It 
seems therefore that hypothermia has minimal effect on the activity of rFVIIa. 
 
The effect of haemodilution is unclear. Some studies with evidence of 
haemodilution and or consumption have demonstrated efficacy of rFVIIa, 
whereas others have suggested that coagulation factors should be at or near 
normal levels (Rizoli et al., 2006; Pusateri and Park, 2005; Boffard et al., 2005). 
Most guidelines for the use of rFVIIa suggest that there should be a minimum 
platelet and fibrinogen level prior to administration. 
7.4 Animal studies 
Animal studies, conducted mainly on pigs, have produced conflicting evidence. 
This is in part due to the differing models, end points and doses used. Most 
studies have looked at the effect of rFVIIa on survival, blood loss or changes in 
clotting parameters. Only one study looked at the use of rFVIIa with a trauma 
model (Wade et al., 2010; Howes et al., 2007). Doses ranged from 90µg/kg 
(McMullin et al., 2008) to 720 µg/Kg (Klemcke et al., 2005; Jeroukhimov et al., 
2002), although most studies either use, or include doses of 180µg/Kg. Some 
studies used blood that developed coagulopathy (Sapsford et al., 2007) or had 
coagulopathy induced (Klemcke et al., 2005; Schreiber et al., 2002; Lesperance 
et al., 2012).  
The results of these studies are also variable, with some seeing an effect, and 
some not. In general there was a reduction in bleeding volume from the rFVIIa 
group, and improvement in clotting indices In one study, rFVIIa was shown to 
improve survival time in anaesthetised pigs suffering haemorrhage and 
hypotensive resuscitation (Sapsford et al., 2007). All animals received a 40% 
blood volume haemorrhage, and infra renal aortotomy. The pigs received either 
normotensive or hypotensive resuscitation with either rFVIIa or placebo. There 
was no difference in survival between rFVIIa and placebo in the normotensive 
group, however there was a significant increase in survival (214 [79-349] vs 35 
[19-52] minutes) between rFVIIa and placebo in the hypotensive group. The 
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conclusions from this study, were that rFVIIa combined with hypotension in a 
model of arterial haemorrhage improved survival to a clinically relevant time for 
military trauma. 
7.5  rFVIIa in Lung haemorrhage  
A case of rFVIIa (two doses of 60µg/Kg) has been reported in a case of a 
patient with severe traumatic intra thoracic haemorrhage where it appeared to 
control the bleeding (Kamphuisen et al., 2002). There have also been some 
reports of its use in the treatment if diffuse intra alveolar haemorrhage (DAH). 
 
DAH is caused by pulmonary microvascular bleeding and is life threatening. It’s 
known causes include connective tissue disorders, cardiac disease, drugs, 
complications of bone marrow transplantation, pulmonary metastasis and 
anatomical abnormalities. Treatment is of the underlying cause and reversal of 
coagulopathies with supportive therapy as required.  Several cases of rFVIIa 
use following failure of conventional therapy have been reported. The doses 
used vary between 90µg/Kg and 180µg/Kg either in single or multiple 
intravenous doses (Hicks et al., 2002; Henke et al., 2004).  
7.6 rFVIIa use in Blast lung 
Blast lung is thought to be as a consequence of intra alveolar haemorrhage 
similar to DAH. There are no published trials on the use of rFVIIa to treat blast 
lung, however with increasing numbers of survivors of blast injured patients, the 
prevalence of blast lung on military intensive care units is increasing. Novel 
therapies, such as rFVIIa to treat blast lung, require examination. 
7.7 Summary 
In summary the off label use for rFVIIa has increased dramatically over recent 
years in an attempt to “boost” coagulation after haemorrhagic shock in trauma 
patients. There is no strong evidence that the use of rFVIIa leads to a decrease 
in mortality, and some evidence that its use leads to an increase in 
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thromboembolic events. However comparison of the studies is limited by the 
variable doses used, variable end points and, in animal studies, variable models 
used.  
 
Across many of the studies there appears to be a boost in coagulation after 
rFVIIa use manifest by a reduction in blood products used and reduction in 
haematoma sizes. There also is some speculative evidence that rFVIIa use may 
be of benefit in blast lung. 
 
There is some doubt as to the sensitivity of standard tests of coagulation 
(PT/aPTT, ROTEM® and TEG®) at monitoring the effects of administered 
rFVIIa. There is, however, renewed interest in modifying these tests and using 
dilute tissue factor as an initiator, which appears to provide a more sensitive 
and realistic assessment of the effects of rFVIIa. 
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Chapter 8. Aims  
8.1 The aims of the Research 
1. A human study of a clinical assessment of ROTEM® to assess 
coagulation status in severely injured military casualties. 
2. An in vivo animal based study investigating the impact of simulated pre 
hospital administration of O2 and rFVIIa on coagulation status in a model 
of battlefield injury, 
3. A laboratory based in vitro study to examine the effects of a second 
dose of rFVIIa on coagulation status rFVIIa compared to buffer. 
 
• To address the first aim a clinical study was performed on severely 
injured military casualties in Camp Bastion, Afghanistan. The severity 
and nature of injury may have an effect on coagulopathy. Military trauma 
is characterised by severely injured casualties who have suffered high 
velocity penetrating and blast injures. This necessitated the study to be 
performed in Afghanistan since UK civilian trauma is characterised by 
low velocity penetrating injuries and blunt trauma. 
 
• The second aim required an animal based study since it would be 
impossible to conduct a randomised controlled trial to administer, for 
example, rFVIIa, in a non permissive, military prehospital environment. 
To achieve this aim I utilised a model of complex battlefield injury, in 
terminally anaesthetised animals that had been developed, and was 
being used as part of the on-going work by the combat casualty care 
team at DSTL, Porton Down 
 
• The third aim was achieved by performing an in vitro laboratory based 
study where blood samples from various time points, taken from the 
animal study, had either rFVIIa or placebo added to them. The effects of 
this dose of rFVIIa on coagulation was assessed using TEG® 
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Chapter 9. Origin of the model used as the basis of the animal 
work 
9.1 Hypotensive resuscitation 
A decade ago civilian practise in trauma was based around hypotensive 
resuscitation in the belief that hypotension allowed better clot formation, and 
that normotension would disrupt any formed clot, leading to further 
haemorrhage (Bickell et al., 1994). The Defence Medical Services wanted to 
determine if this practise was applicable to military trauma.  
 
A large animal model was developed at DSTL, Porton Down (Garner et al., 
2009) to investigate the impact of blast injury on the effectiveness of 
resuscitation after haemorrhagic shock. The study showed that hypotensive 
resuscitation was associated with poor tissue oxygen delivery, which led to the 
development of a significant shock state and metabolic acidosis. While survival 
was good during the first hour of resuscitation, the degree of shock became 
overwhelming thereafter, when hypovolaemia was combined with blast injury. 
The problem seemed to be due to reduced tissue blood flow associated with 
hypotensive resuscitation, especially when combined with blast injury since the 
improved oxygen transport associated with normotensive resuscitation 
revearsed the shock and improved survival (Garner et al., 2010). However it 
should be noted that the study was designed as a physiological investigation of 
potential problems associated with hypotensive resuscitation and the model, by 
design, had no element which would lead to re-bleeding during resuscitation 
(Garner et al., 2010). 
9.2 Novel Hybrid resuscitation 
A subsequent study looked at the effects of hypotensive resuscitation for the 
first hour, with a return to normotension by the infusion of 0.9% saline after 60 
minutes (novel hybrid resuscitation) (Kirkman and Watts, 2011). The animals 
were subject to blast or sham blast, a 30% blood volume controlled 
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haemorrhage followed by a grade 4 liver injury, which was left uncompressed, 
in order to allow the possibility of a rebleed once the blood pressure was raised. 
This study demonstrated a significant improvement in survival, reversal of base 
deficit, reduction in oxygen extraction with no evidence of re-bleeding in the 
novel hybrid group (Kirkman and Watts, 2011) and an improvement in 
coagulation associated with the improved tissue perfusion during novel hybrid 
resuscitation (Doran, 2012). 
9.3 Intravenous dose of rFVIIa 
There is no consensus regarding the appropriate dose of rFVIIa in trauma or in 
lung injury. Most trials used a dose between 60 – 120 µg/Kg. Pigs have reduced 
sensitivity to human rFVIIa, and a dose of 180 µg/kg has been adopted by 
several investigators as an equivalent clinical dose (Lynn et al., 2002; Sapsford 
et al., 2007; Schreiber et al., 2002). This dose has been shown to improve 
survival in pigs with incompressible haemorrhage (aortotomy). 
9.4 Prehospital supplemental oxygen and rVIIa for haemorrhagic 
shock and blast injury 
The study which forms the experimental work for this thesis examined changes 
in clotting status associated with treatment using rFVIIa and oxygen following 
blast injury, haemorrhagic shock and hypotensive resuscitation. 
 
A strategy was required to target patients at high risk of rebleeding after blast 
injury where a novel hybrid strategy might be potentially harmful (i.e. injury type 
had a significant risk of rebleeding). The strategy needed to address shock by 
increasing oxygen delivery without increasing blood pressure. This can be 
achieved by administering supplemental oxygen, or by increasing the efficiency 
of gas exchange in the blast damaged alveolus. rFVIIa was given intravenously 
in an attempt to decrease alveolar haemorrhage and thereby increasing 
pulmonary gas exchange.  
 
This model incorporated blast injured pigs who suffered a controlled 
haemorrhage, a grade 4 liver injury and hypotensive resuscitation. After 30 
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minutes, simulating the arrival of specialist medical help on the battlefield, the 
animals were divided into groups that either remained breathing air (control 
group), were given supplemental oxygen to target SaO2 95% or given 
intravenous rFVIIa. 
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Chapter 10. Utility of interim ROTEM® values of clot 
strength, A5 and A10, in predicting final assessment of 
coagulation status in severely injured battle patients.  
10.1 Introduction 
The effective treatment of trauma induced coagulopathy with massive 
haemorrhage protocols requires rapid assessment of patient’s dynamically 
changing coagulation status and their response to treatment. As discussed in 
section 4.2.4, conventional tests (PT, aPTT) take too long to provide a 
meaningful result, rendering the results historical and of little value in guiding 
resuscitation. 
 
Viscoelastic methods potentially provide more rapid feedback and could 
therefore be more useful in determining contemporary coagulation status of the 
patient. Key parameters include measures of clot initiation time, the dynamics of 
the clotting process and clot strength.  Unfortunately even in viscoelastic 
methods, it can take up to 45 mins for a full picture to emerge in a 
coagulopathic patient, although interim values are reported sooner.  The 
purpose of the study presented in this thesis was to evaluate the utility of these 
interim values in predicting whether the ROTEM® test would indicate 
coagulopathy when run to completion. 
 
10.2 Aims 
The aim of this study is to determine whether measures of clot strength 
determined by ROTEM® at 5 and 10 min after initiation of clotting (defined by 
ROTEM® as A5 and A10) provide a reliable indication of coagulopathy when 
the ROTEM® EXTEM test is run to completion on blood derived from severely 
injured battlefield casualties. 
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10.3 Methods 
In accordance with standard laboratory practise (TEM, 2010), normal range 
data was derived from venous samples collected, with informed consent, from a 
population of 50  healthy volunteers undergoing routine assessment as part of 
the Emergency Donor Panel (EDP) at the UK DMS deployed Role 3 Field 
Hospital at Camp Bastion (R3 Bastion), Afghanistan.  For the patient population, 
venous blood samples were collected prospectively, as part of their routine 
clinical evaluation, on battle patients presenting to R3 Bastion during the study 
period (21 May 09 – 3 Jul 09).  This amounted to 48 seriously injured patients 
(48:0 male:female, 24[21-26] yr mean age[IQR]).  The predominant mechanism 
of injury involved Improvised Explosive Devices (IED's), with a number of 
casualties suffering traumatic amputations (48%).  The dataset also contains 
some patients with ballistic injuries (29%) and a few with burns and injuries 
resulting from road traffic accidents (4% in each).  All patients presented in this 
report were classified as seriously injured patients and had been triaged as T1 
or T2. T1 and T2 casualties are those that have immediate or urgent clinical 
problems requiring full trauma team activation. ROTEM® values from the 
injured patients were compared to the reference range derived from the 
uninjured service personnel at Bastion. 
 
Blood samples were collected by assigned nurses or doctors as part of their 
defined role in the trauma team. Samples were collected from either 16 G 
peripheral cannulae or 8.5 Fr central venous line (depending on the first 
vascular access gained). Samples for ROTEM® were analysed within 5 mins by 
designated operating room staff. Blood samples sent to the laboratory were 
immediately placed on a standard laboratory tube roller until analysis was 
performed. 
 
ROTEM® analysis was performed according to the manufacturers instructions 
for EXTEM and FIBTEM. The following parameters are routinely reported: 
Clotting time (CT) representing clot initiation, Clot Formation Time (CFT) and 
angle representing clot dynamics and Maximum Clot Firmness (MCF) 
representing ultimate clot strength. Amplitude at 5 mins (A5) and 10 mins (A10) 
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are interim values of clot strength and relate to the amplitude at 5 and 10 mins 
after CT. 
10.3.1 Definition of coagulopathy as determined by ROTEM®. 
There are no formal definitions of coagulopathy as determined by viscoelastic 
methods, including ROTEM® (see section 3.5.1), and no published peer 
reviewed papers defining actual parameters to establish the presence or 
absence of coagulopathy. In 2008 the ROTEM® Expert Working Group Meeting 
(Expert meeting working group, 2008) recommended that an EXTEM MCF of 35 
to 45 mm may require treatment depending on the clinical condition of the 
patient. Experimental dilution of blood to model coagulopathies (60% dilution) 
(Weiss et al., 2010) , and PT of 1.7 times normal (Bolliger et al., 2010) have 
corresponding EXTEM MCF of 40mm and 39mm. Davenport et al (Davenport et 
al., 2011) studied 300 patients admitted to the Royal London Hospital and found 
that an A5 of <36mm identified ATC with a detection rate of 77% and a false 
positive rate of 13%. We have used a figure of EXTEM MCF <40mm as one 
definition of hypocoagulation as this represents a risk of bleeding and may 
require treatment to prevent further deterioration to a clinical coagulopathy.  
 
Using a single parameter such as MCF to diagnose coagulopathy is potentially 
too simplistic a tool and of no real value unless it is grossly abnormal. It is 
unlikely that a result 1 or 2 mm outside normal is a clinical problem, unless that 
subtle abnormality is present in more than one clotting domain. In this case the 
patient may be at increased risk of a clinical bleeding problem and as such 
could be assumed to be at increased risk of coagulopathy.  As such a subtle 
abnormality in 2 out of 3 domains should alert the clinician to the possibility that 
there is a clinical problem, and in the context of the specific circumstances of 
the patient may represent coagulopathy. We have adopted an alternative 
definition of coagulopathy; the presence of abnormal values in two of the three 
domains (initiation (CT), dynamics (CFT or angle) and strength (MCF)) termed 
the 2/3 rule. 
 
Therefore, in this study two alternative definitions of coagulopathy were used, 
the first based on the 2/3 rule (using the locally-derived normal values, Table 1) 
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and the second as an MCF of<40mm. The sensitivity and specificity of an 
abnormal A5 and A10 in predicting coagulopathy was determined for each 
definition. 
10.3.2 Conventional assessment of clotting using prothrombin time. 
Venous blood samples were collected into citrated Vacutainer (9NC 0.105M 
Vacutainer 367691, Beckton Dickinson, UK), and sent for standard laboratory 
testing in the hospital laboratory. A coagulopathy based on PT is defined by the 
British Committee for Standards in Haematology and the American College of 
Pathologists as a PT greater than 1.5 times normal values (Lang et al., 2005), 
corresponding to PT > 18s. 
10.3.3 Statistical analysis 
Data was separated into ‘normal’ (control) subjects (members of the Emergency 
Blood Donor Panel) and injured patients.  The distribution for each parameter 
was examined in each group and normalised if necessary by transformation 
(e.g. log transformation).  Summary values for data with a normal distribution 
(parametric data) are presented as means and 95% confidence intervals while 
non-parametric data are summarised with medians and inter-quartile ranges. 
 
For control subjects untransformed data were used to produce the normal 
ranges except for A5 and A10, which were derived from log-transformed data. 
Parametric tolerance limits were calculated for each parameter (Equation 10.1) 
This approach allows us to be 95% confident that 99% of the uninjured 
acclimatised control population are to be found within these limits. 
 
Tolerance limits = mean ± KS 
Equation 10.1 Calculation of tolerance limits for control (uninjured) acclimatised personnel at R3 
Bastion (members of the Emergency Blood Donor Panel). S, standard deviation; K, reliability 
coefficient taken from tables or calculated from the confidence coefficient, gamma. 
 
  80 
The proportion of patient samples falling outside the control range was 
calculated for each parameter. 
 
A comparison of the statistical distribution of data was made between normal 
controls and injured patients by informally comparing distribution dot-plots and 
by formal assessment of normal probability plots. 
10.4 Results 
10.4.1 Reference ranges based on samples from uninjured volunteers 
The reference range derived from 50 uninjured control subjects at R3 Bastion 
(members of the Emergency Blood Donor Panel) and the published reference 
ranges based on non-coagulopathic patients and staff at northern European 
hospitals are shown in Table 10-1, Bastion ranges were not significantly 
different to TEM’s® published ranges (TEM, 2010). 
Table 10-1 Reference range EXTEM data from uninjured, non-coagulopathic, subjects 
(members of the Emergency Blood Donor Panel undergoing routine assessment at R3 Bastion, 
(EBDP) and published normal range data presented by TEM® based on Lang et al 2005. 
10.4.2 Early prediction of coagulopathy based on interim ROTEM® 
parameters 
The age, admission pulse and blood pressure, blood count and clotting indices 
together with injury severity and blood product use are shown in Table 10-2,108 
samples (which included multiple assessments) from 48 trauma patients were 
used to assess the utility of A5 and A10 to predict hypo-coagulation (attenuated 
clotting).  58% of these samples were found to be hypo-coagulable based on 
the 2/3 rule and the remainder were normal (none were hyper-coagulable, i.e. 
Subjects CT (s) CFT (s) α 
Angle 
(°) 
A5 
(mm) 
A10 
(mm) 
MCF 
(mm) 
CLI30  
(%) 
EBDP 
(R3Bastion) 
25-90 43-173 58-81 32-71 40-72 44-74 40-102* 
Pentapharm 38-79 34-159 63-83  43-65 50-72 94-100 
  81 
enhanced clotting, with respect to any parameter). A5 and A10 below their 
respective reference ranges predicted hypo-coagulation (as defined by the 2/3 
rule) in individual samples with respective sensitivities[95%CI] / 
specificities[95% CI] of 0.97[0.93-1.00] / 0.68[0.54-0.82] (A5) and 0.98[0.95-
1.00] / 0.80[0.68-0.92] (A10). 
 
Table 10-2 showing baseline blood pressure, heart rate, age, blood results, injury severity and 
blood product use during initial surgery. 
 
51% of samples were found to be hypocoagulable according to the MCF < 
40mm rule.  In this case A5 and A10 (below their respective reference ranges) 
predicted hypocoagulation in individual samples with sensitivities / specificities 
of 0.96[0.91-1.00] / 0.58[0.45-0.71] (A5) and 1.00 / 0.70[0.58-0.82] (A10) 
respectively. 
10.4.3 Incidence of hypo-coagulation in admission samples at R3 Bastion 
Blood samples from 31 of the severely injured patients were taken on arrival at 
R3 Bastion or soon as possible (within approximately 30 min) thereafter.  The 
proportion of patients showing abnormal EXTEM parameters indicative of hypo-
coagulation on admission to R3 Bastion is shown in Table 10-3. Approximately 
 Mean [95% CI] Median [IQR] Range 
MBP (mmHg) 92[83-100]   
Heart rate (b/min) 111[102-119]   
Initial [Hb] (g/dl) 10.8[9.8-11.8]   
Plt (109/L)  142[107-213] 48-459 
Fib (g/dl)  2.9[2.3-3.7] 0.9-5.9 
pH  7.30[7.22-7.37] 6.90-7.43 
BE (mM)  -4[-8 - -2] -22 - 2 
Age (y)  24[21-26] 18-50 
NISS  34[17-43] 5-75 
PRBC (units)  10[6-17] 0-39 
FFP (units)  10[4-14] 0-90 
PLT (units)  0[0-2] 0-10 
Cryo (units)  0[0-1] 0-6 
Total Blood products 
(units) 
 21[11-35] 0-101 
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the same proportion of patients had abnormalities in all 3 domains of clotting 
(initiation, dynamics and strength). No patient showed abnormalities indicative 
of hyper-coagulation.  Prior to the first sample being taken for ROTEM® 
analysis 19 patients had received no or minimal blood products, the remainder 
had preceding blood products.  39% (21%-59%, 95%CI) of patients were found 
to be coagulopathic as defined by the 2/3 rule, and 40% (23%- 59%, 95% CI) as 
defined by MCF < 40mm rule on admission. 
Table 10-3 Proportion of 31 severely injured patients showing abnormal values on EXTEM 
compared to the EBDP and Pentapharm reference ranges on presentation at R3 Bastion. 
10.4.4 Comparison of ROTEM® and prothrombin time (PT) 
Of the EXTEM ROTEM® samples analysed in the entire dataset, 40 samples 
from 30 patients were also subjected to conventional laboratory testing.  There 
was agreement between conventional testing and ROTEM® for only 24/40 
(60%) of these samples (5/24 coagulopathic and 19/24 normal clotting 
samples).  Of the remaining 16 samples 8 were abnormal by ROTEM® only and 
the remaining 8 abnormal by conventional testing only.  Conventional and 
ROTEM® assessment therefore does not appear to provide good agreement on 
coagulopathic samples. 
10.4.5 Statistical comparison of ROTEM® parameter distributions between 
volunteer and admission samples from trauma patients 
A detailed comparison of the distribution of EXTEM data from patient and 
uninjured volunteer groups revealed differences between various ROTEM® 
parameters.  Parameters relating to clot initiation (CT) and dynamics (CFT and 
Angle) showed similar distributions between patient and control groups, with a 
significant number of outliers in the patient groups Figure 10-1. 
Reference 
Range 
CT CFT α Angle MCF 
EBDP (R3 
Bastion) 
0.29 0.33 0.31 0.43 
Pentapharm+ 0.39 0.41 0.45 0.63 
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Figure 10-1. Normal probability plot of EXTEM CT, EXTEM MCF and FIBTEM MCF on normal 
volunteers (Red) and admission samples from the injured patients (Blue) groups 
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By contrast, parameters relating to clot strength (MCF) showed a fundamental 
difference in distribution between the volunteer and patient groups Figure 10-1. 
However, when the MCF data derived from the FIBTEM assay were compared, 
the differences in distribution between patient and volunteer groups were much 
less marked Figure 10-1. 
 
Platelet counts were available for 23/31 of the patient admission samples and 
showed a mean value of 142 x 109 litre-1 [107 - 213 x 109, IQR].  The difference 
in distribution of MCF values for EXTEM was therefore unlikely to be due to a 
gross abnormality in platelet numbers since the values were broadly within the 
normal range. 
10.5 Discussion 
The principal finding of this study is that a value of ROTEM® A5 and in 
particular A10 below the reference range predicts a final conclusion of 
coagulopathy with a high degree of sensitivity and specificity. This is true for 
either the 2/3 rule or the MCF<40mm rule. 
 
ROTEM® values are known to be influenced by age and sex (Lang et al., 2005)  
and there is no data to determine whether the effects of acclimatisation to an 
environment such as that found in Afghanistan (compared to northern Europe, 
which forms the basis of the published ranges) has any influence on ROTEM® 
parameters. Consequently the reference range for Bastion was viewed as the 
most applicable to the patient population of this study. This approach is also 
consistent with the advice that each hospital should derive its own reference 
range as a basis for assessing their patients (TEM, 2010).  
 
Complex trauma coagulopathies are not simply a failure of clot initiation. They 
represent an imbalance between clot formation, clot breakdown and innate 
anticoagulation with dimensions of clot dynamics and ultimate clot strength. 
Additionally there are complex interactions between factors and cellular 
elements (platelets) of clotting. In our injured population approximately 40% of 
patients had admission coagulopathy. Since prehospital times are short and 
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standard operating procedures limit the use of crystalloid resuscitation, it is 
unlikely that dilution has any significant effect on admission coagulopathy. 
Approximately the same proportion of patients had abnormalities in each of the 
three domains of clotting implying that abnormalities affecting initiation, 
dynamics and strength should all be interpreted when diagnosing trauma 
induced coagulopathy. 
 
Definitions, and therefore diagnosis of coagulopathy do not refer to viscoelastic 
methodology (Lundberg, 1994) and using ROTEM® to diagnose coagulopathy 
is therefore impossible until there are accepted definitions. We accept that a 
clinical decision can be reliably made on a grossly abnormal value in any single 
parameter, however it is not clear what weight can be put on a mildly abnormal 
value. Current UK Defence Medical Services policy on the treatment of trauma 
induced coagulopathy (SGOPL 0809, 2009) is directed at preventing 
deterioration in coagulation status. 
 
In order to use any test as a diagnostic tool, there needs to be definitions 
adopted to allow clinicians to follow protocols. We have therefore adopted (non 
validated) definitions to allow ROTEM® use in military protocols whilst formal 
definitions are approved. Expert opinion seems to suggest that an MCF of 
40mm represents coagulopathy, and this is one definition used. In this study it is 
proposed that a single abnormality just below the normal range does not, on its 
own, indicate failure of the coagulation system, however if there are 
abnormalities below the normal range in two or more of the three domains of 
the clotting process (initiation, dynamics and clot strength), then there is 
potential failure of coagulation or coagulopathy (the 2/3 rule). Since the 2/3 rule 
incorporates more than simply clot strength, it is potentially a better definition.  
The 2/3 rule is defined as: 
 
“Any values outside the normal range in two out of the three domains of clotting 
(initiation, dynamics and strength)”  
 
In the profoundly coagulopathic patient it takes a long time to reach CFT and 
MCF (MCF is reached in 30 mins [IQR 15 – 45 mins]). Therfore A clinician will 
use an interim value of A5 or A10 as predictor of final MCF. This represents a 
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time saving of approximately 19 minutes compared to running the ROTEM® 
test until MCF is achieved, since A10 was reported within 11 min (CT plus 10 
minutes) of initiating the test. This time saving is of considerable benefit during 
the initial process of damage control resuscitation as the results are 
contemporaneous enough to allow clinical decisions to be made. However this 
study shows that A10 is not simply a predictor of final MCF, since it also 
predicts coagulopathy, as defined by the 2/3 rule, with a high degree of 
sensitivity and specificity. 
 
Since ROTEM® is a near patient test there is the added advantage of the trace 
developing in real time on the screen, thus anaesthetists and surgeons are able 
to look at the developing trace and make judgments based on the shape of the 
curve produced (Luddington, 2005). The rapidity of obtaining and interpreting 
ROTEM® results makes it a useful tool in guiding trauma resuscitation once 
resuscitation has started, rather than as a means to initiate haemostatic 
resuscitation in severely injured patients. It is likely that the initial in hospital 
resuscitation will follow predefined massive transfusion protocols that are 
empiric to all trauma (SGOPL 0809, 2009). Whilst massive transfusion protocols 
are essential, a one-size fits all approach is not necessarily correct for all 
trauma. It is not clear what the optimum ratio of transfused PRBC:FFP (Hess 
and Holcomb, 2008; Duchesne et al., 2008; Midwinter and Woolley, 2011; 
Maegele et al., 2008; Kashuk et al., 2008) should be, and as soon as possible a 
patient should have timely, directed therapy in order to ensure that the right 
product is given to the right patient at the right time. Since A10 is a reliable 
predictor of coagulopathy as defined by the 2/3 rule, an abnormal A10 can alert 
the clinician to the real possibility of the presence of trauma induced 
coagulopathy, or the timely monitoring of efficacy of treatment allowing an 
informed decision to be made on the immediate management of the patient. 
 
This study was not designed to compare incidences of coagulopathy defined by 
viscoelastic tests on whole blood versus plasma-based clot initiation tests such 
as prothrombin time, both of which are established methods of assessing 
clotting problems.  However, it was of interest to note that, in the small sample 
where data was available from both forms of testing, agreement was good for 
non-coagulopathic blood.  Conversely, agreement appeared poor in blood that 
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was found to be coagulopathic by either one test or the other. This conclusion 
has been borne out in other studies (Davenport et al., 2011) which also states 
there is poor correlation between PT testing and ROTEM®. The number of 
samples investigated here are far too small to make any definitive conclusions 
but clearly a larger study is necessary to underpin clinical standards for trauma 
patients where there are no universally agreed techniques for assessing 
coagulopathy. 
 
Finally, a statistical comparison of the distribution of values representing clot 
initiation, dynamics and strength between normal volunteers and injured 
patients revealed some potentially interesting similarities and differences.  The 
distribution of values representing clot initiation and dynamics (based on the 
EXTEM) between the normal and injured group, suggested a fundamentally 
similar population  (with outliers in the trauma population). However the 
distribution for clot strength was fundamentally different between normal and 
trauma group. 
 
It is unlikely that this difference between clot initiation/dynamics and strength is 
a quirk of the statistics since similar findings of a fundamentally different 
distribution between control and injured groups were found for the other 
parameters relating to clot strength (A5 and A10).  This difference was 
significantly reduced when the normal/trauma comparison was made for 
FIBTEM data where the platelets were disabled as a part of the test.  Again, the 
findings relating to final clot strength in FIBTEM were corroborated by similar 
findings for FIBTEM A5 and A10. 
 
Interpreting the physiological significance of these initial findings is highly 
speculative.  However, one important difference between EXTEM clot strength 
parameters and measures of clot initiation and dynamics, is that the clot 
strength parameters depend on platelet and fibrinogen function whereas clotting 
factors play the pivotal role in the clot initiation and dynamic parameters.  By 
contrast, in the FIBTEM test the platelets are pharmacologically disabled, 
leaving only the clotting factors and fibrinogen . Since platelet numbers are 
above recommended platelet targets (100x109 litre-1) (SGOPL 0809, 2009; 
Rossaint et al., 2010), it is  possible that these findings, taken collectively, 
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indicate that the initial clot development is similar between control and injured 
groups, but that there is a difference clot strength relating to platelet function 
early after injury.  This conclusion is at present speculative but the data suggest 
that there may be some merit in a further detailed investigation of platelet 
function early after injury as this may help clarify mechanistic aspects of trauma 
coagulopathy and possibly provide a focus for developing targeted treatments. 
10.6 Conclusions 
Trauma coagulopathy is a significant problem in severely injured patients and 
requires prompt, targeted resuscitation in order to reverse coagulopathy and 
restore the patient’s physiology. During the dynamic phase of early resuscitation 
rapid assessment of the injured casualty is viewed as being of paramount 
importance.  Interim ROTEM parameters A5 and particularly A10 were found 
to accurately predict the outcome of the ROTEM® EXTEM test, and can be 
used to determine coagulopathy by either predicting a low MCF, or a positive 
2/3 rule. In spite of these definitions not being validated, A5 or A10 can be used 
clinically to evaluate whole blood clotting in patients. 
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Chapter 11. Effects of simulated pre-hospital treatment with 
oxygen or rVIIa: Methods 
The underlying survival study that provided the basis for this research was 
conducted on 18 terminally anaesthetised Large White pigs, weighing 51.8 ± 
2.2 [48-56] Kg (mean+/-SD [range]). A power analysis based on an increase 
from 0.1 to 0.8 in the proportion of animals surviving to 8 hours from the onset 
of resuscitation indicated that 7 animals would be required in each of the 
hypotensive and new treatment groups (Power 0.8, Alpha 0.05, Chi Squared 
test), with a total of 21 pigs. However an interim analysis by a statistician 
(independent of the study team) was planned and performed when n=6 had 
been attained in each group which revealed that there was a clear statistically 
and clinically significant increase in survival associated with supplementary 
oxygen and therefore the study was terminated with a final sample size of 6 
animals in each group.  
 
The study was ethically reviewed and conducted in accordance with the 
Animals (Scientific Procedures) Act 1986.  
 
Prior to the study the animals were housed indoors and fed on a complete 
wheat-soya based ration at 1.5–1.7 kg per day. They were fed and allowed 
water ad libitum. Feeding was discontinued 18 hours before planned induction 
of anaesthesia and the animals allowed continuous access to water.  
11.1 Induction and maintenance of anaesthesia 
All animals premedicated with midazolam (0.1mg/Kg), anaesthesia was induced 
by inhalation of Isoflurane, O2 and N2O (1:1 ratio) and the animal intubated. 
Initially anaesthesia was maintained with isoflurane, O2 and N2O and the animal 
ventilated with a Manley Ventilator for the duration of the surgery. Once 
vascular access had been obtained (see section 11.2), anaesthesia was 
converted to intravenous anaesthesia using alfaxalone (Alfaxan, Vetoquinol UK 
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Ltd, Buckingham UK) for the remainder of the study. Initial monitoring consisted 
of end-tidal CO2, pulse oximetry and ECG monitoring. The animals were 
humanely killed at the end by a lethal overdose of phenobarbitone. 
11.2 Surgical preparation 
The skin was prepared with povidone-iodine solution. The left carotid artery, left 
internal jugular vein, left femoral artery and vein were all cannulated (Portex 
8FG, Hythe, UK). A background infusion of 0.9% Saline at 10 ml/kg/hr was 
given during surgery to cover insensible losses. A balloon tipped pulmonary 
artery flotation catheter (744MF75 Swann-Ganz, Edwards Life Sciences Ltd, 
Newbury, UK) was advanced through an introducer sheath (Desivalve Catheter 
Introducer, Vygon, Cirencester UK) in the right internal jugular vein.  Pulmonary 
arterial placement was confirmed by pressure wave monitoring (Propaq 106 EL, 
Dräger Medical AG &Co. Lübeck, Germany).  
 
A midline laparotomy was performed and the spleen contracted by topical 
application of adrenaline (1.0 to 1.5 ml of a 1mg/ml solution), vascularly isolated 
and then removed. A surgical snare was placed around the left medial lobe of 
the liver and exteriorised for later induction of a grade IV liver injury as a source 
of incompressible haemorrhage. 
 
The bladder was cannulated suprapubicaly (14 G Foley catheter), and the 
catheter secured using a purse string suture. The bladder was emptied. Once 
all surgical procedures were complete the surgical wounds were sutured.  
 
The animals were weaned from the ventilator and continued to breathe air 
spontaneously for the remainder of the experiment unless the study protocol 
dictated otherwise (see section 11.3, O2 group). If there were clinical signs of 
respiratory depression (RR<10, PaCO2 >6KPa, PaO2 <7 KPa  synchronised 
intermittent mandatory ventilation was instituted. The animals recovered for 1 
hour from surgery before baseline measurements were made, during which 
time they were transported to the blast arena. 
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11.3 Protocol 
11.3.1 Overview 
The animals were randomly allocated to one of three groups corresponding to 
treatment during resuscitation;  
• Control (treated with placebo, breathing air throughout) 
• Oxygen (treated with placebo, supplementary oxygen during 
resuscitation) 
• FVIIa (treated with intravenous rFVIIa during resuscitation, breathing air 
throughout).  
 
All animals received a standardised injury comprising of blast exposure, 
haemorrhage, haemorrhagic shock followed by hypotensive resuscitation. The 
protocol is summarised in Figure 11.1. 
11.4 Blast exposure 
After baseline measurements were made, animals were placed supine on a 
trolley and covered with a Kevlar blanket to protect them from minor debris 
during the blast exposure. Physiological monitoring during this phase consisted 
of respiratory rate and ECG. The animals were placed 2.1m from a standard 
2.2Kg charge of Octol, which was detonated remotely. The animals were then 
removed to the physiological monitoring suite for the remainder of the study. 
  
  92 
  
Figure 11.1: Experimental protocol commencing approximately 60 minutes after the end of surgery 
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11.4.1 Haemorrhage 
Fifteen minutes after blast exposure all animals received a controlled 
haemorrhage of 30% total blood volume via the femoral artery catheter. The 
blood volume was estimated according to Equation 11.1. Blood was removed 
using a computer controlled pump (MasterFlex® LIS® Computerised Drive 
Pump, Cole-Palmer Instrument Co. Il, USA). The bleed occurred over 5.3 
minutes, with a progressively decreasing flow rate (Equation 11.2) designed to 
reflect the reducing flow over time from a real arterial injury (Stern et al., 1993). 
By monitoring the weight of removed blood, the accuracy of exsanguination 
volume was confirmed.   
 
Total Blood Volume (B0) (ml/kg) = 161.4751(Wt-0.2197) 
Equation 11.1 Blood volume by swine body weight 
 
Arterial Rate of Exsanguination (V) = B0(1-e-0.04t) 
Equation 11.2 Haemorrhage rates in arterial exsanguination (V=the total blood loss (ml/Kg) and 
the per cent time until death)  
 
Immediately after completion of the controlled haemorrhage, an incompressible 
haemorrhage was simulated by amputating a section of the liver by traction on 
the pre-implanted liver snare (Figure 11.2). This was left uncompressed for the 
remainder of the study and injury confirmed on post mortem analysis. The liver 
injury represents approximately 6% (by weight) of the liver and does not 
transect major blood vessels.  
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Figure 11.2: Amputated section of liver at post mortem demonstrating the size (approx 6%) of the 
amputated section and surface clot on remaining liver 
11.4.2 Haemorrhagic shock resuscitation 
After completion of the haemorrhage, there was a 5 minute shock phase, during 
which no treatment was given, designed to reflect a realistic minimum time 
interval before resuscitation could commence in a military environment.  Time 
‘0’ was designated as the onset of resuscitation (end of the shock phase).  
Warmed 0.9% saline was infused into the femoral vein, at a rate of 3ml/kg per 
minute to attain a target systolic blood pressure (SBP) of 80 mmHg. Further 
aliquots were given as necessary to maintain the target SBP (80mmHg) during 
the remainder of the experiment (up to 480 minutes after the onset of 
resuscitation unless death occurred sooner). 
11.4.3 Treatment Groups 
All groups were given fluid resuscitation as described in section 11.4.2. The 
three treatment groups diverged 30 minutes after the onset of resuscitation. 
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Control group: Placebo (0.18 ml/kg) was administered 30 minutes after the 
onset of resuscitation. Animals breathed air throughout. 
Oxygen group: Placebo (0.18 ml/kg) was administered 30 minutes after the 
onset of resuscitation. FiO2 elevated to attain a SaO2 of 95%. SaO2 was 
monitored continuously and FiO2 adjusted to maintain the target for the 
remainder of the study. 
rFVIIa group: Intravenous  rFVIIa (180 µg/kg, 0.18 ml/kg) was administered 30 
minutes after the onset of resuscitation. Animals breathed air throughout. 
11.4.4 Physiological monitoring 
Cardiovascular variables were recorded continuously (except for the period 
immediately surrounding the blast exposure) using a computerised data 
acquisition system (Maclab 8/s, AD Instruments, UK) and associated software 
(Chart v4.2.3, AD Instruments, UK). Arterial blood pressure, pulmonary arterial 
and central venous pressures were recorded using a strain gauge manometer 
(Sensonor 840, SensoNor a.s., Norway). Zero pressure for all transducers was 
set at heart level. Continuous cardiac output was monitored as a 6 minute 
rolling average using a cardiac output monitor (Vigilance™ Volumetrics CEDV, 
Edwards Lifesciences™, USA).   
 
Paired arterial and mixed venous blood samples were taken anaerobically into 
heparinised syringes from the carotid and pulmonary artery catheters 
respectively for blood gas, base excess and lactate analysis (Gem Premier 
3000 Blood Gas Analyzer, Instrumentation Laboratories, Warrington, UK).  
 
Body temperature was maintained at approximately 38°C using external 
heating/cooling and blankets as appropriate. The bladder was drained at hourly 
intervals. 
11.4.5 Haematology 
Arterial blood samples taken for assessment of haematocrit (by centrifugation, 
HaematoSpin 1300, Hawksley, UK) platelet count (details) and Clauss 
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Fibrinogen (details). Arterial blood samples were also taken for coagulation 
assessment as described in section 11.5 
11.5 Assessment of coagulation 
11.5.1 PT, aPTT and ROTEM® analyses 
Arterial blood samples were taken into citrated vacutainers (9NC 0.105M 
Vacutainer 367691, Beckton Dickinson, UK), centrifuged at 1500 x g for 10 min 
and the plasma separated and stored at -80°C for determination of PT and 
aPTT using the ACL Elite (Beckman Coulter, UK). Further citrated samples 
were immediately subjected to standard ROTEM® analysis (EXTEM, FIBTEM) 
(section 4.4). Finally fresh (uncitrated) blood samples were processed 
immediately for TEG® analysis as described in section 14.2.2 
11.5.2 Individual factor assays 
Citrated plasma samples were stored at -80°C for batched analysis. This aspect 
of the study was conducted as a supplementary rather than as a pre-planned 
analysis (see section 13.9). 
 
Factor II, V, VII and X are PT based assays (see section 4.9) and were 
performed using standard factor deficient plasma kits (HemosiL, 
Instrumentation Laboratory, Warrington, Cheshire). TFPI, syndecans, and 
heparans were analysed by ELISA respectively using Imubind TFPI ELISA, 
Sekisui, Invitech Ltd, Huntingdon, Cambridge,  Diaclone Human sCD138 
(syndecan-1) ELISA kit 2B Scientific Ltd, Upper Heyford, Oxfordshire ; General 
Heparan sulphate ELISA kit, AMS Biotechnology (Europe) Limited, Abingdon, 
Oxfordshire ). 
 
The analysis described in this sub-section were all performed in collaboration 
with Professor Beverley Hunt, Director of the Thrombosis and Haemostasis 
research Unit, Guys and St Thomas’s hospital, London. 
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11.6 Exclusion of data points during extreme dilution 
In this current study, the protocol required infusion of 0.9% saline to keep the 
systolic blood pressure at 80mmHg. For the majority of the time during the 
resuscitation phase, while the animals were relatively stable, target blood 
pressure was maintained with repeated small aliquots of 0.9% saline. This 
resulted in a gradual decline in haematocrit, and consequently haemodilution in 
all groups. However when animals started to decompensate the protocol 
demanded that a continuous infusion of saline was given in an attempt to 
maintain blood pressure. However during this brief terminal phase this was 
ineffective, resulting in a relatively large amount of 0.9% saline being given over 
a short period of time as the animal slipped towards death. Therefore during this 
terminal phase there was a very marked haemodilution that was not 
representative of the remainder of the study. Since such haemodilution would 
be expected to have a profound effect on clotting, which is of little interest in the 
context of this thesis since it is dilutional, all data relating to that terminal time 
point where haematocrit had fallen to <15%, was excluded from analysis. 
11.7 Statistical analysis 
11.7.1 Phases of treatment 
Phase 1 of the study encompasses all the pre-treatment time points and thus 
includes baseline, blast injury, haemorrhagic insult, shock phase and initial 
hypotensive resuscitation (target SBP 80mmHg). There were no injury or 
treatment differences between groups during this phase therefore the only 
anticipated differences were those resulting from the injurious insult and the 
magnitude of differences should be the same between groups. 
Phase 2 refers to the time period T30 to T60. Since treatment with either O2 or 
rFVIIa was initiated immediately after the T30 time point, this is the time in 
which the effects of rFVIIa are likely to be the greatest and is considered in the 
early treatment phase. Within this period, the T30 time point represents a pre-
treatment time point. However it is considered in the early treatment phase 
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since it is the last time point prior to treatment and thus could be considered the 
baseline measurement for this early treatment phase. 
 
Phase 3, is the late treatment phase, T60 to T180. There were insufficient 
animals in the control group to perform meaningful analysis between either the 
O2 group and control groups, or the IV rFVIIa group and control groups.  
Therefore for this phase of the study, the statistical comparison could only be 
made between the O2 group and the rFVIIa groups. 
11.7.2 Statistics 
All data are presented as mean +/- s.e.mean unless indicated otherwise.  
Survival times in were compared using Kaplan-Meier analysis (Mantel-Cox log 
rank test) using SPSS v10.  Data from animals still alive after 8 hours were 
treated as right-censored. Cardiovascular, blood gas and chemistry data were 
compared using two-way analysis of variance (ANOVA) with repeated 
measures over time.  Single time-point analyses were made using 2 way and 1 
way ANOVA as appropriate.  Where data was found to be non-normal a non-
parametric equivalent was used as indicated in the text.  In all cases a 
significance level of P≤0.05 (two tailed) was used. 
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Chapter 12. Results 
12.1 Survival 
Figure 12-1. Kaplan-Meier survival graph for the three study groups. Phase 1 (Pre treatment 
phase, blue), phase 2 (Early treatment phase, purple) and Phase 3 (late post treatment phase, 
green). The data analysed in this thesis was taken from the first three phases of resuscitation 
(coloured area on the graph). The survival study (not the subject of this thesis) extends to 8 
hours of resuscitation (grey area of the graph) during which physiological and coagulation data 
were not analysed. The asterix denotes treatment with either O2 or FVIIa  
 
Survival times in the group treated with rFVIIa were not significantly different 
from those seen in the placebo-treated animals (P = 0.649, Figure 12-1) By 
contrast, survival times in the group treated with supplementary oxygen was 
significantly better than those seen in both rFVIIa and placebo-treated animals 
(P=0.020 and P=0.014 respectively, (Figure 12-1) 
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It is possible that rFVIIa conferred a small survival advantage compared to 
placebo, but that the study did not have sufficient statistical power to detect it.  
A post hoc power calculation (Power 0.80, alpha 0.05, Log rank test) indicated 
that 23 animals per group would be required to determine whether the small 
difference in survival between rFVIIa and placebo shown in Figure 12-1 was 
statistically significant.  Since oxygen showed a far superior effect it was 
decided that pursuit of this relatively small effect of rFVIIa did not justify the use 
of additional animals. 
12.2 Oxygen Saturation 
 
Figure 12-2 O2 Arterial oxygen saturations (A) and venous oxygen saturations (B) over time in 
each group. Phase 1 (Pre treatment phase, blue), phase 2 (Early treatment phase, purple) and 
Phase 3 (late post treatment phase, green). The asterix denotes treatment with either O2 or 
rFVIIa. Dotted line in control group denotes insufficient number of animals to allow meaningful 
statistical comparisons. Mean values +/- SEM 
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12.2.1 Arterial oxygen saturation 
Assessment of arterial oxygen saturation (SaO2) revealed a significant 
difference between groups in the pre-treatment phase of the experiment, phase 
1 (P=0.0373) and a significant effect over time (P=0.0003) (Figure 12-2 A). The 
difference between groups was in the control group at baseline prior to any 
blast, haemorrhage or treatment. Since the magnitude of the difference was 
small, and both values lie within the normal range, this difference is not clinically 
significant. The effect over time occurred around the blast injury, haemorrhage 
and shock period and was a rapid drop in arterial O2 saturations in all groups. 
 
In the early treatment phase, there was a significant effect between groups 
(P=0.0003) and a significant effect over time (P=0.0053) due to the 
administration of O2 to the O2 group at T30, the beginning of phase 2 and 
represented a higher SaO2 in the O2 group by T60. 
 
In phase 3 there remained a significant effect between groups (P<0.0001), 
however there is no significant effect over time (P=0.6938). The higher SaO2 
was in the O2 group due to the administration of O2 throughout this phase of the 
experiment.  
12.2.2 Mixed venous oxygen saturations 
Assessment of venous oxygen saturations (SvO2) in the pre-treatment phase of 
the study showed a significant difference between groups (P=0.0136) and a 
significant effect over time (P<0.0001) (Figure 12-2 B). This difference occurred 
in the control group at the baseline measurement prior to any blast, 
haemorrhage or treatment. Since the magnitude of the difference was small, 
and both values lie within the normal range, this difference is not clinically 
significant.  
 
In the early treatment phase, T30 to T60, there was a significant difference 
between the O2 group, who had O2 administered at T30 (P=0.0057) and the 
control and rFVIIa groups, however there was no significant effect over time 
(P=0.506). The level of SvO2 in the O2 group by T60 is 33.31% (+/- 2.72) 
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compared with the rFVIIa group level of 21.83% (+/- 2.89), or the control group 
19.72% (+/- 1.85). Therefore, in spite of the statistically significant difference 
between the groups, the values are so low compared to the normal range of 60-
80%, that this is unlikely to represent a clinically significant difference 
 
The difference between the O2 and rFVIIa groups remained significant in phase 
3 of the study (P=0.0025), however the effect over time is not significant 
(P=0.6587). The higher SvO2 was in the O2 group due to the administration of 
O2 throughout this phase of the experiment. 
 
In summary there was a difference in arterial oxygen saturation in the O2 group 
after treatment with O2 at T30, however this effect does not result in a clinically 
significant difference in venous oxygen saturation even in the O2 group after 
treatment with O2 at T30. 
12.2.3 Oxygen extraction ratio 
 
Figure 12-3 Oxygen extraction ratio over time in each group. Phase 1 (Pre treatment phase, 
blue), phase 2 (Early treatment phase, purple) and Phase 3 (late post treatment phase, green). 
The asterix denotes treatment with either O2 or rFVIIa. Dotted line in control group denotes 
insufficient number of animals to allow meaningful statistical comparisons. Mean values +/- 
SEM 
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Assessment of oxygen extraction ratio (OER) (Figure 12-3) during phase 1 
showed a significant change over time (P<0.0001) as OER increased during 
shock, although there is no difference between groups (P=0.1097). 
 
During phase 2 there is no further change in OER over time (P=0.8885) and no 
difference between groups (P=0.1368). During the third phase a small 
difference between groups became apparent (P0.0475), although post hoc 
analysis could not specify a difference between any two groups. There was no 
overall significant difference over time during phase 3 (P=0.9171) 
 
12.3 Assessment of shock 
12.3.1 Arterial Base Excess 
Assessment of arterial base excess in the pre-treatment phase of the study 
showed no significant effect between groups (P=0.0595) however there was a 
significant effect over time (P<0.0001) (Figure 12-4 A), due to a progressive 
worsening of base excess due to the onset of tissue shock over the blast and 
haemorrhage phase of the study. 
 
During the early treatment phase of the study, in spite of a trend for a 
deteriorating ABE in the control and rFVIIa groups, there was no significant 
difference between groups (P=0.1796) and no significant effect of time 
(P=0.0588).  
 
Likewise in the late post-treatment phase of the study, the significant effect of 
group remained (P=0.0025), and there remained no differences over time 
(P=0.9677). The value of ABE at T180 in the O2 group was -12.27 mM (+/- 
3.03), and the value of the rFVIIa group was -18.7 mM (+/- 1.34). 
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Figure 12-4. Measurement of arterial base excess (A) and pH (B) in all three groups. Mean +/- 
SEM. (For further details see Figure 12-2) 
12.3.2 pH 
Assessment of pH in the pre-treatment phase of the study revealed no 
significant differences between groups (P=0.6371), however there was a 
significant effect overtime (P<0.0001) (Figure 12-4 B) due to a falling pH during 
the blast, haemorrhage and shock phase of the experiment. 
 
During the early treatment phase, phase 2, there was no significant difference 
between groups (P=0.7616) and no significant effect over time (P=0.2916) 
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However by the late post-treatment phase, there was a significantly higher pH in 
the O2 group (P=0.0068), however there was no significant effect over time 
(P=0.8619). The pH in the O2 group at T180 was 7.22 (+/- 0.06) compared to 
the rFVIIa group, which was 7.05 +/- 0.05.  
 
In summary the fall in both ABE and pH in the pre-treatment phase of the study 
represented the physiological insult of the blast, haemorrhage and shock 
period. In the late post-treatment phase there was a difference in the O2 and 
rFVIIa groups with the O2 groups having a higher (better) pH and ABE 
compared with the rFVIIa group. The difference between groups may well be of 
clinical significance (pH 7.22 vs 7.05, ABE -12.27mM vs -18.7mM), however 
both values fall in the range of values define shock (definition of shock 
commonly pH <7.2 and ABE >-6.0 mM) and therefore both groups have a 
clinically significant degree of shock. 
12.4 Prothrombin time and activated partial thromboplastin time 
12.4.1 Prothrombin time 
Clotting assessment using prothrombin time revealed no difference between 
groups (P=0.239) during the pre-treatment phase (phase 1) of the study 
protocol. However during phase 1 there is a significant change over time 
(P=0.0079) with an increase in PT during the short period immediately before 
the onset of resuscitation at T0 in all groups. The magnitude of this change is 
small and unlikely to be of clinical significance (Figure 12-5 A).  
 
During the early treatment phase (phase 2), 30 to 60 minutes after the onset of 
resuscitation, there was a significant difference between groups (P=0.0003) and 
change over time (P=0.0264) due to shortening of PT (enhancement of clot 
initiation) in the rFVIIa group. 
 
Thereafter in the late post-treatment phase (phase 3) analysis of the rFVIIa and 
O2 groups showed a significant difference between groups (P=0.0095) and a 
significant change over time (P=0.0002) The difference is due a progressive 
increase in PT in the rFVIIa group after an initially shortened PT. 
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In Summary the main difference in PT was seen as a shortening of PT in the 
rFVIIa group at T60 with a subsequent increase in the rFVIIa group over late 
phase of the study.  
 
 
Figure 12-5. Measurement of prothrombin time (A) and activated partial thromboplastin time (B) 
in all three groups. Mean +/- SEM. (For further details see Figure 12-2) 
 
12.4.2 Activated partial thromboplastin time 
Activated partial thromboplastin time in the pre treatment phase of the study 
showed a significant difference between groups (P=0.0145) and a significant 
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change over time (P=0.0499). The differences are clinically insignificant (Figure 
12-5 B). 
 
A significant difference over time was apparent between groups (P=0.0137),  
with the rFVIIa group displaying the longest aPTT in the early treatment phase. 
However there is no significant change over time in this phase (P=0.6636).  
 
In the late post-treatment phase of the study, a comparison of the O2 and rFVIIa 
groups revealed a significant difference between groups (P=0.0003) and a 
significant change over time (P=0.0182). This is due to a prolongation of aPTT 
the rFVIIa group whilst the O2 group remained unchanged. 
 
In summary the main differences in aPTT show a progressive lengthening of 
aPTT over time, especially in rFVIIa group in the late phase of the study. 
12.5 Clotting assessment by ROTEM® and TEG® 
12.5.1 Clot Initiation 
There was no significant difference in the ROTEM® clotting time (CT) between 
groups (P=0.0524) or over time (P=0.3028) during the baseline, immediate post 
injury and pre haemorrhage periods. (Figure 12-6 A) 
 
Thereafter there was a statistically significant, clinically insignificant reduction in 
CT in the rFVIIa group only, between pre-haemorrhage and 30 minutes after the 
onset of resuscitation (P=0.0295). This resulted in a statistically significant 
difference between groups at 30 minutes after the onset of resuscitation, with 
CT being highest in the O2 groups and lower in the rFVIIa and control groups. 
 
Treatment with either rFVIIa or O2 was given immediately after the T30 blood 
sample was taken, and the next time (T60) shows a significant difference 
between groups (P=0.0031), although there was no significant change over 
time (P=0.319). 
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Figure 12-6. Measurement of clot initiation in all three groups using standard ROTEM® clotting 
time (A) and dilute innovin TEG®  R time (B). Mean +/- SEM. (For further details see Figure 
12-2) 
 
Beyond T60 there was an insufficient number of survivors in the control group to 
allow meaningful statistical analysis, limiting the comparison to the rFVIIa and 
O2 groups. In the period T60 to T180 there was a significant difference between 
groups (P=0.0006), with the rFVIIa being lowest, but no significant change over 
time (P = 0.7975). 
 
Assessing clot initiation by TEG® (R-time) revealed a different pattern. There 
were no significant differences between groups (P=0.6058), or changes over 
time (P=0.6752) during the early part of the study (pre rFVIIa or O2 treatment) 
(Figure 12-6 B)  
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Furthermore, administration of rFVIIa or O2 did not cause a significant change in 
R-time (P=0.3516) and there were no significant differences between O2, rFVIIa 
or control groups by T60 (P=0.853)  
 
However, thereafter there was a significant difference between rFVIIa and O2 
groups (P<0.0001), together with a significant change over time (P < 0.0001), 
due to an increase in R-time in the rFVIIa group, while O2 group remained 
unchanged throughout this period. 
 
In summary the main change in clot initiation was seen in the rFVIIa group 
during the period T60 - T180 minutes after the onset of resuscitation; ROTEM® 
indicating an enhancement in clot initiation (a significant reduction in CT), whilst 
TEG® showed the opposite (significant increase in R-time). No change was 
detected in clot initiation in the O2 group by either method. 
12.5.2 Clot dynamics 
There were no significant differences between groups (P=0.1082) or changes 
over time (P=0.2647) in clot dynamics assessed by ROTEM® (CFT) during the 
initial phases of the study (up to T30, Figure 12-7 A).  
 
Furthermore, administration of rFVIIa or O2 immediately after T30 did not cause 
a significant change in CFT (P=0.8131), so that at T60 there were no significant 
differences between groups (P=0.9381).  
 
Again, because of loss of animals in the control groups, further comparisons 
could only be made between the rFVIIa and O2 groups. During the period T60 – 
T180 there was a significant change in CFT over time (P<0.0001) and between 
groups (P=0.032) as CFT increased in the rFVIIa group but remained 
unchanged in the O2 group. 
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Figure 12-7. Measurement of clot dynamics in all three groups using standard ROTEM ® clot 
formation time (A) and dilute innovin TEG® (B). Mean +/- SEM. (For further details see Figure 
12-2) 
 
A similar picture was seen when clot dynamics was assessed using TEG® (K-
time). There were no significant differences over time (P=0.6216) or between 
groups up to T30 (P=0.8599) (Figure 12-7 B). Administration of rFVIIa and O2 
did not cause a significant change in K- time (P=0.8262) so that there were no 
differences between the control, rFVIIa and O2 groups at T60 (P=0.8324).  
 
Thereafter analysis of the rFVIIa and O2 groups revealed a significant difference 
between groups during the period T60 – T180 (P=0.0001) and a significant 
change over this time period (P=0.0001). As with the ROTEM® analysis the 
  111 
change during T60 to T180 was due to a progressive increase in K-time in the 
rFVIIa group, whilst the O2 group did not change. 
 
In summary the main difference in clot dynamics was seen with both techniques 
and represented a reduction in clot dynamics (increase in CFT and K-time) in 
the rFVIIa group during the period T60 – T180, whilst the O2 group remained 
unchanged. 
12.6 Clot Strength 
Clot strength assessed using ROTEM® (MCF) revealed no difference between 
control, rFVIIa and O2 groups (P=0.6587) or over time (P=0.1304) during the 
initial period up to T30 (Figure 12-8 A).  
 
Furthermore immediately after administration of rFVIIa (between T30 and T60) 
there is no difference in clot strength between the groups (P=0.1203) or over 
time (P=0.4744).  
 
Thereafter comparison could only be made between rFVIIa and O2 groups in 
the period T60 – T180. Here there was a significant difference between groups 
(P=0.0105) and over time (P=0.0048). This difference was due to a fall in MCF 
in the rFVIIa group whilst it remained unchanged in the O2 group. Due to loss of 
animals and failure to reach MA in a number of samples when assessed using 
TEG®, meaningful statistical analysis could not be performed for clot strength 
data using this technique. However a qualitatively similar pattern can be seen in 
TEG® derived data as in ROTEM® derived data (Figure 12-8 B). 
 
In summary the change in clot strength was seen in the period T60 – T180 and 
represents a reduction in clot strength in the rFVIIa group whilst it remained 
unchanged in the O2 group. 
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Figure 12-8. Measurement  of clot strength in all three groups using ROTEM® maximum clot 
firmness (A) and TEG®  maximum amplitude (B). Mean +/- SEM. (For further details see Figure 
12-2) 
12.7 Fibrinogen 
12.7.1 Clauss fibrinogen 
Assessment of fibrinogen levels with Clauss fibrinogen measurements during 
the initial phases of the study, showed no significant differences between 
groups (P = 0.1689), however there was a significant effect of time (P= 
<0.0001). This effect of time is immediately prior to onset of resuscitation at T0 
and reflects the early effects of blast and haemorrhage on Clauss fibrinogen 
levels (Figure 12.9A). 
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Figure 12-9. Measurement of fibrinogen levels in all three groups using Clauss fibrinogen (A) 
and FIBTEM maximum clot firmness (B). Mean +/- SEM. (For further details see Figure 12-2) 
 
In the time period T30 to T60 there are no differences between groups 
(P=0.0853) and no effect of time (P=0.2962) 
 
Comparing O2 and rFVIIa groups only in the latter phase reveals a difference 
between groups (P=0.0057), however there is no difference over time  
(P=0.0653) 
 
In summary there was a significant drop in CF levels after blast and 
haemorrhage in all groups reflecting activation of coagulation. Thereafter there 
was a progressive difference between O2 and rFVIIa groups over time, 
particularly in the late phase of the study. During this time there was no 
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significant change over time, but there was a trend towards a decrease in CF 
levels. 
12.7.2 FIBTEM MCF 
Assessment of functional fibrinogen using FIBTEM MCF revealed no difference 
between groups in the pre-treatment phase of the study (P=0.646), and no 
significant change between baseline and 30 mins after the onset of 
resuscitation (p=0.8137) (Figure 12.9 B). 
 
During phase 2 of the study there was also no significant difference between 
groups (P=0.6998) and no change during the first 30 mins after rFVIIa/ O2 
treatment (P=0.7864). 
 
However in phase 3 comparing, O2 and rFVIIa only, there was a significant 
difference between groups (P=0.0017) and a significant change over time 
(P=0.0213). This is characterised by a marked drop in FIBTEM MCF by T180 in 
the rFVIIa group, but not in the O2 treatment group 
 
In summary there is a significant fall in FIBTEM MCF in the rFVIIa group late 
after administration of rFVIIa. 
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12.8 Platelet count 
 
Figure 12-10. Platelet count in all three groups. Mean +/- SEM. (For further details see Figure 
12-2) 
 
There was a significant difference in platelet count during phase 1 (P=0.0105), 
but not in phase 2 (P=0.2086). This difference was due to a higher value in the 
control group compared to the O2. Overall there were no changes in time during 
the initial phases (P=0.894 and 0.9222 respectively) (Figure 12.10). 
 
In the late phase, comparing O2 and rFVIIa groups only. There was no 
difference in groups (P=0.0663) however there is a significant effect over time 
(P=0.0099). 
 
In summary the main changes in platelet count is a progressive reduction in 
platelet numbers over time but no difference between groups. 
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12.9 Hct 
 
 
Figure 12-11. Measurement of haematocrit in all three groups. Mean +/- SEM. (For further 
details see Figure 12-2) 
 
There were no significant differences between groups in haematocrit during 
Phase 1 (P=0.4537), however there were significant changes over time in this 
Phase (P<0.0001), with a sharp fall in haematocrit in all groups associated with 
haemorrhage and the shock phase (Figure 12.11). 
 
It is of note that the greater part of the fall in haematocrit had occurred before 
the onset of resuscitation at time 0.  Thereafter there was a continued trend of a 
fall in haematocrit during Phase 2 in all groups, although this did not attain 
statistical significance (P=0.2891) and, again, there were no significant 
differences between groups (P=0.5128).  Comparing the O2 and rFVIIa groups 
only during Phase 3 there was no significant difference between the two groups 
(P=0.0544), although there was a significant change over time during this late 
post-treatment period (P=0.0384). 
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12.10 Follow up analysis of Individual clotting factors and natural 
anticoagulation 
Due to the numbers of samples available for individual factor assays it is only 
possible to report results in the following way. 
All groups (Control, O2, rFVIIa) were assessed at the experimental baseline and 
T60 (30 mins after treatment with O2 or rFVIIa). The remaining comparison was 
only able to made between the O2 and rFVIIa for the pre-treatment phase, 
(baseline to T30), the early treatment phase (T30 to T60) and late post-
treatment phase (T60 to T120) only. This is due to the amount of stored plasma 
available for the follow on analysis and is discussed in the methods (section 
13.9). 
12.10.1 FX 
 
Figure 12-12. FX assay in all three groups. Special considerations in interpreting rVIIa group 
must be considered when intepreting the results. (see section 13.10) Mean +/- SEM. (For 
further details see Figure 12-2) 
 
Looking at the pre-treatment phase and the early treatment phase (baseline and 
T60) in all 3 groups (control, O2 and rFVIIa), there was a significant difference 
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between groups (P=0.0128) with a significant effect of time (P=0.0014) (Figure 
12.2). The difference lies at T60 in the rFVIIa group.  
 
Looking at the rFVIIa and O2 only, in the pre-treatment phase (baseline to T30) 
there was no difference between groups (P= 0.5648), however the effect of time 
was significant (P<0.0001). This was due to a drop in FX levels following the 
blast injury and controlled haemorrhage and the initial 30 minutes of 
hypotensive resuscitation, and may reflect a consumption of FX due to the 
activation of coagulation.  
 
In the early treatment phase, T30 to T60, there was a significant effect of group 
(P=0.0035) and a significant effect of time (P=0.0011). This was due to a 
difference in the rFVIIa group at T60  
 
Thereafter from T60 to T120 there remained a significant difference between 
groups (P=0.0036) and a significant effect of time (P=0.0005). This was due to 
a difference in the rFVIIa group, which was declining rapidly over time so that by 
T120 there was no difference between the groups. 
 
In summary FX levels were significantly higher in the IV rFVIIa treatment group 
compared to the other two groups at T60. Thereafter there was a rapid decline 
in FX levels in the rFVIIa group between T60 and T120 so that by T120 the 
levels in the rFVIIa and O2 groups were not significantly different. It should be 
noted that there are special considerations which must be made when 
interpreting the results in animals given a therapeutic dose if rFVIIa which are 
discussed in section 13.10). 
12.10.2 FV 
Looking first of all at all 3 groups at the experimental baseline and T60 (30 mins 
after treatment with IV rFVIIa or O2), there was no significant difference 
between groups (P=0.2824), however there is an effect of time (P=0.0127) 
(Figure 12.13). The lack of plasma available for analysis is probably the reason 
for the lack of statistical significance in this phase. FV levels did appear to be 
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high at T60 in the rFVIIa treatment group. Lack of significance between groups 
may be due to the small number of plasma samples available for assay. 
 
 
Figure 12-13. FV assay in all three groups. Special considerations in interpreting rVIIa group 
must be considered when intepreting the results. (see section 13.10). Mean +/- SEM. (For 
further details see Figure 12-2) 
 
Looking at the O2 and rFVIIa groups only in the pre-treatment phase, there was 
no difference between groups (P=0.1508) and no effect of time (P=0.6499) 
 
In phase 2, however, there was a significant effect of group (P=0.0066) and a 
significant effect of time (P<0.0001) due to a rise in FV levels in the rFVIIa 
group. 
 
Finally in the late post-treatment phase (T60 to T120) there remained a 
significant difference between groups (P<0.0001) and a significant effect of time 
(P<0.0001) and a rapid decline of FV levels in the late post-treatment phase. 
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12.10.3 FII 
Looking at al 3 groups at baseline and T60, there was a significant difference 
between groups (P<0.0001) and a significant effect of time (P<0.0001) (Figure 
12-14). Similar to FX and FV assays, the difference is due to the high levels of 
FII in the rFVIIa treatment group at T60. 
 
Looking at the rFVIIa and O2 only: in the pre-treatment phase, there was no 
significant effect between groups (P=0.8133), however there is a significant 
effect of time (P<0.0001). This is due to a drop in FII levels following the blast 
injury and controlled haemorrhage and the initial 30 minutes of hypotensive 
resuscitation, and may reflect a consumption of FII due to the activation of 
coagulation.  
 
Figure 12-14. FII assay in all three groups. Special considerations in interpreting rVIIa group 
must be considered when intepreting the results. (see section 13.10). Mean +/- SEM. (For 
further details see Figure 12-2) 
In the early treatment phase there was a significant difference between groups 
(P<0.0001) and a significant effect of time (P<0.0001). The early treatment 
phase likewise showed significant difference between groups (P<0.0001) and a 
significant effect of time (P<0.0001), which is the same for the late post-
treatment phase, a significant difference between groups (P<0.0001) and a 
significant effect of time (P<0.0001). Similar to the other factor assays the 
  121 
difference is due to a rise of FII at T60 in the rFVIIa treatment group, followed 
by a rapid decline to T120. 
 
In summary the assessment of factor levels is complicated due to the 
administration of rFVIIa at T30 in the rFVIIa group. This means that the assay is 
performed with an unknown concentration of the factor in question, and an 
unknown concentration of the rFVIIa administered at T30. Thus the levels in the 
rFVIIa group qualitatively reflect the action of rFVIIa and the factor in question, 
rather than simply a quantitative assessment of the factor itself. This does not 
allow meaningful comparison of absolute levels between groups, but does 
reflect the effect that the rFVIIa has on the coagulation system in vivo. The only 
conclusions that can be drawn from these results are that the action of rFVIIa 
causes a “boost” in activity beyond T30, which declines rapidly by T120.  
12.10.4 FVII:  
There was not enough plasma to obtain enough results to allow statistical 
comparison and so no comparisons were made 
12.10.5 HS, TFPI, Syndecans 
For all of these assays the results fell well below the lower limit of the detection 
range for each assay. Since the assays are research assays for human plasma, 
it is possible that these assays are not suitable for porcine blood. The results 
have therefore not been analysed 
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Chapter 13. Discussion 
13.1 Introduction 
The principal findings of this study were that blast and haemorrhage in a 
hypotensively resuscitated pig model leads to acute trauma coagulopathy 
characterised by a progressive deterioration in coagulation parameters. As 
expected, the administration of intravenous (IV) rFVIIa confers a short “boost” in 
clotting, however it was followed by an exaggerated deterioration in coagulation.  
This exaggerated deterioration, superficially, is a surprising result but has 
potentially important implications for military resuscitation. In a military context 
with limited logistical support and finite amounts of blood products, there is a 
potential role for the use of rFVIIa as a resuscitation adjunct to “boost” clotting 
and reduce blood loss (see section 7.2.1). If the administration of rFVIIa causes 
a late deterioration in clotting, albeit when no further treatment was given in the 
current study, then the use of rFVIIa may be contraindicated.  Potential causes 
of the deterioration in the rFVIIa group are consumption of clotting factors, 
increased expression of natural anticoagulation or the presence of acidosis. The 
limitations of this study make it impossible to categorically differentiate between 
these factors as the underlying cause, although consumption appears to be 
most likely. 
 
In the current study, coagulation deteriorated over time, implying that prolonged 
hypotension is detrimental to clotting. In a clinical setting, therefore, the ongoing 
presence of coagulopathy may be symptomatic of ongoing microcirculatory 
shock caused by under resuscitation, even if appropriate blood product 
replacement has occurred using local transfusion policies. If a clinician is able to 
rapidly assess coagulation and assess the results together with other clinical 
information, the presence of ongoing coagulopathy may point towards an under 
resuscitated patient. 
  123 
The following discussion will lay out the evidence for these conclusion, address 
the limitations of this study and outline future work to expand and corroborate 
the findings. 
13.2 Survival 
This study formed part of a survival study based on the investigation of O2 or 
rFVIIa as a treatment of blast lung. The survival in the O2 was significantly 
higher that in either the rFVIIa or control group rendering comparisons between 
groups in the late phases of the study more difficult. This represents one of the 
limitations of this study. 
13.3 The injury Model  
The injury model was successful in producing representative aspects of a 
battlefield injury, incorporating blast injury and haemorrhagic shock with the 
ensuing trauma induced coagulopathy. 
 
The blast loading was of sufficient magnitude to produce significant lung 
contusions and a clinically significant fall in PaO2. The presence of blast lung 
was confirmed at post mortem. At the same time, the blast loading was not 
overwhelming and compatible with survival of the animals. 
 
The combination of the blast and the haemorrhage produced significant 
changes in arterial oxygen saturation (SaO2), venous oxygen saturation (SvO2) 
and in arterial base excess (ABE). The low SvO2 and ABE confirmed the 
presence of shock in the animals. In this model the severity of the shock is of 
sufficient magnitude to cause acute trauma coagulopathy. 
 
The liver snare was deployed successfully and amputated the desired section of 
the liver. This was confirmed at post mortem. The amputated section was a 
“clean” wound with relatively little tissue damage. There was a robust clot on the 
remaining liver, also confirmed at post mortem... Since the amputated section of 
the liver amounted approximately 6% of liver mass, it is unlikely to consume a 
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significant amount of clotting factors. Also the liver injury was performed in all 
groups prior to treatment with either O2 or rFVIIa and in any case a well 
developed clot would have formed within the 30 minutes between the 
deployment of the liver snare and the administration of either O2 or rFVIIa. The 
clot size and characteristics were the same between all groups with no 
evidence of on-going bleeding in any group and is therefore unlikely to be the 
cause of any differences between groups. 
13.4 Injury Burden 
Shock is defined as the inability of whole body oxygen delivery to meet the 
metabolic demands of the tissues. After trauma, shock can occur due to 
inadequate perfusion of the tissues due to a fall in cardiac output after 
haemorrhage, or inadequate oxygenation due to altered gas exchange in the 
lungs. In this model the shock occurs due to both the effects hypovolaemia after 
the 30% blood volume haemorrhage and the effects of blast lung decreasing 
oxygen diffusion in the alveoli.  
 
As oxygen delivery to the tissue falls, the body tries to compensate by 
extracting more O2 from the blood resulting in less O2 at the venous end of the 
circulation measured by the SvO2. When oxygen supply does not meet the 
demands of the tissue the body is unable to produce energy via aerobic 
respiration, and relies instead on anaerobic respiration producing lactic acid as 
a byproduct. This metabolic acidosis is reflected as a fall in base excess and a 
fall in pH.  
13.4.1 Acute Trauma coagulopathy in relation to oxygen delivery and shock. 
In the current study there was a noticeable drop in the SaO2 around the time of 
the blast and the haemorrhage. The SaO2 then remained at low levels 
throughout the remainder of the experiment in the rFVIIa and control group 
(around 80%), however they were returned to normal levels in the O2 group 
once supplementary oxygen was given. This is a clinically significant difference. 
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SaO2 determines the oxygen saturation of the inflow to the microcirculation 
whereas SvO2 reflects the oxygen saturation of blood leaving the 
microcirculation and therefore represents the oxygen “left over” after the tissues 
have extracted all they need. SvO2 reflects oxygen delivery and oxygen uptake; 
if SvO2 is low, in spite of a high SaO2, then the oxygen supply is still unable to 
meet the oxygen requirement of the tissues and in the presence of a 
simultaneous metabolic acidosis, microcirculatory shock is present.  
 
During the late phase of this study the rFVIIa group had SvO2 levels around 
25%, and the O2 group had levels around 30 %. In humans, in the intensive 
care unit, SvO2 rarely falls below 60% and sustained low levels are associated 
with increased mortality, with levels around 50% deemed critical (Rivers et al., 
2001). In both the O2 and the rFVIIa group, the SvO2 levels are significantly 
lower than 50% and are so low that microcirculatory shock is present in both 
groups. Microcirculatory shock is thought to be the driver for ATC (Gruen et al., 
2012; Curry et al., 2012) (Section 3.4.1 ). Since the difference in SvO2 between 
the O2 and rFVIIa groups is likely to be clinically insignificant as far as the 
effects on the microcirculation is concerned, it is unlikely that the difference in 
SaO2 is responsible for any differences in coagulation between groups. This 
view is confirmed by a change in OER to maximum levels during shock, with 
little difference between groups during subsequent treatment. This means that 
the tissues are extracting maximal oxygen from the blood, which is unable to 
meet the metabolic demands of the tissues (confirming shock) and is the same 
in all groups in spite of the O2 group receiving oxygen. 
 
However, in spite of low SvO2 confirming the presence of microcirculatory shock 
in both the O2 and the rFVIIa groups, the O2 group does have a clinically 
significant increase in SaO2. This leads to an improved survival in the O2 group 
and is therefore exerting a clinically significant effect at a metabolic level. It is 
therefore not possible to exclude the administration of O2 after T30 as a 
potential reason for any improvement in clotting indices compared to the rFVIIa 
group. 
 
Most of the studies that examine the aetiology of ATC do not relate either SaO2 
or SvO2 to the development of ATC (Brohi et al., 2008; Curry et al., 2012; Gruen 
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et al., 2012). The studies discuss poor tissue perfusion and tissue hypoxia as a 
potential driver for ATC and appear to use these terms interchangeably.  A low 
SaO2 or low SvO2 confirms poor tissue oxygen delivery, which leads to 
anaerobic respiration, and subsequently to acidosis with a low pH or a low ABE. 
These studies therefore use ABE as a marker of tissue shock.  
13.4.2 Arterial Base excess 
Base deficit or negative arterial base excess or are the most described 
parameters when relating trauma induced coagulopathy with evidence of tissue 
shock. An ABE <-6mM is generally accepted as a definition of hypoperfusion 
(Brohi et al., 2007b; Curry et al., 2012) and linked to the development of ATC. 
Brohi et al demonstrated that as ABE worsened, so PT and aPTT increased, as 
did levels of enzymes involved in the activated protein C pathway. He did not 
further categorise data beyond an ABE of -7.7mM and therefore it is impossible 
to determine how coagulation changes as ABE worsens beyond 6mM.  
 
Other studies have attempted to stratify the degree of hypoperfusion based on 
ABE. Jansen et al (Jansen et al., 2011) further subdivided patients in ABE 
groups of normal perfusion (ABE 0 to-6mM), moderate hypoperfusion (ABE -7 
to -12mM) and severe hypoperfusion (ABE <-12mM). Whilst there were 
significant differences between groups in factor levels of FI, VII, IX, X and XI the 
majority of values were in the normal range. In addition, it appears that the 
difference is between the severe hypoperfusion group and normal group. This 
study concluded that there was a relationship between ABE and factor levels, 
however the association is only moderate and the effect on coagulation tests 
such as PT or aPTT was not reported. It therefore remains uncertain what effect 
a progressively worsening base deficit has on coagulation levels beyond a base 
deficit of 6mM. 
 
In the current study ABE levels are significantly different between groups after 
T30 reflecting administration of O2 treatment, The Control and rFVIIa groups 
have ABE of -14 to -18 in phase 2 and 3, whereas the O2 group had a ABE of  -
10 to -12. Whilst the difference may be statistically and may even be clinically 
significant, all 3 groups fall in the category of  “hypoperfusion’ or “severe 
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hypoperfusion” as defined by Brohi and other authors. Mutshler et al (Mutschler 
et al., 2013) performed a retrospective analysis of the German trauma registry 
and determined that as ABE worsened so mortality increased. He demonstrated 
that an ABE between -6 and -10 mM had a mortality of 23.9%, whereas an ABE 
<-10 mM had a mortality of 51.5%. It is unknown what ABE is the threshold for 
hypoperfusion in pigs, however Garner et al (Garner et al., 2010) in previous 
work at DSTL demonstrated that prolonged hypotension and worsening ABE 
was associated with an increased mortality. He didn’t directly relate ABE to 
mortality, however interpreting the presented results suggests that an ABE of 
around -10mM in Garner’s study was associated with a mortality of around 
50%, comparable with humans. The similarities between pigs and humans in 
terms of mortality, would suggest that it would not be unreasonable to assume 
an ABE <-6 in pig represents the same degree of hypoperfusion as seen in 
humans. In the current study, the ABE was well below -6mM and therefore 
represents hypoperfusion in all groups. 
13.4.3 pH 
Acidosis is known to effect clotting and the activity of rFVIIa (See section 7.3) 
on phospholipid membranes, however the exact level at which pH has an effect 
is uncertain. Decreased thrombin generation has been shown to occur at a pH 
of 7.1 in pigs (Curry et al., 2012; Martini and Holcomb, 2007), however does not 
appear to affect clot initiation measured either by TEG® or PT (Martini et al., 
2005; Viuff et al., 2008). In Martini’s studies the pH is induced to 7.1 with an 
infusion of HCl and is not physiological acidosis, and Vuiff’s study with an acidic 
buffer.  Other authors suggest problems occur at a pH of only 7.2 (Gruen et al., 
2012; Meng et al., 2003). What is well accepted, however, is that a reduction of 
pH will affect platelet activity (Djaldetti et al., 1979; Etulain et al., 2012), 
microparticle formation (Etulain et al., 2012) and coagulation factor activity 
(Curry et al., 2012). The efficacy of rFVIIa at a pH <7.2 has been questioned 
(Meng et al., 2003; Knudson et al., 2011) and recent clinical recommendations 
suggesting restoring pH to at least 7.2 to ensure efficacy of rFVIIa action 
(Spahn et al., 2013). However other experimental work has suggested that that 
rFVIIa will work even in the presence of a physiological lactic acidosis in a pig 
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model (pH 7.14) (Lesperance et al., 2012) or an in vitro  induced pH of 6.8 (Viuff 
et al., 2008). 
 
In the current study the pH is between 7.05 and 7.22 in phase 2 and 3 in all 
groups. There is a statistical difference between the rFVIIa group (being lower) 
and the O2 group (being higher). The question is “does that difference in pH 
make a clinical difference in coagulation?” Both groups fall into the pH range 
(7.0 to 7.2) where uncertainty exists as to the exact effect on coagulation. 
Therefore, because of this uncertainty, it remains possible that the difference in 
pH seen between the O2 and the rFVIIa groups might explain any differences 
seen in coagulation between the groups. 
 
In summary, SaO2 is significantly different between groups in statistical and 
clinical terms, which has resulted in improved survival in the O2 group. The 
SvO2, is also significantly different between the groups although the level has 
fallen so low that the difference between groups is unlikely to be of clinical 
significance. There is a statistical difference in the ABE and pH between 
groups, which is likely to be the consequence of the increased arterial oxygen 
content/ delivery in the O2. This difference may well be clinically significant, 
although its effect on clotting is not clear. It is therefore not possible to rule out 
the effects of acidosis as an explanation for the differences seen in clotting 
between the O2 and rFVIIa groups. 
13.5 The effect of dilution on clotting 
Dilution of clotting factors with either infused fluids, or movement of fluid from 
the extracellular to intravascular space, is known to affect clotting. Maegele et al 
(Maegele et al., 2007) noted that the incidence of coagulopathy after trauma 
increased with the volume of fluid administered. However the coagulopathic 
group also had significantly higher injury severity scores. The incidence of 
coagulopathy increases as injury severity score increases (Brohi et al., 2003) 
and so it is not possible to rule out the effect of worse injury as the cause of the 
increased coagulopathy in Maegele’s study. 
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Bolliger et al (Bolliger et al., 2009) studied the effects of dilution on thrombin 
generation. He diluted clotting factors to about 20% of baseline, although he 
maintained haematocrit at 20 – 23%. He noted that peak thrombin generation 
was reduced by about 50% after dilution, however the lag time remained 
unchanged.  Based on these findings it would be expected that dilution would 
effect clot dynamics and/or clot strength, but would not affect clot initiation. 
 
In the present study, there is no difference in Hct between groups, although 
there is a difference over time. Some very dilute samples, due to the protocol 
driven increase in fluid administration in the terminal phase of an individual 
animal, were excluded as these data point were not representative of the study 
as a whole (see section 11.6)  
 
In phase 1 of the experiment there is a significant effect over time in all groups. 
This difference is, prior to treatment with either O2 or rFVIIa, was as a 
consequence of the blast and haemorrhage and would be expected.  
 
The effects of dilution would not simply affect the Hct, but also the factor levels 
including the fibrinogen. An estimate of the degree of haemodilution at any 
timepoint can be made from the proportional fall in haematocrit from baseline in 
each animal.  This figure can then be applied to each animal’s baseline 
fibrinogen level to predict the fibrinogen level that would be seen at each 
timepoint simply as a result of haemodilution.  If this predicted figure is 
subtracted from the actual (observed) fibrinogen level an evaluation can be 
made regarding the impact of haemodilution on fibrinogen level.  A difference of 
zero would imply that the observed fibrinogen level is likely to be due simply to 
haemodilution, while a negative difference would indicate that the observed 
value is lower than would be predicted simply by the effects of dilution i.e. an 
additional process such as consumption may also be playing a part.  These 
data are plotted in Figure 13-1. 
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Figure 13-1. Arithemetic differences between observed Clauss fibrinogen levels and values 
predicted based upon resuscitation-induced haemodilution (assessed by fall in haematocrit). 
Mean +/- SEM. 
 
During Phase 1 and Phase 2 there was no significant difference between 
groups (P=0.1118), nor any significant difference from zero or change over time 
(P=0.4808), suggesting that the fall in fibrinogen levels seen during this period 
is principally the effects of haemodilution in all groups.  In Phase 3 it is only 
possible to compare the IV rFVIIa  and O2 groups up to T120, due to loss of 
data points in the Control group and at T180 in the IV rFVIIa  group.  During this 
period there is a significant difference between the IV rFVIIa and O2 groups 
(P=0.0176) due to the IV rFVIIa  group falling significantly below zero at T120 
(P=0.0058) while the O2 group does not (P=0.8198).  The implication from these 
findings is that the fall in fibrinogen levels in the IV rFVIIa group during Phase 3 
(Figure 12.9 A) is due to some process(es) in addition to simple haemodilution, 
while the fall in fibrinogen in the O2 group can be accounted for by dilution 
alone.  Caution must always be attached to analyses such as this one where 
group sizes are small, which renders statistical analysis and interpretation 
difficult.  These data would, however, be consistent with the suggestion that 
there is additional consumption in the IV rFVIIa group during Phase 3, which is 
not occurring in the O2 group, although a firm conclusion could only be drawn 
with a study over an extended timeline with greater numbers.  Since we do not 
have a sufficient dataset in the Control group it is impossible to ascertain 
whether it is the IV rFVIIa that has caused accelerated consumption or O2 that 
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has attenuated consumption.  However, it is likely that O2 is the better treatment 
compared to IV rFVIIa with respect to fibrinogen levels in Phase 3. 
 
In summary dilution does not appear to explain the difference between the IV 
rFVIIa and oxygen groups in the late past-treatment phase. Any dilution that did 
occur would be expected to affect clot dynamics and would not explain any 
differences seen in clot initiation between groups. Comparing fibrinogen levels 
with estimated dilution, suggests that dilution alone does not explain the fall in 
fibrinogen levels. 
 
13.6 The rationale for using dilute Innovin to measuring clotting 
The rationale for the use of dilute Innovin as a reagent for TEG® analysis 
comes from the presumption that the increased sensitivity is likely to detect 
changes not seen in the PT or ROTEM®. 
 
PT and ROTEM® are designed so that the amount of tissue factor used 
overwhelmingly activates all the clotting factors present in the sample. However 
visible fibrin clot develops in vivo after only 3-5% of total thrombin is produced, 
the remaining 95% of thrombin production occurring after clot formation has 
started (Young et al., 2013).  
 
Sørensen et al looked at ROTEM® activation using different dilutions of TF 
(diluted from 1:17 to 1:34  000) (Sørensen et al., 2003). Sørensen and 
colleagues compared blood from haemophiliacs, who clinically had slow, 
depressed clotting, with that from normal volunteers. Both groups of patients 
had identical results when high concentrations of TF were used. However lower 
concentrations of TF revealed differences between the groups that were 
commensurate with the clinical effects of haemophilia. He found the best 
dilution to be 1:17 000 providing enough initiation to activate the test in a useful 
time, but sensitive enough to detect differences between groups. He concluded, 
therefore, that ROTEM® initiated with dilute TF may reflect better the 
haemostatic potential in patients with suspected impaired haemostasis. 
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Ganter et al (Ganter et al., 2008a) investigated the optimum way to monitor the 
effects of rFVIIa. He recommend that to detect the effects of rFVIIa, only dilute 
amounts of TF should be used for best sensitivity since high amounts of TF may 
directly activate coagulation and bypassing the requirements for FVIIa. He 
recommended a dilution of 1:1000 to effectively monitor rFVIIa therapy. When 
Comparing Sørensen’s dilution and Ganter’s dilution, it should be remembered 
that Sørensen described a final concentration of 1:17 000 . Ganter added 20µl 
of 1:1000 TF to 340µl of blood giving a final concentration of 1:17 000. In this 
current study the final dilute innovin concentration was 1:50 000, comparable in 
magnitude to Sørensen and Ganter and therefore is likely to be effective at 
monitoring rFVIIa therapy. 
 
13.7 Assessment of clotting 
 
In this section I shall deal with all the aspects of clotting (initiation, dynamics 
and strength) in turn before considering the process as a whole, which is often 
an easier way to conceptualise the process. 
13.7.1 Clot initiation 
The changes in PT and ROTEM® CT are broadly the same, particularly in the 
early phases of the experiment. They demonstrate no real clinically significant 
difference between the groups up until T30. Thereafter the IV rFVIIa group 
shows a marked reduction in the time taken for clot initiation. This effect would 
be expected since rFVIIa works by increasing thrombin generation and 
decreasing the lag time for thrombin generation, either via its TF dependent 
pathway, initiating clot via the TF-VIIa pathway, or by its TF independent 
pathway directly producing FXa from the activated platelet (Grounds et al., 
2006). 
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In the late phase of the study observed from T60 through to T180 the O2 and 
rFVIIa groups only, show differences between the PT and ROTEM®. PT shows 
a marked deterioration in the rFVIIa group over time. ROTEM® however, 
showed no difference over time in the rFVIIa group.  
 
PT and ROTEM® differ in that PT is performed in platelet poor plasma. 
ROTEM®, by contrast, uses whole blood and therefore contains platelets as 
well as other cellular components.  Since rFVIIa works, in part, by releasing 
thrombin from the activated platelet, it is possible that the difference in the PT 
and ROTEM® trend over this time is due to the ongoing, albeit increasingly 
weak, stimulation of thrombin release from the platelets in the ROTEM® 
sample. 
 
In contrast, the dilute Innovin TEG® shows a different finding from PT and 
ROTEM®. The dilute Innovin TEG® was performed as it is known to have an 
increased sensitivity to coagulation changes, particularly in abnormal blood 
(See section 13.6). The initial assumption was that the dilute Innovin TEG® 
would mirror ROTEM® results, although the changes might be detected earlier 
in the experiment, however the results showed a surprising, opposite effect.  
 
Initially, up to T60, there were no differences between groups, or over time, and 
the Innovin TEG® results mirrored ROTEM® and PT. However in phase 3 of 
the study (T60 – T180) TEG® R time increased significantly (demonstrating a 
deterioration in clot initiation). This result is, on the face of it, different from 
ROTEM® and PT.  
 
A possible explanation is that the amount of TF present in PT and ROTEM® is 
sufficient to maximally stimulate all the available clotting factors in the sample. It 
may well be that the dilute Innovin TEG® is detecting a change masked by the 
concentration of TF in the ROTEM® and PT. The increased sensitivity of the 
dilute Innovin TEG® might therefore be performing as was originally intended, 
and picking up changes in the coagulation system earlier than ROTEM® or PT.  
 
A final consideration for the difference between the TEG® results and ROTEM® 
is also due to the increased sensitivity of the dilute Innovin TEG®. Whilst the 
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pathophysiology of ATC remains unclear, microcirculatory shock and the 
hypoxic endothelium as a driver for the altered balance between coagulation, 
natural anticoagulation and fibrinolysis is increasingly accepted as the likely 
cause. It is plausible, therefore, that the dilute innovin TEG® is detecting the 
effects of the natural anticoagulants such as tissue factor pathway inhibitor 
(TFPI), anti thrombin (AT) and heparans.  
 
It is possible that the dilute innovin TEG® is sensitive to the effects of TFPI. 
TFPI acts by complexing with FXa and inhibits the TF-VIIa complex in a FXa 
dependent manner (Lupu et al., 1995) (see section 2.6.1) It is therefore possible 
that the extra FXa, produced after the administration of rFVIIa, complexes with 
the increased TFPI produced from the activated endothelium, which may exert 
an exaggerated natural anticoagulant effect causing delayed clot initiation and a 
prolonged R -time. This is highly speculative. 
 
Increased TFPI levels have been shown to affect clot initiation and dynamics. 
Audu et al. (Audu et al., 2006) investigated the effects of TFPI on TEG® kinetics 
and found that addition of TFPI (in large doses, twice normal concentration) 
delayed clot initiation (prolonged R time). Dahm et al. (Dahm et al., 2005) 
looked at the difference between standard TFPI assays (ELISA) and the dilute 
prothrombin assay using dilute tissue factor. He found that the dilute 
prothrombin assay was sensitive to the effects of full-length TFPI chains that 
are released from the endothelium after stimulation by thrombin.  
 
Prolongation of R time is also a feature of heparin administration, which acts in 
conjunction with AT. Whist none of these animals received heparin, there is a 
possibility that they have increased heparans produced after endothelial 
damage and activation following trauma and microcirculatory shock.  
 
Heparans act in a similar way to heparin and also act in association with AT and 
are also a potent inhibitor of clotting. It may be that the dilute innovin TEG® is 
detecting the heparin like effect of heparans produced in ATC. 
 
Liener et al. (Liener et al., 2001) looked at AT activity after trauma and found an 
initial drop in AT activity in blood samples drawn immediately at the site in 
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injury, followed by a rapid rise in activity after admission to hospital, despite no 
administration of AT. This effect was most significant in the more severely 
injured group and the rise in activity to near normal levels occurred within the 
first 2 hours. He speculated that the initial drop is due to consumption, in 
response to activation of coagulation, and the rapid return to normal levels is 
due to upregulation of AT production.  
 
Heparan levels have not been reported after trauma, however are attached to 
the endothelium via syndecan-1. Syndecan-1 levels as a marker of endothelial 
cell wellbeing have been looked at in recent work by Johansson et al. 
(Johansson et al., 2011a; 2013). They demonstrated that trauma increases the 
degradation of the endothelial glycocalyx (raised syndecan-1 levels), with 
associated increases in TFPI and DAMPS. Haywood-Watson et al (Haywood-
Watson et al., 2011) have also demonstrated an increase in syndecan -1 levels 
after trauma which improved after resuscitation. Raised Syndecan-1 levels 
imply endothelial damage and poor endothelial health. Raised syndecan-1 
levels may not themselves exert an anticoagulant effect, however they are 
attached to the heparans, which may exert an anticoagulant effect, and are a 
marker of endothelial activation, the driver behind ATC.  
 
The evidence for natural anticoagulants affecting coagulation, or being detected 
by viscoelastic methods remains patchy and warrants further investigation. 
However it appears that TFPI levels increase after trauma, that glycocalyx 
degradation, with presumed associated rises in syndecans and heparans 
increases after trauma and that AT levels fall due to their increased requirement 
to provide natural anticoagulation protection to the increased activity of clotting 
pathways. It is therefore possible that the increased sensitivity of the dilute 
Innovin TEG® can detect the imbalance of these natural anticoagulants after 
trauma. 
13.7.2 Clot dynamics 
Assessment of clot dynamics in both ROTEM® and TEG® followed the same 
pattern, There were no differences between groups over time in the first 2 
phases of the study up to T60. Between T60 and T180, however, there is a 
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significant deterioration in clot dynamics in the IV rFVIIa group. The dynamic 
phase of clot formation represents the interaction between platelets, fibrinogen 
and clotting factors. The dynamics will be affected by absolute amounts of these 
factors, but also their activity.  
 
This deterioration in dynamics can be explained by decreased factor, 
specifically fibrinogen levels, in the rFVIIa group, the presence of increased 
natural anticoagulation due to ATC, or simply due to the increased acidosis in 
the rFVIIa groups inhibiting enzyme function.  
 
Low fibrinogen levels and low platelet levels are known to affect clot dynamics. 
Fenger-Erikson et al. (Fenger-Eriksen et al., 2009) examined the effect of 
dilution on clot dynamics, and how the addition of fibrinogen altered these 
parameters. He found that the addition of fibrinogen improved clot dynamics 
and clot strength, but not clot initiation. Fibrinogen levels are significantly lower 
in the rFVIIa group and discussed in more detail in the section on clot strength 
(section 13.7.3). These low levels may explain the deterioration on clot 
dynamics seen, particularly in the rFVIIa group. 
 
Similarly to the role of anticoagulants in clot initiation, the presence of inhibitors 
such as TFPI may have an effect on clot dynamics. Audu et al. (Audu et al., 
2006) demonstrated that  that addition of TFPI (in large doses, twice normal 
concentration) reduced clot kinetics (decreased angle) as well as delayed clot 
initiation (prolonged R time). However the ROTEM® is insensitive to the effect 
of natural anticoagulation, due to the large dose of TF used as an initiator, 
therefore the presence of natural anticoagulation cannot explain the differences 
seen. 
 
Enzyme function is impaired by acidosis. The rFVIIa group is significantly more 
acidotic than the O2 group, although it is unclear the effect that acidosis has on 
rFVIIa activity (Lesperance et al., 2012).This is discussed in more detail in 
section 13.4.3  but remains a possibility to explain the effects in clot dynamics 
seen in the rFVIIa group. 
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13.7.3 Clot strength 
Clot strength remains largely unchanged in the first two phases of the study in 
both ROTEM® and TEG®. When assessing clot strength using ROTEM®, there 
is a statistically significant fall in clot strength over time in the rFVIIa group, such 
that by T180 there is a statistically significant difference between the rFVIIa 
group and the O2 group. Failure to reach MA in the TEG® assessment means 
that it was impossible to perform meaningful analysis of the TEG® data, 
however qualitatively it agreed with the ROTEM® results. 
 
 Clot strength is determined by the availability of functional platelets and 
fibrinogen. Examining the platelet count over the same time periods 
demonstrated a significant effect over time in both the O2 and rFVIIa groups with 
a drop in platelet count over this period. This represents ongoing consumption 
of platelets due to activation of clotting and would be a normal effect of 
prolonged activation of coagulation.  
 
However the platelet count does not qualitatively assess the function of 
platelets. Both ROTEM® and TEG® are influenced by the qualitative function. It 
is speculated that there is a platelet dysfunction early after trauma (see section 
3.2.5) (Jansen et al., 2013) and thus a loss of functional platelets can reduce 
clot strength in spite of a high platelet count 
 
Assessment of Clauss fibrinogen levels shows a reduction in fibrinogen levels in 
the rFVIIa group over the latter phases of the study. Examining the time point 
T180 between the O2 and the rFVIIa group there was no statistical difference 
between groups, however the trend over time is such that the final fibrinogen 
level in the rFVIIa group is 0.796 g/dl (+/- 0.565) compared with a level of 
1.62g/dl (+/- 0.223) in the O2 group. It is unclear what a clinically significant low 
fibrinogen level is in a pig, however this value would be well below the 1.5 to 2.0 
g/dl target for a human (Spahn et al., 2013) and may therefore represent a 
critically low fibrinogen level in the pig. This level could significantly impact the 
final clot strength.  
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FIBTEM MCF, which assesses functional fibrinogen levels, demonstrated a 
statistically significant difference between the O2 and rFVIIa groups at T180, 
and a statistically significant fall in MCF over time thus confirming a clinical 
significant low fibrinogen level in the rFVIIa group. 
 
It is plausible therefore that the loss in clot strength is caused by a progressive 
consumption of fibrinogen and/or functional platelets in the rFVIIa group. 
13.8 Overall assessment of clotting 
Whilst the ability to differentiate the phases of clotting is useful in targeting 
therapy, it is often easier to look at the overall picture when describing the 
whole process. 
 
The clotting, as assessed by ROTEM® suggests that the addition of rFVIIa 
causes a short term “boost” in clotting manifest by a shortened clot initiation, 
although there is no effect on clot strength or clot dynamics. After T60, 30 
minutes after the administration of IV rFVIIa, the effect changes. There is a 
gradual, progressive deterioration in clot initiation, clot dynamics and clot 
strength. This results in a coagulation taking a long time to produce a poor 
quality clot.  
 
The clotting as assessed by TEG® has a slightly different result. The initial 
phases are the same as for ROTEM®, however the addition of rFVIIa at T30 
presents a different picture and does not demonstrate a short term “boost”. By 
T60 there is a rapid worsening of clot initiation with a rapid, progressive 
worsening of clot dynamics and clot strength. This picture is not dissimilar 
qualitatively to ROTEM, but is different quantitatively.  
 
The causes for these changes are still unclear. There is the possibility that the 
rFVIIa follows the normal pattern, but the administration of O2 at T30 provides 
enough O2 to the inflow of the microcirculation (raised SaO2) that it has a 
beneficial effect on clotting. This is less likely than some of the other potential 
causes since the SvO2, representing O2 uptake is so low. There is the potential 
action of the natural anticoagulants, particularly TFPI and heparans that may 
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have an effect that can be measured using the dilute innovin TEG®. The rFVIIa 
group has a worse acid base status, which will affect clotting, and may well be 
clinically significant. Finally, as an additional alternative mechanism, there is 
evidence of consumption of both platelets and particularly fibrinogen in the 
rFVIIa group. 
13.9 The evidence for consumption and inhibitors 
The original study was not intended to perform any assessment of coagulation 
other than PT, ROTEM® and TEG®. However the possibility that increased 
consumption after rFVIIa may cause a progressively worse coagulopathy, and 
the possibility that the natural anticoagulant pathways may have a more 
significant role in the development of acute trauma coagulopathy prompted a 
further set of investigations. 
 
These investigations were done on completion of all the in vivo experiments and 
analysis of clotting parameters (PT, ROTEM®, TEG®) and so the opportunity to 
collect plasma specifically for clotting factors and inhibitors had passed. There 
were small amounts of plasma from a limited number of animals and time points 
available, so the supplementary analysis was considered worthwhile, however 
the assays required prioritisation as discussed below.  
  
The original data set included the ROTEM® and TEG® results which implied 
consumption due the gradual deterioration over time of clot initiation, clot 
dynamics and cot strength, which was worse in the rFVIIa group. Some of these 
effects could be attributed to the presence of inhibitors as described in section 
13.7.1 However combining the gradual decline in platelet numbers, fibrinogen 
/FIBTEM levels particularly in the rFVIIa group, and the suggestion that the 
administration of rFVIIa accelerates fibrinogen consumption (see section 13.5), 
then the consumption theory is perhaps more plausible than the very 
speculative inhibitor theory. This view was supported by personal 
communication with Professor Beverley Hunt. The effect of acidosis always 
exists, as the possibility for the differences between the rFVIIa and O2 groups, 
however the effects of acidosis cannot be investigated by further plasma 
analysis. 
  140 
 
It was therefore decided to prioritise the investigation towards consumption over 
inhibitor, consequently further assays were performed where possible outlined 
in section 13.10. 
13.10 Supplementary analysis of clotting factors 
The final pathway of coagulation involves the production of FXa and the 
production of thrombin. It is the production of FXa and FIIa that are key, 
whether produced via the normal clotting process initiated by the interaction 
between FVIIa and TF, or whether produced from the activated platelet 
stimulated by the administration of rFVIIa. 
 
With the limited plasma available, it was decided that FII, FV, FVII and FX were 
the main extra coagulation factor assays of interest. Assays for TFPI and 
heparans were performed to assess the contribution of the natural anticoagulant 
pathways and the presence of syndecan-1 as a marker of endothelial cell 
degradation. 
 
Previous work from DSTL has demonstrated that PT based human factor 
assays (FII, FV, FVII and FX) can be applied to pig blood. However the 
measurement of TFPI, heparans and syndecans have not been reported on pig 
blood before and so it was unknown if the assays would be effective. 
 
The factor assays showed interesting findings. FII, FV and FX all follow the 
same pattern. There is a significant difference in the measurement of the 
individual factors at T60 in the rFVIIa group, followed by a sharp decline. The 
other groups (control and O2) show a gradual and progressive decrease in 
activity down to critically low levels. Fibrinogen, platelets, and factors II, V and X 
all fall throughout the course of the study. The longer the experiment lasts for, 
the longer there is activation of clotting. It would be expected, therefore, that 
over time there would be a progressive consumption of clotting factor levels, 
which would lead to a progressive deterioration in clotting factors over time. 
This may be compounded by the presence of ATC with an increase in natural 
anticoagulation and fibrinolytic pathways.  
  141 
 
Interpretation of the factor assays in the rFVIIa group is difficult due to the 
unknown levels of rFVIIa in the sample. I shall use the FX assay to explain how 
the results of the PT based assay in this study should be interpreted, and this 
can be applied to the FII and FV results. The treatment with rFVIIa at T30 
means the FX assay is not simply a quantitative assessment of FX. The PT 
assay utilises a maximal dose of tissue factor as an initiator in order to fully 
activate all the clotting factors in that sample. It then measures the time for clot 
initiation in this fully activated plasma. If there are low levels of FX or FXa 
present then the PT will be prolonged. This prolonged time is compared to a 
reference plasma with dilutions of 25, 50 and 100%, and the results are given 
as a percentage, with normal values of 50 – 150% (in human blood). 
 
In this study I would hypothesise the following scenario: FX levels are likely to 
be the same in all the groups in phase 1 of the study, since up to this time there 
has been no difference in treatment. In phase 2, the time when the IV rFVIIa 
would be having its greatest effect, as plasma concentrations are highest, there 
should be increased FXa, compared to the O2 group, and therefore decreased 
FX. This boost in conversion of FX to FXa would extend throughout phase 3 so 
that by the end of phase 3 there would be reduced amounts of FX in the rFVIIa 
group. To measure this we need a pure FX and FXa assays, however there is 
no FXa assay available and it is therefore only possible to measure the effects 
indirectly.  
 
At first glance the FX assay looks like there is an increased amount of FX 
produced in the rFVIIa group. As discussed above, the FX assay is a PT based 
assay and assumes an unknown concentration of FX in the sample plasma on a 
background of a known concentration of all other factors. Therefore any 
differences in PT are solely due to the amount of FX in the sample plasma. In 
our study there is also the added complication of the rFVIIa in the IV rFVIIa 
group. Therefore the assay is measuring not only the amount of FX in the 
sample, but the effect of a raised FVIIa as well. Whilst this measurement cannot 
quantify the amount of FX in the sample, it does reflect the in vivo situation 
where we have artificially raised the amount of VIIa available to activate 
coagulation. 
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Therefore the results indicate that qualitatively there is a boost in clotting due to 
the effects of the IV rFVIIa. This activity rapidly declined, such that by T120 
there was no difference between groups. The effects of rFVIIa would be 
wearing off by this time due to its half-life of around 2 hours and so it is not clear 
whether the lack of difference between groups at T120 is due to the reduced 
amounts of rFVIIa, or due to the accelerated consumption of factor X caused by 
the “boost” in clotting. 
 
The FII analysis follows the same pattern as the FX assay, which is not a 
surprise since FII is converted to FIIa (fibrin) due to the action of FXa. FV levels, 
however, are slightly different although this may be due to the small numbers of 
samples available for assay. 
 
The results for TFPI and heparans were all below the minimum detection range 
for the assay, and the syndecan value was 0 in all samples. It is therefore clear 
that the assays for TFPI, heparans and syndecans were not effective in these 
samples and so no further analysis has been performed on these results. It has 
therefore not been possible to comment on the potential role of natural 
anticoagulants in the development of ATC. FVII analysis was not possible due 
to limited plasma available for analysis. 
 
In summary the PT based factor assay indirectly measures the effect of rFVIIa 
on FX, FV and FII activity, which showed a “boost” after treatment with rFVIIa at 
T30. Unfortunately there was limited plasma available for assay at the later time 
points and so it was not possible to determine if an increase in consumption of 
clotting factors occurred in the rFVIIa group. The assay for natural 
anticoagulants failed to produce a result. 
  143 
Chapter 14.  An in vitro assessment of the effects of rFVIIa 
on coagulation 
14.1 Rationale 
It is well understood that treatment with rFVIIa will have an effect on clotting 
which may lead to a reduction in blood product use but may or may not have an 
effect on clotting (See section 7.1). However what is less well understood is 
what happens if a second dose of rVIIa is given. The military clinical scenario is 
the following: 
 
 A soldier is injured by a blast device and exhibits clinical signs of 
respiratory distress. 30 minutes after injury he is administered  
rFVIIa as a potential treatment for blast lung (See section 7.6). He 
is hypotensively resuscitated as per UK military battlefield 
resuscitation guidelines(Joint Service Publication 999, 2012). On 
arrival in hospital he is found to be coagulopathic. What effect will a 
second dose of rFVIIa, as a treatment for coagulopathy, have, and 
when is the best time to administer this second dose? 
 
Preliminary investigations into the optimal timing of drug administration can be 
conducted in vitro whereby rFVIIa is added to appropriate samples of blood 
from the animal model. The impact of the added rFVIIa on clotting can be 
assessed using TEG® or ROTEM®. These types of studies are often referred 
to colloquially in the published literature as “spiking” studies since the sample of 
blood is “spiked “ with the drug in question. Careful application of this approach 
allows a significant amount of progress to be made without the need for large, 
multiple groups of animals. 
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14.2 Methods 
14.2.1 Blood samples 
Blood samples drawn form the pigs from the animal study described in Chapter 
11 were analysed, at the same time points as the coagulation assessment, with 
the administration of an in vitro spike of rfviia. To avoid confusion, rfviia refers to 
the spiking dose of rfviia, whereas rFVIIa refers to the intravenous dose used 
in the animals. 
14.2.2 TEG® analysis and in vitro administration of rFVIIa 
Fresh arterial blood was divided into two 942µl aliquots. One aliquot was treated 
with 29µL of rFVIIa (final concentration of 2.6µg/ml equivalent to a clinical dose 
of 180 µg/kg). The second aliquot was treated with 29µl of buffer (the solvent for 
rFVIIa, in order to match the dilution as control). These are known as the rfviia 
spike and the buffer spike. Both aliquots had 29µl of dilute tissue factor  
(Innovin, Dade Behring; marketed by System UK Ltd, Milton Keynes, UK) added 
to make a final volume of 1000µl, with a final innovin dilution of 1:50 000. TEG® 
analysis was performed in the standard way (see section 4.5). All TEG® 
analyses were performed in triplicate. 
14.2.3 Statistical analysis 
The phases of treatment were the same for the spiking study as for the animal 
study (see section 11.7.1) and consisted of phase 1 (baseline to T30), phase 2 
(T30 to T60) and phase 3 (T60 to T180) 
 
Paired assessment of buffer and rfviia spiked blood samples were performed to 
determine the effects of a rfviia spike on clot initiation, dynamics and strength 
(TEG R time, K time and MA). The data are presented as the difference 
between the rfviia and buffer spiked samples: a positive difference indicating a 
larger value in the rfviia spiked sample and a negative difference representing a 
smaller value in the rfviia spiked sample compared to the buffer spiked sample. 
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Time series data were compared using two-way analysis of variance (ANOVA) 
with repeated measures over time.  Single time-point analyses were made 
using 2 way and 1 way ANOVA as appropriate.  Where data was found to be 
non-normal a non-parametric equivalent was used as indicated in the text.  In all 
cases a significance level of P≤0.05 (two tailed) was used 
14.3 Results 
14.3.1 R Time 
 
Figure 14-1. Effect of spiking study on R time. Values plotted are paired analysis and the 
difference between rfviia spike and buffer spike. Mean +/- SEM. (For further details see Figure 
12-2) 
During the pre-treatment phase a rfviia spike led to a significantly shorter R time 
compared to buffer spike (negative value rfviia spike - buffer spike), this was 
significantly different from 0 (P=0.0261). During phase 1 there was no 
difference between groups (P=0.2867) or over time (P=0.5167) (Figure 14-1) 
 
Again, during phase 2 there were no differences between groups (P=0.1334) or 
over time (P=0.06819).  
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Comparing the O2 and IV rFVIIa groups in phase 3 (T60 and T120 only due to 
loss of data points at T180) there was a difference between groups (P=0.0363), 
with the IV rFVIIa group being more positive than the O2 group, but no 
difference over time (P=0.6529). 
 
In summary prior to initiation of treatment at T30, the rfviia spike caused a 
shortening of R time (enhancement of clotting) in all groups. During the late post 
–treatment phase there was a difference between the IV rFVIIa group and the 
O2 group, the IV rFVIIa  group being more positive, meaning that there was a 
reduced effect of the rfviia spike. 
14.3.2 K time 
 
Figure 14-2. Effect of spiking study on K time. Values plotted are paired analysis and the 
difference between rfviia spike and buffer spike. Mean +/- SEM. (For further details see Figure 
12-2) 
 
In phase 1 rfviia spike led to a significantly shorter K time compared to buffer 
spike (P=0.0442). The difference between rfviia spike and buffer spike was not 
different between groups (P=0.6877) and did not change significantly over time 
(P=0.4165) (Figure 14-2). 
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Similarly, during phase 2 there is no difference between groups (P=0.2597) and 
no difference over time (P=0.5881). 
 
During phase 3 (O2 and IV rFVIIa groups only at T60 and T120) there were no 
significant differences between groups although there was a trend for the IV 
rFVIIa group to be less negative (P=0.0582). There were no significant changes 
over time during this period (P=0.7441). 
 
In summary prior to initiation of treatment at T30, the rfviia spike caused a 
shortening of K time (enhancement of clotting) in all groups. During the late post 
–treatment phase there was a trend for the rfviia group being more positive, 
meaning that there was a reduced effect of the rfviia spike 
14.3.3 MA 
 Due to failure to reach MA in a number of samples, sample size was too small 
to draw meaningful inference, however the trends suggest that during phase 1, 
rfviia spike enhanced clot strength, but there was a trend for this effect of rfviia 
spike to be lost in the IV rFVIIa group, while it persisted in the O2 group during 
phases 2 and 3 (Figure 14-3).  This is the same pattern as in the R time and the K 
time where the effect of the rfviia spike seems diminished over time in the IV 
rFVIIa group. 
  148 
14.4 Discussion 
The spiking study was performed to investigate the efficacy of a dose of rfviia 
on coagulation as measured by dilute innovin TEG. The spiking was performed 
on all three groups, however due to loss of animals by T120, the late phase of 
the comparison could only be made between the O2 and rFVIIa groups. To 
avoid confusion when discussing the spiking study the term “IV rFVIIa” group 
refers to the animals treated with IV rFVIIa at T30, whilst the term “rfviia” refers 
to the rfviia used in the spike. To take advantage of the paired nature of the 
samples, the results are presented as the difference between the rfviia spike 
and the buffer spike (rfviia – buffer). Thus a negative result is a smaller number 
in the rfviia group, whilst a positive result is a larger number in the rfviia group. 
Therefore when assessing R time or K time, a smaller number in the rfviia 
group, leading to a negative difference, means a shorter time for clot initiation 
and clot dynamics and therefore an improvement in clotting. In relation to MA, a 
smaller number in the rfviia group means a smaller amplitude and therefore a 
weaker clot. 
Figure 14-3. Effect of spiking study on MA. Values plotted are paired analysis and the 
difference between rfviia spike and buffer spike. Mean +/- SEM. (For further details see 
Figure 12-2) 
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14.4.1 The effect of the rfviia spike on clot initiation 
In the early pre-treatment phase of the study, the effect of the rfviia spike was to 
produce a shorter R time compared to the buffer, with no difference between 
groups. This is to be expected since at this stage all the groups have undergone 
the same procedures and have not been treated with either O2 or IV rFVIIa.  
The implication is that at this stage a dose of rfviia would improve (shorten) the 
time taken for clot initiation. This effect was maintained throughout phase 2. At 
this early stage of the study, therefore, a dose of rfviia would be effective in 
shortening the time taken for clot initiation. The mechanisms are the same as 
the mechanisms whereby the IV rFVIIa dose had an effect on clot initiation 
beyond T30 (See section 13.7.1), that is a boost in the production of thrombin 
due to the actions of rfviia on activated platelets and the TF-FVIIa activated 
pathway. 
 
This effect of the rfviia spike diminishes however in the late post-treatment 
phase of the study when comparing the O2 and IV rFVIIa groups only. During 
this phase the rfviia spike has less effect in the IV rFVIIa group. The potential 
causes of this are the same as discussed in section 13.8 and remain 
consumption (most likely), natural anticoagulation and acidosis. 
14.4.2 The effect of the rfviia spike on clot dynamics 
The results of the rfviia spike on the clot dynamics broadly follow the same 
pattern as the results on the clot initiation. There is an improvement in clot 
dynamics after rfviia spike compared to buffer spike (negative difference) in the 
pre-treatment phase and in the early treatment phase. In phase 3, the trend was 
for a reduction in the efficacy of the rfviia spike compared to buffer spike in the 
same manner as the clot initiation, however this did not reach statistical 
significance. 
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14.4.3 The effect of the rfviia spike on clot strength. 
Unfortunately it has been impossible to run comparisons between the groups 
using MA due to the number of samples failing to reach MA. This has been 
discussed in more detail in section 13.7.3 and is due to the run time of the TEG 
being inadequate for the relatively mild initiation of clotting with dilute innovin 
thereby taking a long time to reach MA. However the pattern broadly follows 
that of the spiking study pertaining to clot initiation and dynamics. Clot strength 
is improved after the rfviia spike in the early phases of the study, but the effect 
diminishes in the IV rFVIIa group in the late phase of the study 
14.4.4 Summary of the spiking study 
The three phases of coagulation (initiation, dynamics and strength) assessed in 
the spiking study with dilute innovin TEG® broadly follow the same pattern. A 
spike of rfviia is effective early, but the effect diminishes over time in the IV 
rFVIIa group. 
 
The exact reason for this can not be distinguished between consumption, 
natural anticoagulation and acidosis.  
 
Using the clinical scenario describe in section 14.1, where a hypotensively 
resuscitated soldier, injured by a blast device with concomitant haemorrhage, 
arrives at hospital and is administered rFVIIa either as a first dose (O2 and 
control group) or as a second dose (IV rVIIa group). The results show that over 
time, administration of rFVIIa is increasing less effective, and this is worse for a 
second dose of rFVIIa. Therefore the clinical analogy is that if rFVIIa is to be 
used, it is best used early, and if a second dose is to be used it will be 
increasingly less effective over time. 
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Chapter 15. Overarching discussion and future directions 
15.1 Overall summary 
The interpretation of the results from the animal experiments are made difficult 
due to the lack of a control group out to T180. Late comparisons can only be 
made, therefore, between O2 and rFVIIa groups, which have a significant 
difference in arterial oxygen levels, and acid base status. The difference in 
SaO2 seems to have an overall clinical effect, as survival in the O2 group is 
significantly higher than either the Control or rFVIIa groups, and may well affect 
clotting. However the presence of very low levels of SvO2 in all groups, 
including the O2 group, may mean that the effect of the oxygen on clotting is 
mild. This is because as the blood traverses the microcirculatory vasculature, 
from the arterial to the venous side, the overall elevation in oxygen seen by the 
endothelium in the O2 group is modest which is reflected in the significant 
oxygen extraction by the tissues. Conversely the acid base status might have 
had a clinical effect contributing to the differences seen between the O2 and 
rFVIIa groups late in the study. The underlying picture is that hypotension and 
blast injury cause a deterioration of coagulation measured by either PT, aPTT, 
ROTEM® or TEG® characterised by a progressive consumption of clotting 
factors, particularly fibrinogen. It is impossible to ignore the potential effect that 
acidosis may have on the coagulation system that may well explain the “slowing 
down” of clot initiation and dynamics, but would not explain the loss in clot 
strength or the difference in fibrinogen levels. Finally there is the potential that 
as ATC develops, so the natural anticoagulant pathways become more 
important. Whilst the natural anticoagulant pathways are less likely to explain 
these results, since ROTEM® and PT are insensitive to these pathways, it has 
been impossible to exclude them as a potential explanation. 
 
The spiking study showed that the efficacy of rfviia administration in the IV 
rFVIIa group declined over time, however it is impossible to determine if this is 
due to the diminished effects of rfviia in the presence of low fibrinogen and low 
platelet activity or the effects of acidosis impairing enzyme function. It is also 
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unclear how much effect acidosis has on the efficacy of spiked rfviia since in 
recent studies, (Lesperance et al., 2012; Viuff et al., 2008) rfviia spikes have 
been shown to be effective in acidotic blood. 
 
Finally, the premise of the study was to determine the effect of O2 and rFVIIa on 
clotting in a model that represented a military casualty who received only 
minimal treatment of O2 or rFVIIa soon after injury, and remained hypotensive 
thereafter. The results show that O2 administration increases survival and has a 
less detrimental effect on clotting than the administration of rFVIIa.  
 
It is therefore impossible to recommend the use of rFVIIa as a treatment aimed 
at improving coagulation unless there is concomitant resuscitation aimed at 
restoring oxygen delivery to the microcirculation. 
15.2 Future directions 
Military operations dictate that advanced medical care must be administered to 
very severely injured casualties in a resource constrained environment. In this 
context it is imperative to investigate the possible use of medical adjuncts that 
may improve the clinical situation, in this case coagulation, which have less of a 
logistical requirement than fresh and frozen products such as blood and FFP. 
rFVIIa is stable at room temperature, has a long self life and is reconstituted 
with sterile water. 
 
Administration of rFVIIa does cause a short term “boost” in clotting and has 
been shown to decrease blood transfusion (see section 7.2.1). If this is 
combined with resuscitation, there may be a place for the use of rFVIIa in 
resource limited environments, specifically if used in conjunction with other 
medical therapies and used to target coagulation specifically (Gruen et al., 
2012). 
 
A follow up study should be performed to investigate the effects of rFVIIa and 
adjunct therapy on the coagulation system. Since consumption of fibrinogen 
particularly, seems important, the combination of rFVIIa and fibrinogen should 
be compared to fibrinogen or rFVIIa alone. This should be performed in animals 
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undergoing concomitant resuscitation following current resuscitation protocols 
using early blood products and limited crystalloid. This future study should 
utilise dilute innovin TEG® and dilute innovin ROTEM® as well as formally 
collecting plasma for specific factor activity assays rather than simply a PT 
based factor assay. This would require some model development in order to 
ensure that the assays are suitable for porcine blood. The study itself should not 
be a survival study (i.e. although a severe, representative insult is utilised the 
treatment should be sufficient to ensure survival of all/most subjects to a 
predefined time), ensuring enough control animals for comparison at later 
phases of the study. 
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